Join the community shaping what's next in immuno-oncology and advanced therapies at #esmoimmuno26.
📍 London, United Kingdom
📅 14-16 Dec 2026
⏰ Late registration closes 18 Nov, 23:59 CET
Register today:
www.esmo.org/meeting-calendar/esmo-immuno-oncology-advanc…
#esmomeetings
@DrIgMelero @KippWeiskopf
Sherene Loi
Sherene Loi is an Australian medical oncologist. She is the 2021 winner of the Australian Prime Ministers Prize for Science, in the category of Frank Fenner Prize for Life Scientist of the Year. Loi is Head of Translational Breast Cancer Research, within the Peter Macallum Cancer Centre. Loi's research has advanced understanding into breast cancer, developing and implementing an immune system biomarker. This biomarker will enable improved management for people with advanced cancer. This biomarker is now part of routine pathology reporting across many countries and also is included in the World Health Organization Classification of Tumours (the WHO Blue Book on Breast Tumors). More on Wikipedia
-
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
This media couldn't be displayed. See it on the original post. -
Sherene Loi, MD
@LoiSher
🤩 What’s next for personalised mRNA cancer vaccines?
At #esmo26, 2 yr recurrence free survival after melanoma surgery was 82.2% with vaccine + pembrolizumab vs 70.0% with pembrolizumab alone.
Edward Fritsch and Cathy Wu discuss what comes next in #esmoiotech. -
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
Sherene Loi @LoiSher offers a succinct review of the ADCs presented this AM & what we know about payload resistance at #esmo26 @OncoAlert
-
Sherene Loi, MD reposted
Sara Tolaney
@stolaney1
Wonderful discussion by @LoiSher
@OncoAlert #esmo26 -
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
#esmo2026 very nice discussion by @LoiSher on novel ADC trials and switching. Be sure to watch on line! Beautiful comments about biomarkers. @OncoAlert
-
Sherene Loi, MD
@LoiSher
Excellent rapid oral session 2 in #advancedbreastcancer today
New advances in #adc, #cns treatment in #her2 #breastcancer #esmo26 #esmoambassadors
ESMO - Eur. Oncology
@myESMO
#esmo26: Practice-changing improvement in intracranial progression-free survival seen with the addition of tucatinib to standard therapy in HER2-positive metastatic #breastcancer (#mbc) in the BRIDGET #clinicaltrial.
Read more www.esmo.org/insights-by-esmo/all-news/tucatinib-improves…
#insightsbyesmo -
Sherene Loi, MD reposted
-
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
Interest is growing in multispecific antibodies to target tumour types that are unresponsive to current #immunotherapy, as illustrated by #clinicaltrials presented at #esmo26 in #colorectalcancer and #clearcellrenalcellcarcinoma
🔗 www.esmo.org/insights-by-esmo/all-news/are-multispecific-…
#insightsbyesmo
@MdCurioni -
Sherene Loi, MD
@LoiSher
#keynoteb49- @myESMO #esmo26
Adding ICB/ immunotherapy in advanced HR+ #breastcancer - wishful thinking 🤔 this context is immune deplete! -PFS 6-6.7 mo
➡️ Early high grade immune + HR + BC is the right place for it
#esmoambassadors
ESMO - Eur. Oncology
@myESMO
#esmo26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #advancedbreastcancer after failure on endocrine therapy in the phase III KEYNOTE-B49
🔗 www.esmo.org/insights-by-esmo/all-news/is-there-an-early-…
#clinicaltrial #breastcancer #insightsbyesmo
@PTarantinoMD -
Sherene Loi, MD
@LoiSher
#esmo2026
PostMonarch - change to Fulvestrant v placebo with Abema- continues to show better PFS and OS
➡️ results by ESR1 status eagerly awaited!
#esmoambassadors @OncoAlert
Published online in @Annals_Oncology -
Sherene Loi, MD
@LoiSher
🎉The only agent that can really increase pCR in a subset of early HR+ #breastcancer is #icb
#esmo2026 #esmoambassadors
ESMO - Eur. Oncology
@myESMO
#esmo26: Final results from the TALENT #clinicaltrial show low pathological complete response rates with the antibody–drug conjugate (#adc) trastuzumab deruxtecan in HR-positive, HER2-low #earlybreastcancer, as discussed by @breastDoktor #insightsbyesmo
➡️ www.esmo.org/insights-by-esmo/all-news/low-rates-of-patho… -
Sherene Loi, MD reposted
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
Giredastrant improved IDFS and had a better tolerability (less arthralgia) compared to AI
#esmo26
#esmoambassadors
#esmocommunity
@myESMO @GustavoWerutsky -
Sherene Loi, MD
@LoiSher
#esmo2026
Panku-breast01
Izabren sig. improves PFS in met HR+HER2 post CDK4i
#breastcancer
👏New targets 🎈impressive ORR too
➡️broadly comparable to DB04 - here all HER2
But 🎈haem tox
Still have the what next issue 🤷🏻♀️
Online publication in @TheLancetOncol
#esmoambassadors #bcsm @OncoAlert @myESMO -
Sherene Loi, MD
@LoiSher
#esmo26
Natalee 6 year data with improvement in OS including in node negative & no prior chemo patients - with online publication in @Annals_Oncology
#bcsm #esmoambassadors
@OncoAlert -
Sherene Loi, MD
@LoiSher
Why CD4+ T cells matter in adoptive cell therapy for solid cancers -well worth a read
www.esmoiotech.org/article/S2590-0188(26)00034-1/fulltext
@myESMO @esmo_iotech #immunoncology #adoptivecelltherapy -
Sherene Loi, MD reposted
Eric Topol
@EricTopol
How should immunotherapy be optimally applied for breast cancer? Excellent review of all the work being done in this field, and emphasis of the patient, not just the tumor, immune status (see Figure B below) @jclinicalinvest
www.jci.org/articles/view/207634 -
Sherene Loi, MD
@LoiSher
Brillant summary 👏 thank you 🙏 @NeilVasan
A paradigm changing decision and much food for thought @OncoAlert
Neil Vasan
@NeilVasan
Live tweeting on the @FDA AdComm on @GrailBio Galleri.
Right off the bat CEO Josh Ofman emphasizing 1) the cancer types we *don’t* have screening tests for, 2) idea of cancer signal recognition independent of cancer type, 3) favorable risk/benefit mirroring voting question language, 4) concept of cancer yield, 5) adding Galleri to conventional screening -
Sherene Loi, MD
@LoiSher
Red alert 🚨
👏👏🎉🎈New how to score #breastcancer #til PHONE APP
Download here ⬇️
apps.apple.com/us/app/bctils/id6782548427
@TILsWorkGroup
Thank you to @BCRFcure
@OncoAlert -
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
📢 Two new Cancer Grand Challenges 📢
We're calling on international, multidisciplinary research teams to come together and propose bold, innovative approaches to some of the most complex and pressing challenges in gastroesophageal cancer.
With more than 1 million lives lost to gastric and oesophageal cancers each year globally, the need for bold new solutions has never been greater.
Applications close 24 November.
Discover the new challenges: www.cancergrandchallenges.org/apply-for-a-challenge
Winning teams will be funded by the Torrey Coast Foundation and Cancer Research UK (CRUK), through Cancer Grand Challenges. -
Sherene Loi, MD reposted
Jose Fernando Moura, PhD
@FernandoOnco
We are @TILsWorkGroup @LoiSher
-
Sherene Loi, MD
@LoiSher
A #tils @TILsWorkGroup trifecta- exploring pathology vs AI TILS in #breastcancer @OncoAlert #bcsm
The Lancet Oncology
@TheLancetOncol
🆕Our Sept issue is now live!
📊Articles: #hepatocellularcarcinoma #nsclc #rectalcancer #breastcancer #prostatecancer
📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18
🎨Cover: breast cancer, TILs, and AI
🖱️Read here: www.thelancet.com/issue/S1470-2045(26)X2008-3 -
Sherene Loi, MD reposted
Eli Van Allen
@VanAllenLab
In our latest, we studied how certain immune cells surround bladder tumors and contribute to chemotherapy resistance, pointing to a surprising potential therapeutic target ...
Congrats @CarvalhoFilipeL @mouwlab et al! @CellPressNews @cellpressblue www.cell.com/cell-press-blue/fulltext/S3051-3839(26)00098-8 -
Sherene Loi, MD reposted
Waggoner Lab
@LabWaggoner
Perspective @NatureCancer @PeterMacCC @slaney_clare
Rewiring immunity with in vivo CAR T cell engineering
www.nature.com/articles/s43018-026-01216-0 🇦🇺 -
Sherene Loi, MD
@LoiSher
🚩Can an mRNA vaccine make “cold” tumours more responsive to immunotherapy 🌶️?
A recent @Nature study suggests mRNA vaccination may activate systemic innate immunity & potentially sensitise tumours to checkpoint blockade.
The clinical data need prospective validation, but the biological concept is compelling.
The Authors discuss the implications in an @esmo_iotech commentary. 🙏@adam_grippin @StevenLin_MDPhD
Nature article linked: www.nature.com/articles/s41586-025-09655-y
IOTECH commentary: www.esmoiotech.org/article/S2590-0188(26)00015-8/fulltext
@myESMO @esmo_iotech #cancerimmunotherapy #mrna #immunooncology #esmo #esmoiotech -
Sherene Loi, MD
@LoiSher
Looking fwd to this conference #dnadamage
Fusion Conferences
@Fusion_Conf
Following the highly successful inaugural Fusion DNA Damage Response for Cancer Therapeutics meeting, we are delighted to announce its return for a second edition!
Taking place from 07 - 11 July 2027 in Lisbon, Portugal, the meeting has expanded to 5 day programme, bringing together leading experts to explore the latest advances in DNA damage response research and cancer therapeutics.
Sign up for updates and be the first to hear when registration opens: fusion-conferences.com/conference/219/ -
Sherene Loi, MD
@LoiSher
🚩🚩latest from the #loilab
"Germline BRCA1 pathogenic variants and T cell dysfunction" www.sciencedirect.com/science/article/pii/S2590018826000201
We’ve traditionally viewed BRCA1 as a tumour suppressor acting within epithelial cells.
Our study suggests germline BRCA1 pathogenic variants may also impair host T cell function, providing a new perspective on hereditary breast cancer biology.
congrats 👏👏 Jasmine Kay @PeterMacRes @OncoAlert #bcsm -
Sherene Loi, MD
@LoiSher
🚩🚩latest research from the #loilab
We studied in a prospective randomized trial if single vs multi fraction SABR+ Atezo was effective in patients with advanced #tnbc in an era prior to routine pembrolizumab.
👏👏Congratulations to @drspdavid @pssavas
thank you 🙏to the patients and families, TROG, @PeterMacRadOnc @PeterMacCC @NatureComms @Roche @genentech
#bcsm @OncoAlert
rdcu.be/fxdVt -
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
A landmark study
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early #breastcancer.
🔓pubmed.ncbi.nlm.nih.gov/42229584/
@DrHBurstein @puglisi_fabio @mpgoetz @VeredStearns @DrEricWiner @Annals_Oncology -
Sherene Loi, MD reposted
Philippe Aftimos, MD
@aftimosp
Very fortunate to be part of the 4th Antibody Drug Conjugates (ADC) Workshop organiser by @etop_ibcsg in Zurich.
A stellar program and plenty of opportunity to network and learn from academic colleagues and industry partners. -
Sherene Loi, MD
@LoiSher
Note ➡️Incredible outcomes for OFS + ET vs TAM alone in premenopausal women at final 15yr follow up #earlyonset #breastcancer #bcsm
Bravo to 👏Prue Francis Meredith Regan @etop_ibcsg
Now we need better therapies for young women to improve adherence & longterm QOL
@PeterMacCC @OncoAlert
Annals of Oncology
@Annals_Oncology
🆕 article in press: Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer @DrHBurstein @LoiSher
doi.org/10.1016/j.annonc.2026.05.704 -
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
TDXd + Durva shows improved activity in immune-enriched HER2+ MBC in DESTINY-Breast07 @LoiSher @OncoAlert #asco26
-
Sherene Loi, MD
@LoiSher
🤩 ✅ EU CHMP approval: Cami is beneficial in emerging ESR1 mt resistant disease.
Remember also ✴️
1. Genomic biomarkers will only just get cheaper 💰
2. Oncology already accepts the principle that biochemical or molecular progression occurs prior to clinical PD ie in prostate cancer - why do #breastcancer patients need to show OS benefit? 🥴
3. Precision medicine also provides better health economics 🎓
OncoAlert
@OncoAlert
News from industry: SERENA6 Update in #breastcancer
Source : AstraZeneca
www.astrazeneca.com/media-centre/press-releases/2026/cami…
EU CHMP has recommended approval of AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations after first-line endocrine therapy. Based on SERENA-6, the regimen reduced risk of disease progression or death by 56%, improving median PFS to 16.0 vs 9.2 months. PFS2 also improved, with overall survival data still maturing. #breastcancer
Ping
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H
@nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc -
Sherene Loi, MD
@LoiSher
Great to have this recent conversation with @OncoAlert @ElisaAgostinett during the recent #esmobreast26. on HR+/HER2- neg #breastcancer and the rapidly changing treatment landscape 👏 #bcsm
OncoAlert
@OncoAlert
OncoAlert Horizons | Focus: Breast Cancer
Educational Series 🚨
In this session, we explore:
Therapeutic options after CDK4/6 inhibitor + endocrine therapy in HR+, HER2– advanced/metastatic breast cancer, and the emerging role of SERD-based combination strategies in this setting.
👩⚕️ Faculty:
Dr. Sherene Loi @LoiSher Peter MacCallum Cancer Centre, Australia 🇦🇺
Dr. Elisa Agostinetto @ElisaAgostinett Institut Jules Bordet, Belgium 🇧🇪
The post-CDK4/6 inhibitor landscape in HR+/HER2– advanced breast cancer represents one of the most pressing unmet needs in oncology. While CDK4/6 inhibitors combined with endocrine therapy have firmly established themselves as the frontline standard, disease progression on this backbone remains nearly universal, driven by heterogeneous resistance mechanisms including ESR1 mutations, PI3K/AKT/mTOR pathway alterations, and RB1 loss. This biological diversity highlights the limitations of one-size-fits-all approaches.
Next-generation oral selective estrogen receptor degraders (SERDs)—such as elacestrant, camizestrant, and imlunestrant—are reshaping the field. These agents achieve more complete estrogen receptor degradation than fulvestrant, show activity in ESR1-mutant disease, and are being actively evaluated in combination strategies with CDK4/6 and targeted therapies. Together, they are helping shift the post-CDK4/6 setting toward a more dynamic, biomarker-informed treatment paradigm.
This OncoAlert Horizons educational series was supported by an unrestricted educational grant from Roche. All content was independently developed and fully controlled by the faculty.
OncoAlert Horizons faculty:
@LoiSher
@JavierCortesMD
@BarbaraPistill2
@BianchiniGP
@ElisaAgostinett
Sybille Loibl
Rupert Barsch
Francois Clement Didard
Cristina Saura
Pinging our #breastcancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H
@nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @Onco_Cifu88This media couldn't be displayed. See it on the original post. -
Sherene Loi, MD reposted
Lorenzo Galluzzi
@deadoc80
Happy to share our latest @NatRevImmunol review on the #immunology of breast #cancer in #patients. Kudos to @bk_esme and @txi_ber for the monumental effort. Not possible w/o critical input from @LoiSher & Roberto Salgado! @FoxChaseCancer @PeterMacCC See rdcu.be/fji5F
-
Sherene Loi, MD
@LoiSher
#esmobreast26
Giredestrant with & w/o OFS -premenopausal WOO c/w AI+OFS
Strong anti- proliferative effect of G w/o OFS esp in older premopausal women similar to AI+ OFS. Despite NS results these data provide support that G w/o OFS IS an option - further work to be done ✅ @elisabettasabet 👏@breastDoktor @etop_ibcsg -
Sherene Loi, MD
@LoiSher
#esmobreast26
Mirinae study- 👏👏interesting signal for Atezo in PD-L1 pos RD post NAC for eTNBC (no NA Pembro). Immune cold tumors here.
Underpowered but lesson is that these RD IO studies need to be powered for & enrol the immune HOT 🥵 group only
@myESMO @OncoAlert -
Sherene Loi, MD
@LoiSher
➡️As a biomarker advocate, this decision needs commenting.
#serena6 proves #camizestrant has strong drug activity in emerging ESR1m disease, stronger than approved SERDs post-progression. FDA accepts PFS without OS for other SERDs at radiographic progression; the higher bar here is apparently the earlier PFS start point.
But the 9.2m control PFS does not mean "no need to act" it is a window where ESR1 subclones can be intercepted before broader and tougher to treat resistance biology beyond ESR1m emerges and dominates. Two separate questions: drug efficacy evidence (clearly established) vs strategy evidence (needs further study).
Demanding a definitive strategy trial before approving a drug with this activity sets a precedent that, IMO, will harm precision oncology. Such a trial needs years more time, money, patients & impossible in a changing 2L landscape. @oncoalert @FDAOncology #bcsm
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
The @FDAOncology just posted materials for the ODAC on camizestrant in SERENA-6 trial. Key issue: PFS/PFS2. Should be a very interesting discussion.
www.fda.gov/media/192156/download -
Sherene Loi, MD
@LoiSher
Didn’t Serena-6 show a >9 mo improvement in ESR1 mt 🤔@oncoalert #bcsm
Aya Mohamed | MSc, MD 🎗
@Dr_Oncologista
FDA approval of vepdegestrant marks a targeted advance in ESR1-mutant HR+/HER2– mBC post CDK4/6.
VERITAC-2: improved PFS (5.0 vs 2.1 mo; HR 0.57) vs fulvestrant; OS immature.
www.fda.gov/drugs/resources-information-approved-drugs/fd…
@OncoAlert @FernandoOnco #breastcancer #bcsm @FDAOncology @FDA -
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
What are the key issues that have emerged on the @NatureMedicine time-of-day IO paper?
1. The clinical trial protocol uploaded to Nature was v1 dated Jan 2, 2022; however, the protocol includes references published in 2024. This calls into question when the protocol was written and if/when it was amended.
2. The clinicaltrials.gov record is concerning and calls into question whether the study was actually randomized.
a. In the first record 9/2022, although the study was noted as randomized, the inclusion/exclusion criteria read as though it was a retrospective study, e.g., “First-line patients received immunological monotherapy or immunological combined chemotherapy” as an inclusion criteria and “Lack of clinical diagnosis and treatment information or loss of follow-up” as an exclusion criteria.
b. In the first record, the primary endpoint, sample size, treatment and ECOG criteria do not match what was in the protocol dated Jan 2, 2022.
c. On 3/19/2024, the study was changed from randomized/interventional to an observational case-control study
d. It was not until 3/30/2024 (2 months before end of randomization) that the study was changed to the design described in the manuscript.
3. The OS K-M curve presented at ASCO had errors – i.e., the censor marks do not match the at-risk table. This raises concerns about the integrity of statistical analyses.
4. The shape of the PFS does not match expectations. With a 6-week scan schedule, one would expect a stair-step drop every 6 weeks when patients have their scheduled imaging. Their PFS curve does not – it is smooth. Of note, in an observational study, a PFS curve generally does not have a staircase look because scans are not performed on a regular set schedule.
5. The 95% CI for the lower bound of the median OS in the manuscript is NE. This is not possible as the median was estimated. There are inconsistencies in the p-values in Table 1 (Baseline Characteristics)
Credit to Daniel Brickman, Amanda Nottke and David Swank for creating this list — and to @houndcl for first identifying several of these issues.
Paolo Tarantino
@PTarantinoMD
Impressive job of post-publication Twitter peer review on this paper!
With the effect size appearing inexplicably massive, plus the many inconsistencies in study conduct and reporting, it’s safe to assume the “time-of-day IO” question still fully open. www.nature.com/articles/s41591-025-04181-w -
Sherene Loi, MD
@LoiSher
👏👏👏 Must read from @S_LoboMartins in @NatRevClinOncol on ER+ early breast cancer in younger women.
Key point: outcomes reflect an aggressive tumour genotype/phenotype that can overcome strong host immunity, combined with constant hormonal cycling that remodels the breast and immunity systemically ➡️we need treatments focussed for young biology @oncoalert #breastcancer #bcsm
Soraia Lobo-Martins
@S_LoboMartins
Read our latest #review on tailoring targeted therapies for #younger women with #er+ early #breastcancer in @NatRevClinOncol, @SpringerNature.
We discuss biology-driven treatment strategies beyond age alone.
With Stephen Luen, Martine Piccart & @LoiSher
🔗doi.org/10.1038/s41571-026-01120-7 -
Sherene Loi, MD
@LoiSher
🌟new from @Nature TRM vs TEX have different regulatory programs- important in helping us steer T cells to TRM-like states - could be helpful for #cancer prevention and #immunotherapy treatment www.nature.com/articles/s41586-025-09989-7
-
Sherene Loi, MD
@LoiSher
👀Low dose immunotherapy - effective and less side effects! 👏👏👏👏@OncoAlert #immunotherapy
Alfredo Addeo MD
@Alfdoc2
Outstanding phase III trial!
Ultra-low-dose nivolumab (20 mg q2w) improves overall survival vs chemotherapy, with less toxicity and better QoL in pretreated solid tumors.
A landmark study challenging conventional ICI dosing and opening the door to more sustainable, globally accessible immunotherapy.
Congratulations to the authors for this practice-changing work! @VanitaNoronha
ascopubs.org/doi/10.1200/JCO-25-01546 -
Sherene Loi, MD reposted
Eric Topol
@EricTopol
The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system
www.nature.com/articles/s41591-025-04181-w -
Sherene Loi, MD reposted
G Curigliano MD PhD
@curijoey
Extending ET with OFS in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment is associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences. ascopubs.org/doi/10.1200/JCO-25-01660 @IEOufficiale @LaStatale @myESMO @ASCO
-
Sherene Loi, MD reposted
Trends in Immunology
@TrendsImmuno
Lactation, tissue-resident immunity, and protection against breast cancer www.cell.com/trends/immunology/fulltext/S1471-4906(25)003…
-
Sherene Loi, MD reposted
Eli Van Allen
@VanAllenLab
Here's our latest, a perspective on the convergence of machine learning and genomics for precision oncology - exciting for 2026 and beyond! Congrats @brendan_reardon @AedinCulhane @NatureRevCancer
-
Sherene Loi, MD reposted
David Usharauli
@3DiMMUNE
1/ There is still debate whether antigen is required to generate memory T cells. I think true memory T cells cannot form in the presence of their cognate antigen.
#immunology
#science
www.nature.com/articles/s41590-025-02352-y
www.nature.com/articles/s41590-025-02347-9 -
Sherene Loi, MD reposted
Klebanoff_Lab
@KlebanoffLab
🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in @NatRevDrugDisc 👇. A wonderful collaboration between @KlebanoffLab, @ND_BakerLab, @QuezadaLab, and @ToniRibas12. @MSKCancerCenter @parkerici rdcu.be/dpCtp
-
Sherene Loi, MD reposted
OncoAlert
@OncoAlert
FDA Approval: fam-trastuzumab deruxtecan-nxki in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer
Based on DESTINY-Breast09
www.fda.gov/drugs/drug-approvals-and-databases/fda-approv…
On December 15, 2025, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive #breastcancer , alongside companion diagnostic assays to identify eligible patients. The approval was based on the phase 3 DESTINY-Breast09 trial, which showed that patients receiving fam-trastuzumab deruxtecan-nxki plus pertuzumab achieved a significantly longer median progression-free survival of 40.7 months compared with 26.9 months for those receiving standard taxane, trastuzumab, and pertuzumab therapy (hazard ratio 0.56; p<0.0001), with high confirmed objective response rates in both arms. Overall survival data were immature at the time of analysis.
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel
#oncoalertaf
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago -
Sherene Loi, MD
@LoiSher
WISDOM trial - risk based BC screening looks safe on stage-shift & at scale ✅- but harm did not drop - biopsies & MMG freq were similar‼️low adherence longterm
My take: it is hard to change screening behaviour even in a highly motivated cohort
But as editorial by @drkellyphillips points out 🔔good chance for changing lifestyle habits & opportunity for prevention
👏👏to Dr Laura Esserman & colleagues for a stunning study 📚
#sabcs25
JAMA
@JAMA_current
In WISDOM, researchers compared risk-based breast cancer screening to standard annual mammography among more than 28 000 US women aged 40 to 74 across all 50 states.
#sabcs25 @SABCSSanAntonio
jamanetwork.com/journals/jama/fullarticle/2842902?linkId=… -
Sherene Loi, MD
@LoiSher
👏👏 for first time presenter at #sabcs25
Thanks to @BCTrialsANZ for supporting our Australian 🇦🇺 clinical fellows overseas @DFCI_BreastOnc
Dr Michelle Li
@michelle_li
Delighted to present our real-world experience with T-DXd at @PeterMacCC with support from @LoiSher @BCTrialsANZ
44% required dose reduction + ~10% discontinued T-DXd. Toxicities occurred at rates higher than reported in trials, eg nausea (any grade 94.7%, ≥G3 9.3%)! #sabcs25 -
Sherene Loi, MD
@LoiSher
👏👏 More work needed on new biomarkers in #lobular #breastcancer in order to design better trials powered for this group
#sabcs25
Philippe Aftimos, MD
@aftimosp
Special session amplifies dialogue on lobular breast cancer www.sabcsmeetingnews.org/special-session-amplifies-dialog…
#sabcs25
@lab_kok @oesterreichs @c_sotiriou @maggiemoo09 @Otto_DFCI @AnneAvincent @elbcc @DynamiFound -
Sherene Loi, MD reposted
Philippe Aftimos, MD
@aftimosp
The PremiÈRe study presented by @BelletMeritxell at #sabcs25 shows activity of oral SERD elacestrant irrespective of the use of OFS for premenopausal ER+/HER2- breast cancer.
@OncoAlert
1/ -
Sherene Loi, MD reposted
Elisabetta Bonzano MD, PhD
@to_be_elizabeth
📌 Poster Spotlight 7: Early Triple Negative Breast Cancer-Biomarkers and Novel Approaches
✨Neo-n (neon): three-year event-free survival and ultrasensitive cdna dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
Presented by @LoiSher 👏🏻
@OncoAlert #oncoalertaf #sabcs25 -
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
#sabcs2025 Honored to present this exciting data. Efficacy seen regardless of mESR1 or mPIK3CA with ela+eve. Data immature for abema. EVERA also shows benefit with giredestrant/EVE across mESR1 as did EMBER3. @OncoAlert
Kazuki Nozawa, MD
@kazuki_nozawa
ELEVATE phase 2 trial
Elacestrant combined with everolimus or abemaciclib provides meaningful PFS in ER+/HER2− metastatic breast cancer (8.3 and 14.3 months).
Both combinations had expected, manageable safety with no new signals.
Elacestrant may become a key oral ET backbone for future combination strategies.
#sabcs25
@OncoAlert -
Sherene Loi, MD reposted
Nancy Lin, MD
@nlinmd
PATINA CNS outcomes
Presented by Dr. Otto Metzger @otto_dfci @DFCI_BreastOnc
-maintenance HP +/- palbociclib after THP in HR+/HER2+ MBC
-palbo associated with lower cumulative risk of brain mets (13% v 19%) !
-limitation- no routine brain imaging on protocol -
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
#sabcs2025 Nick Turner presents our capi291 ctDNA data. Benefit seen in those without ESR1m and large genomic rearrangements more frequently found in ctDNA vs tissue. Nice data supporting this combination, and supports both tissue and ctDNA evals. @OncoAlert
-
Sherene Loi, MD reposted
BreastCancersToday
@BreastCancersTd
INAVO120 exploratory data show the inavolisib + palbociclib + fulvestrant triplet improved PFS across several genomic subgroups in HR+/HER2– advanced breast cancer, including PIK3CA, ESR1, and TP53 mutations. www.docwirenews.com/post/inavo120-inavolisib-triplet-impr… @jhaveri_komal @KalinskyKevin @LoiSher
-
Sherene Loi, MD reposted
Susan G. Komen®
@SusanGKomen
🧬 @LoiSher shared that breast cancer in young women has unique molecular & immune features. Factors like menstrual cycles, pregnancy history, tissue environment & lifestyle can affect tumor development. Future trials should consider age, immunity & genetics. #sabcs25
-
Sherene Loi, MD
@LoiSher
Agree! Begs the comparison btw G mono vs AI+ribo/abema and testing efficacy of G with RIBO/Abema or better CDK4i in a selected population
#sabcs25 @SABCSSanAntonio
VIRGINIA KAKLAMANI
@VKaklamani
Positive Lidera results including ddfs. Exciting results. Unanswered question is where to place it with cdk46i. But obviously favorable tox profile. Would consider it a soc option when approved. @dradityabardia @SABCSSanAntonio #sabcs2025 #bcsm
-
Sherene Loi, MD
@LoiSher
#sabcs25 Nice data from tumor non-informed #ctdna methylation assay in HER2+ BC
clearance at C3D1 & pre surgery correlated with pCR.
🙌Need to design prospective decision making studies combing ctDNA & TIL in #tnbc #her2 #breastcancer
Hope Rugo
@hoperugo
#sabc25 A Llombert phergain ctDNA dynamics HER2+ ESBC. 3/4 + at baseline. Poor clearance assoc with worse pCR and IDFS. This is an opportunity to individualize therapy based on a dynamic biomarker. @OncoAlert
-
Sherene Loi, MD
@LoiSher
#sabcs25 #youngwomen #her2 #breastcancer
This is about better shutdown of ER signaling, avoiding SERM partial agonism, & preventing crosstalk driven resistance mechanisms @oncoalert Bravo 👏👏@matteolambe
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Important lesson here for treatment of premenopausal women that OFS + AI is substantially better than tamoxifen in HER2+ early breast cancer, a finding also supported by SOFT/TEXT trial.
-
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
One more supportive slide from Ciara OSullivan
Hope Rugo
@hoperugo
Ciara O’Sullivan gives an excellent discussion of these results. Here I include the comparative patina results in HR+/HER2+ where all had ET. This is very important - why are docs not using ET in this setting? It works!!
-
Sherene Loi, MD
@LoiSher
First trial #her2climb05
#sabcs25 - maintenance tucatinib + T+ P
Looks better for HRneg>pos, ⬆️higher tox hepatic 43%, diarrhoea 70% all grade
Only 45% HRpos got concurrent ET
@oncoalert -
Sherene Loi, MD
@LoiSher
#sabcs25 William McGuire lecture - congrats to Armando Giuliano & pioneering SLNB 👏👏👏 #bcsm
Change is hard @OncoAlert @SABCSSanAntonio -
Sherene Loi, MD
@LoiSher
⛳️join us for more on this on Thursday 11th Educational session 14 -2.30pm #sabcs25 @OncoAlert @SABCSSanAntonio with🤩 @cncurtis @LabPolyak @MelissaTroester
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
#sabcs25 will explore the rising rates, unique complexities, and new insights on the biology of and therapeutic strategies for #earlyonsetbreastcancer.
@AnnPartridgeMD @LoiSher #breastcancer @SABCSSanAntonio -
Sherene Loi, MD
@LoiSher
🙌Happening now in room 302 #sabcs25 @SABCSSanAntonio @SG_BCC St Gallen early #breastcancer encore with @DrHBurstein @MichaelGnant
-
Sherene Loi, MD
@LoiSher
#sabcs25 join us for the St Gallen encore THIS morning 9.30 am room 301 @oncoalert @SABCSSanAntonio
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Timely reading ahead of @SABCSSanAntonio -- the @SG_BCC consensus guideline for early breast cancer, just published in @Annals_Oncology. Comprehensive, readable, global.
www.annalsofoncology.org/article/S0923-7534(25)04718-0/fu…
Article is fully accessible without paywall -
Sherene Loi, MD
@LoiSher
🥳Super exciting that we may be better be able to identify the tumor reactive T cells
👏👏👏 #immunology #cancercure
Dr. Patrick Hwu
@PatrickHwuMD
#sciencesaturday
❓ How do scientists find the immune cells that are truly fighting a tumor?
➡️ A new @Nature study reveals that powerful tumor-killing T cells may be hiding in plain sight, not as single cells, but in clusters attached to tumor cells or antigen-presenting cells. These clusters, often filtered out during traditional cell-sorting, contain CD8 T cells that are more tumor-reactive, more activated and more effective than typical T cells found alone.
➡️ Using advanced flow cytometry and single-cell sequencing, researchers showed that these clustered T cells carry gene signatures linked to strong anti-tumor activity, high TCR clonality (a marker of targeted immune response), and increased ability to kill cancer cells. In fact, T cells taken from clusters were up to nine times more potent at destroying tumor cells compared to single T cells.
➡️ Even more exciting: when these cluster-derived T cells were expanded and tested in mice, they infiltrated tumors more efficiently and significantly slowed tumor growth, showing promise for improving adoptive T-cell therapies.
🌟 Congratulations to senior author Daniel S. Peeper and the collaborative teams at the Netherlands Cancer Institute, Oncode Institute, VIB Center for Cancer Biology, University of Gothenburg, Harry Perkins Institute and others for uncovering a new path to potentially strengthen TIL therapy and immunotherapy outcomes. @d_peeper @vib_ccb @oncodeinstitute @NKI_nl @uniofgothenburg @PerkinsComms
Read more here: doi.org/10.1038/s41586-025-09754-w -
Sherene Loi, MD
@LoiSher
👏👏Not bad for a dedicated Cancer Hospital & Research Centre on an island of 27Mi 🇦🇺🦘🌏and 24 hrs ✈️to get anywhere in the northern hemisphere 🇪🇺🇺🇸 #curecancer #bigimpact @PeterMacCC @PeterMacRes
Peter Mac Cancer Centre
@PeterMacCC
Peter Mac researchers have once again been recognised as among the very best in the world.
Read more: www.petermac.org/about-us/news-and-events/news/details/pe… -
Sherene Loi, MD
@LoiSher
🏁Key lesson IMO: adding tucatinib to T-DM1 does not really overcome key resistance mechanisms ➡️only small gain in PFS seen ⏳. Extra toxicity & strong post-PD options like T-DXd would have reduced OS gain 💊🧠 I wonder if will be similar for a T-DXd+TKI combo
🤔 sequence better?
@OncoAlert #bcsm #her2 #breastcancer
Annals of Oncology
@Annals_Oncology
🆕article in press: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the phase III HER2CLIMB-02 trial. shorturl.at/Md6M7 @LoiSher @stolaney1
-
Sherene Loi, MD
@LoiSher
New data in young women with BRCA1/ BRCA2 #breastcancer suggest not all pathogenic variants are created equal 🚨 Truncating mt in exon 2& 10 link to worse OS while missense variants look better 🧬 No clear DFS signal yet so firmly hypothesis generating ➡️likely about how much & where BRCA function is lost 🧪 @OncoAlert #bcsm 👏 to @matteolambe &team
Annals of Oncology
@Annals_Oncology
🆕article in press: association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study @angela_toss @matteolambe
shorturl.at/6BuPx -
Sherene Loi, MD
@LoiSher
🙌👏👏👏 massive win for #giredestrant now in early #breastcancer #lidera phase 3 study
@Roche an oral SERD finally arrives
@OncoAlert #bcsm
www.roche.com/media/releases/med-cor-2025-11-18 -
Sherene Loi, MD reposted
BreastCancersToday
@BreastCancersTd
In a new interview, Dr. @LoiSher (@PeterMacCC) discusses how immune changes from pregnancy + breastfeeding could inspire new prevention strategies in breast cancer. Watch: www.docwirenews.com/post/parity-immune-priming-and-future… @PTarantinoMD @matteolambe @BlondeauxEva @BalajiVirassamy
-
Sherene Loi, MD
@LoiSher
♨️ ➡️this implies to me that 1. 🎯target biology (as both have the same payload) and 2. the linker chemistry 🧪 may explain diverging ADC results. #her2 seem more meaningful in HR+/HER2- BC whereas TROP2 is less clearly linked to biology & is better target for #tnbc #breastcancer @OncoAlert #bcsm
Paolo Tarantino
@PTarantinoMD
Negative press release from ASCENT-07: in pts with ER+ MBC refractory to endocrine treatment, first-line SG did not improve PFS compared with chemo. In this setting, T-DXd outperformed chemo (DB-06) and a phase 3 is ongoing with Sac-TMT +/- pembro (TF-10). investors.gilead.com/news/news-details/2025/Gilead-Provid…
-
Sherene Loi, MD reposted
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Check out this recent @JournalCancer study looking at the prognostic value of patient-reported depression in women with hormone-responsive early #breastcancer in TEXT and SOFT trails.
👉pubmed.ncbi.nlm.nih.gov/40986647/
@PeterMacCC @DrHBurstein @VeredStearns @LoiSher -
Sherene Loi, MD
@LoiSher
Congratulations to @MyriamChalabi !!
Myriam Chalabi
@MyriamChalabi
Wow! Not 1️⃣, not 2️⃣, but 3️⃣‼️@Nature papers concomitantly published during #esmo25 @myESMO
@LoiSher @adam_grippin @MDAndersonNews @PeterMacCC @NKI_nl @DrChoueiri @VanAllenLab @FAndreMD congrats to all authors and 🙏 for making this very unique session happen also @Nature ! 👇 -
Sherene Loi, MD
@LoiSher
♨️hot off the press2: following after my abstract @myESMO #esmo25 in the basic science outstanding oral abstract session was @adam_grippin also published now in @Nature . 👏
Qu: Should we now be thinking about recommending a covid vaccine to all our #tnbc patients just prior to starting their #immunotherapy + chemo?
Should all mRNA neoantigen vaccine trials also have a sham vaccine arm as well. @OncoAlert #bcsm
Anirban Maitra
@Aiims1742
🤯
New in @Nature from @MDAndersonNews colleagues @adam_grippin @StevenLin_MDPhD
SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
www.nature.com/articles/s41586-025-09655-y -
Sherene Loi, MD
@LoiSher
📌 Just a shout-out that the Peter Mac Breast Cancer Education day is on again NEXT WEEK.
@PeterMacCC
THURSDAY 30th OCTOBER 10-5.30pm with networking drinks after. With special guest Prof. @hoperugo from City of Hope CA.
WITH #esmo25 just behind us this will provide important discussions as well with updates on Surgery and Rad Onc with MDM case panels.
Hope to see you there on site or on zoom. Thanks to our sponsors.
REGISTER HERE: www.eventbrite.com/e/2025-peter-mac-breast-cancer-medical… -
Sherene Loi, MD
@LoiSher
👏👏Bravo @LMalorni @etop_ibcsg This important study shows that endocrine therapy and CDK4+ HER2 targeting therapy in HR+ HER2+ is highly effective with similar rates of pCR to taxol+TP!
Supports #patina study & also removing #chemotherapy in the early stage HER2+ HR+ setting.
now wouldn't that be something.
#her2 #bcsm @OncoAlert
Annals of Oncology
@Annals_Oncology
🆕 article in press: primary results from the randomized phase II TOUCH trial of neoadjuvant palbociclib + letrozole vs paclitaxel combo with trastuzumab + pertuzumab in pts with HR+/HER2+ EBC @LMalorni www.annalsofoncology.org/article/S0923-7534(25)04963-4/ab…
-
Sherene Loi, MD
@LoiSher
✨✨hot off the press from the #loilab. We show here that pregnancy & breastfeeding is associated with increased T cells in the normal breast and protection against #tnbc #breastcancer moving the role of immunity from treatment to prevention.
👏👏Thanks to @FAndreMD @DrChoueiri @MyriamChalabi for the opportunity to present #esmo25 @OncoAlert @myESMO
@PeterMacRes @PeterMacCC @UniMelb
thanks to our funders @BCRFcure @TheMarkFdn @NBCFAus
@Nature Article is here: www.nature.com/articles/s41586-025-09713-5
Jose Fernando Moura, PhD
@FernandoOnco
Translational data shows that #breastfeeding helps personal immunity improving CD8+ T
This work can help to understand better the immune system and breastfeeding mechanisms @LoiSher @OncoAlert #esmo25 @FernandoOnco
Sherene Loi, MD
@LoiSher
👏This was a colloboration with @LMackayLab @TheDohertyInst Terry Speed; Jane Visvader @WEHI_research @malaysia Dr Jia Wern Pan @reversecancer & the Darcy and Neeson labs @PeterMacRes with @pssavas @BalajiVirassamy 👏👏
-
Sherene Loi, MD reposted
nature
@Nature
Pregnancy and breastfeeding induces the accumulation of specialized immune cells that reduce the chances of breast cancer developing
go.nature.com/4hvDWtt -
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
Why does breastfeeding lower breast cancer risk?
A new Nature study led by Prof @LoiSher shows it creates long-lived CD8⁺ T cells in breast tissue – immune “guards” that help stop cancers forming, including triple-negative.
🔗 www.petermac.org/about-us/news-and-events/news/details/br… -
Sherene Loi, MD reposted
Waggoner Lab
@LabWaggoner
Parity and breastfeeding reduce the risk of breast cancer via accumulation of resident memory CD8 T cells in breast tissue @Nature @LoiSher @LMackayLab
@PeterMacCC @UniMelb @BalajiVirassamy @pssavas
www.nature.com/articles/s41586-025-09713-5 🇦🇺 -
Sherene Loi, MD
@LoiSher
😳 no OFS with endocrine therapy for premenopausal #breastcancer patients would be a great advance #esmo25 #esmoambassadors
#bcsm
Matteo Lambertini, MD PhD
@matteolambe
Very interesting preliminary data to support the use of oral #serd (in this case #giredestrant) without ovarian function suppression in premenopausal women with HR+/HER2- early #breastcancer
@OncoAlert @myESMO #esmo25 @AnnPartridgeMD -
Sherene Loi, MD
@LoiSher
KEYNOTE-905 #esmo25 Presidential #gu #mibc - very different population to #breastcancer! but will more MIBC patients now become Cis-ineligible? Interesting to me as a #breastcancer doc that MIBC patients accept to be randomized to EVP vs no treatment? #esmoambassadors @OncoAlert
Toni Choueiri, MD
@DrChoueiri
Bladder cancer #esmo25 in 1 slide. #goosebumps #newsocnow #micdrop #standingovation
Neoadjuvant EVP = New SOC MIBC Cis-ineligible! -
Sherene Loi, MD
@LoiSher
DB05 #esmo25 impressive efficacy for post op node + or inoperable at baseline -balanced with ~10%ILD but 👏less CNS 🧠recurrences 🙌
Bravo to those >70% patients putting up with all that nausea!!
@myESMO #esmoambassadors @OncoAlert -
Sherene Loi, MD
@LoiSher
a new #her ADC "T-Bot (?)" which is better than TDM1. Agree that ocular tox 👁️ here is problem. If efficacy is equal what will patients chose? Ocular tox 👓 vs ILD 🫁vs thrombocytopenia🩸 ❓🤔 #esmo25 #esmoambassadors
Erika Hamilton, MD, FASCO
@ErikaHamilton9
#trastuzumab botidotin (HER-2 ADC w/ microtubule MMAF payload)
No prior TDXd 🤷🏼♀️
Prior tras and a taxane mandated
~ 45% pertuz, ~60% prior TKI
PFS 11.1 mo w/ H-botidotin vs. 4.4 mo w/ T-DM1
OS close, not quite there
#esmo25 #esmoambassadors -
Sherene Loi, MD reposted
Lizzy Smyth
@LizzySmyth1
#esmo25
?TDxD challenger?
Bispecific HER2 anbenitamab shows promise in trastuzumab resistant #gastriccancer.
✅No ILD...
Small study. 🇨🇳 only.
Need larger international trials but this is encouraging...
#esmoambassadors -
Sherene Loi, MD
@LoiSher
#giredestrant positive read out in #evera. nice to see an all oral and effective combination for all HR+ patients, even though driven by ESR1mt which was nearly 50% of ITT in this largely 1L CDK4 "sensitive" population #esmo25 #esmoambassadors @OncoAlert
Matteo Lambertini, MD PhD
@matteolambe
Important data presented at #esmo25 by super @elmayermd from @DFCI_BreastOnc showing the benefit of combining #giredestrant with #everolimus in patients with advanced HR+/HER2- #breastcancer progressing on CDK4/6i
#esmo25 @OncoAlert #evera @myESMO -
Sherene Loi, MD
@LoiSher
Bravo @etop_ibcsg 👏👏
#positive @fredrophd
Those who had a child even did numerically better than the control
#esmo25 #esmoambassadors #bcsm
Philippe Aftimos, MD
@aftimosp
“We made it!”
@fedrophd presenting the updated results of POSITIVE.
After 71 months of median follow-up, temporary interruption of ET for pregnancy was not associated with worse BC outcomes.
Super news for patients! 👏 groups & investigators for this academic effort.
#esmo25 -
Sherene Loi, MD reposted
Matteo Lambertini, MD PhD
@matteolambe
Just presented at #esmo25 by super @fedrophd updated data of the #positive trial showing reassuring evidence to support temporary interruption of endocrine therapy to have a #pregnancy in patients with prior history of low/intermediate risk #breastcancer
@OncoAlert @etop_ibcsg -
Sherene Loi, MD
@LoiSher
NATALEE concurrent publication
#esmo25 #esmoambassadors
@OncoAlert @myESMO
www.sciencedirect.com/science/article/pii/S2059702925017272 -
Sherene Loi, MD
@LoiSher
🤔Anyone got a headache yet trying to make sense of this ? 🤯 @OncoAlert
Erika Hamilton, MD, FASCO
@ErikaHamilton9
Now for the fun - we are likely to have multiple options in 1L HER-2+ #bcsm.
1L THP->TH + tucatinib (HER2CLIMB-05)
1L THP->TH + AI + palbo (PATINA)
1L TDX-d->+/- maintenance? (DB-09)
Desire for maintenance strategy I think remains high (efficacy, QOL, tolerability)! -
Sherene Loi, MD
@LoiSher
#esmo25 🗞️🔦❗️DB-11: interesting that pCR ⬆️ 11% to 67%, 🤔 IMO not that impressive to what we've seen before- but ⏬⏬ less cardiac tox 👏- pity the comparator wasn't TCHP - let's wait to see pCR rates by ER status & HER2+ 2 vs +3 IHC. EFS however looks VERY interesting at 0.56 (immature)- will be interesting to compare to DB-05. #her2 #bcsm
@OncoAlert #esmoambassadors
Paolo Tarantino
@PTarantinoMD
DB-11 abstract just released. In high-risk (≥T3, N+, or IBC) HER2+ eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% vs 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 vs 9%) and low rate of ILD (4.4 vs 5.1%). The last nail in the coffin for anthracyclines.
-
Sherene Loi, MD
@LoiSher
Exciting to see all these #ctdna abstracts at #esmo25 - 🤔how sensitive the next generation assays are & ❓clinical utility.
#esmoambassadors
Also looks out for ➡️LBA64 ✔️➡️Sat 10.15 on early detection of cancer using liquid 🩸😳
Roberto Borea, MD
@RobertoBoreaMD
#esmo25 is approaching!
Here’s a list of some of the most important abstracts that will be presented
Don’t miss them ⏲️
The @isliquidbiopsy Young Committee is gearing up to prepare an editorial on the latest data📰
📻Stay tuned for this important event!
@jlb_islb -
Sherene Loi, MD
@LoiSher
😎if #til had been the prespecified biomarker, pembrolizumab might well be approved for this indication. PD-L1 IHC has real technical limitations- patients deserve multiple validated ways to identified immune enriched tumors. #tils are simple, free & readily available- wait 🤔is that the problem? @oncoalert @TILsWorkGroup #bcsm
Open Medicine Insights
@OpenMedInsights
💫🌟Association of potential biomarkers with clinical outcomes in metastatic TNBC treated with pembrolizumab or chemotherapy
👉 www.nature.com/articles/s41523-025-00814-y?s=08
@JavierCortesMD @ProfAnthoG @ASCOPres @Prof_Nadia_H @LoiSher
🧬 KEYNOTE-119 exploratory biomarker analysis
🔹 TILs ≥5% → ↑ ORR, PFS, OS with pembrolizumab (not chemo)
🔹 T-cell–inflamed GEP → predictive of better ORR, PFS, OS
🔹 TMB ≥10 mut/Mb → trend toward longer OS
🔹 BRCA/HRD → no predictive association
🔹 TILs + GEP show independent predictive value → immune-inflamed tumors benefit most
🧠 Clinical insight: Immune-active biomarkers (TILs, TcellinfGEP, TMB) identify TNBC subsets deriving durable benefit from pembrolizumab.
@myESMO @OncoAlert @ASCO @NatureCancer @BreastCancerRes
#tnbc #breastcancer #immunotherapy #keynote119 #pdl1 #biomarkers #oncotwitter -
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Very excited to see the biennial St Gallen guidance for treatment of early breast cancer published in @Annals_Oncology
Up to date, readable, practical, multidisciplinary, global.
And available to all without paywall.
www.annalsofoncology.org/article/S0923-7534(25)04718-0/fu… -
Sherene Loi, MD reposted
Serena Nik-Zainal
@SerenaNikZainal
And a really great commentary on our paper by @LoiSher & Peter Savas on our paper 🙏
www.sciencedirect.com/science/article/abs/pii/S1470204525…
Serena Nik-Zainal
@SerenaNikZainal
PAPER OUT!! 🥳🥳🥳
Clinical potential of WGS data linked to mortality statistics in patients with breast cancer in England
#shout out to #daniellablack @GenomicsEngland
And all the patients that shared samples across @NHS
1/n www.sciencedirect.com/science/article/pii/S1470204525004000 -
Sherene Loi, MD
@LoiSher
Why Are More Young People Getting Cancer? www.nytimes.com/2025/10/01/well/cancer-young-people.html via @NYTimes
@OncoAlert @PeterMacCC @PeterMacRes @CancerGrand
#breastcancer @NYTScience @nytimes -
Sherene Loi, MD
@LoiSher
➡️New from #loilab
🚩🚩Our new study shows higher baseline tumour burden predicts poorer outcomes on #immunotherapy in metastatic #breastcancer.
🚩Why this matters: maybe surveillance post early #tnbc is now ready for prime time- if ultrasensitive ctDNA can detect relapse months before imaging, we can treat at low volume, when ICI may work better. #ctdna #liquidbiopsy #breastcancerawareness
👏👏👏congrats @J_DixonDouglas 🤩
@PeterMacRes @PeterMacCC @oncoalert #bcsm
www.thebreastonline.com/article/S0960-9776(25)00603-4/ful… -
Sherene Loi, MD
@LoiSher
📰🔦 T-DXd: A New Hope becomes the New World Order in HER2+ BC. #esmo25 #her2 🤩3 big read outs for T-Dxd in #breastcancer
Where will we place T-Dxd preferentially if avail. and all data looks good?
1) residual disease vs 2) 1L metastatic vs 3) neoadjuvant with TCHP 🚩vote (pre ESMO)
Paolo Tarantino
@PTarantinoMD
After improving OS for patients with metastatic disease, the topo1 ADC wave is now reaching its most ambitious goal: preventing recurrence.
DB-05 is positive: adjuvant T-DXd improves iDFS over T-DM1
No info on ILD in the press release. Hoping for no G5.
www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-…
Sherene Loi, MD
@LoiSher
vote: Where will we place T-Dxd preferentially if avail. and all data looks good?
-
Sherene Loi, MD reposted
Toni Choueiri, MD
@DrChoueiri
Wait, whaaaaaaaaaat????
It is confirmed. DESTINY-Breast05 will be at #esmo25 !
LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2+ Breast Cancer with residual invasive disease after neoadjuvant therapy
Presenter: Charles Geyer (@upmc)
Sat 18.10.2025, Berlin Auditorium, 17:04 - 17:14
@MyriamChalabi @curijoey @AndresC27622123 @FAndreMD @myESMO
Toni Choueiri, MD
@DrChoueiri
The #esmo25 Presidential are out--check them:
@FAndreMD @MyriamChalabi @myESMO -
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
Five plenary ADC presentations & multiple additional practice-changing ADC trials to be presented at #esmo25. A clear message: the ADC wave has just started rising. For a critical review of the hottest field in oncology, don’t miss our educational ADC session on Sunday Oct 19 🎯
-
Sherene Loi, MD
@LoiSher
😷📰🔦NEWS: Imlunestrant joins Elacestrant (oral SERDs) for treatment of HR+/HER2- ESR1mt breast cancer post ≥1L prior ET+CDK4. Is monotherapy really a good option? #bcsm @OncoAlert
Eli Lilly and Company
@EliLillyandCo
The @US_FDA approved a new oral therapy for people living with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), estrogen receptor 1-mutated (ESR1m) #metastaticbreastcancer.
Learn more: e.lilly/3W6MBZl -
Sherene Loi, MD
@LoiSher
🚩🚩important to see that the Ribo benefit continues now that all patients have completed the 3yrs of treatment.
Interestingly, the lower risk patients have similar absolute benefit. There will be an OS update at #esmo25 presented with the MonarchE OS data-- apparently now significant- given the OS curves were the overlapping at last reporting both studies should be very interesting viewing! #bcsm
Open Medicine Insights
@OpenMedInsights
🚨 JAMA Oncology NATALEE 4-Year Update
Adjuvant Ribociclib + NSAI in HR+/HER2- early breast cancer
@dradityabardia @LoiSher
🔵 5,101 pts randomized → Ribociclib (400 mg, 3y) + NSAI vs NSAI alone
🟢 4-y iDFS: 88.5% vs 83.6% → HR 0.72 (28.5% ↓ risk of recurrence)
🟡 Absolute benefit ↑ from 2.7% at 3y → 4.9% at 4y
🟣 Benefit consistent across subgroups (stage II/III, N0 & node+)
🔴 Majority of recurrences were distant; ribociclib cut risk by ~30%
🟠 Safety: no new signals; most common AEs = neutropenia, LFT ↑, QT prolongation
🟡 OS data immature but trending favorable (HR 0.83)
🔗 jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
@OncoAlert @ASCO @myESMO @breastcancerorg @theNCI
@DrSLoi @GabrielhortonS1
#breastcancer #oncotwitter #cdk46 #natalee #jamaoncology -
Sherene Loi, MD
@LoiSher
🍾 finally a win for @Roche @genentech who have been very quiet in #breastcancer in recent yrs🤔. An all-oral option post CDK4, apparently broader efficacy than ESR1mt. Look fwd to seeing the data at ?#esmo25 Other Giredestrant trial readouts expected soon. The oral SERD race is heating up! #bcsm @OncoAlert
Paolo Tarantino
@PTarantinoMD
Positive results from the phase 3 evERA trial: we may finally have an oral SERD + everolimus combination available for the 2nd line treatment of HR+/HER2- MBC. Full extent of benefit in ESR1m vs ITT to be determined. www.roche.com/media/releases/med-cor-2025-09-22
-
Sherene Loi, MD
@LoiSher
We were privileged today @PeterMacRes @PeterMacCC to have a special guest #takmak from @pmcancercentre ➡️discoverer of #ctla function; cloned #tcr with @paulbeavis4 @IanParish_AU “we can only see further by standing on the shoulders of giants”. 🪜
-
Sherene Loi, MD
@LoiSher
➡️ nice POC 👏 study but caveats: 1. this ctDNA test is not commercially available & has low sensitivity>=10% tumor fraction. Therefore this is test is really reading out tumor burden (& not mutations such as ESR1 ) 2. no OS data 3. no comparison to other cheaper markers CA153, LDH, 4. ctDNA analysis was only done in 39% of ITT. 5. no independent validation. This limits understanding of who these patients who benefited actually were. @OncoAlert #bcsm #breastcancer
Paolo Tarantino
@PTarantinoMD
ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. www.nature.com/articles/s41591-025-03935-w
-
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Interesting news re: abemaciclib in MonarchE trial. At 5 years, the OS data in @JCO_ASCO was NS with HR 0.9.
Sara Tolaney
@stolaney1
Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients!
www.prnewswire.com/news-releases/lillys-verzenio-abemacic… -
Sherene Loi, MD
@LoiSher
Wow 🤩 #bcsm
Look fwd to seeing the data as well as for 5yr data for NATALEE #esmo25
Sara Tolaney
@stolaney1
Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients!
www.prnewswire.com/news-releases/lillys-verzenio-abemacic… -
Sherene Loi, MD
@LoiSher
Wow 🤩👏👏👏🙌🎯
the future of adjuvant therapy written in blood? 🩸 @NateraGenetics @OncoAlert #ctdna congrats @tompowles1
Toni Choueiri, MD
@DrChoueiri
JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers!
@NateraGenetics @tompowles1 @Roche
www.natera.com/company/news/imvigor011-bladder-cancer-tri… -
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
It has been a big year for long-term follow up of adjuvant endocrine Rx in breast cancer.
1. Extended therapy. Overview shows AI treatment 5 -> 10 years lowers recurrence and distant recurrence. Esp in N+ and patients given tamoxifen in years 0-5.
www.thelancet.com/journals/lancet/article/PIIS0140-6736(2… -
Sherene Loi, MD
@LoiSher
📌 Just a shout-out that the Peter Mac Breast Cancer Education day is on again @PeterMacCC THURSDAY 30th OCTOBER 10-5.30pm. With special guest 🤩Prof @hoperugo from City of Hope CA. This year we will include speakers to give updates on Surgery and Rad Onc with MDM case panels. Hope to see you there on site or on zoom. Thanks to our sponsors.
REGISTER HERE: www.eventbrite.com/e/2025-peter-mac-breast-cancer-medical… -
Sherene Loi, MD reposted
Raj Gauba
@raj_gauba
Excellent updates in the afternoon sessions @AnthonyMJoshua @DKarikios @DrAbhiPal @JiaJennyLiu @anmwongNZ @Robbotommo @LoiSher @TommyJohn00 @drprunellab @MOGA_ORG
Raj Gauba
@raj_gauba
Looking forward to the panel discussion @IshwariaMD @MOGA_ORG @JiaJennyLiu @DKarikios
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
Delighted to welcome Minister @DannyPearsonMP & @BioNTech_Group's David Sparling to Peter Mac for the launch of the new Clinical Trial Oncology Platform.
Together with @Austin_Health , @AlfredHealth & @MonashHealth, we’re expanding access to next-gen cancer treatments.This media couldn't be displayed. See it on the original post. -
Sherene Loi, MD
@LoiSher
⛳️important new data for #bcsm 👏👏👏 on #pregnancy & #breastfeeding feeding after breast cancer @JCO_ASCO
Congrats to all involved, @etop_ibcsg for running this trial, completely funded by philantropy thanks to @BIGxResearch #positive trial @BCTrials
Luca Arecco, MD
@Lucarecco
Published new evidence from #positive (@JCO_ASCO) and #brcabcy (@JNCI_Now) on #breastfeeding after BC:
- ~65% of women breastfed
- Breast-conserving surgery improves feasibility
- No negative impact on prognosis, even in young #brca carriers
@OncoAlert @matteolambe @BlondeauxEva -
Sherene Loi, MD
@LoiSher
Well deserved 👏👏👏👏
ETOP IBCSG Partners Foundation
@etop_ibcsg
The 2025 ESMO Lifetime Achievement Award will be presented to Rolf A. Stahel at the ESMO 2025 Opening Ceremony. Rolf Stahel is President of our ETOP IBCSG Partners Foundation and a leading figure in thoracic oncology and cancer research.
www.esmo.org/about-esmo/awards/esmo-lifetime-achievement-… -
Sherene Loi, MD reposted
OncoAlert
@OncoAlert
The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week July 25-31, 2025
👉REGISTER at www.oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registr…
Discussing:
✅Biomarkers🧬of response and resistance to immune checkpoint inhibitors in #breastcancer by @LoiSher
✅POETIC Trial in Breast #cancer
✅Metabolic adaptations of brain metastasis 🧠
✅ Post Hoc Validation of Platinum Ineligibility in #nsclc From the Phase III IPSOS Study🫁
✅Real-World Outcomes in BRAF-Mutant Non-small Cell #lungcancer 🫁🇹🇷
✅ GENERATE Trial Metastatic or Recurrent #pancreaticcancer
✅Total Neoadj Therapy for Locally Adv. #rectalcancer
✅ Enhancing Outcomes in mCR #prostatecancer : The Impact of ARI Sequencing Before 177Lu-PSMA-617 🇹🇷 @DrYukselUrun @yekeduz_emre
✅The hidden economic burden of cancer caring out in @JournalCancer
@michelle_li
@ilyassahinMD
@onder_haka2124
@CMTLab_IISERBPR
@MalladiLab
@AriellaHanker
@shashankaiims
@DrJNaidoo
@ProfSiowMingLee
@alan_ozkan
@DrHuseyinAbali
@BijoyTelivala
@tuttsakhil
@adelapoite
@SyedAAhmad5
@DrYukselUrun
@matteolambe @Icro_Meattini @PGrivasMDPhD @cdanicas @BenWestphalen @CathyEngMD
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahuaThis media couldn't be displayed. See it on the original post. -
Sherene Loi, MD
@LoiSher
🚨interesting article in @Nature- congrats Degregori lab @CUAnschutz on IL-6 mediated pro-cancer effects related to flu and covid.
human data was pre-Covid vacccine. Also acute viral illness ⬆️⬆️ IFN-I which is anti-tumor?
doi.org/10.1038/s41586-025-09332-0 -
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
Results from VIKTORIA-1 just announced by @celcuity. The addition of gedatolisib to 2L fulvestrant/palbo improved PFS from 2 to 9.3 months (HR 0.24). Also the fulvestrant/gedatolisib combo improved PFS vs fulv mono (7.4 vs 2 mo, HR 0.33). Quite promising. www.morningstar.com/news/globe-newswire/9501173/celcuity-…
-
Sherene Loi, MD
@LoiSher
🏁latest review from #loilab & our Spanish colleagues #vhio #bcsm @OncoAlert @TILsWorkGroup Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer www.thebreastonline.com/article/S0960-9776(25)00562-4/ful…
-
Sherene Loi, MD reposted
Kazuki Nozawa, MD
@kazuki_nozawa
Excited to share our latest publication from the EN-SEMBLE study in ESMO Open! @ESMO_Open Post-T-DXd therapy is a major unmet need in HER2+ mBC. This large, real-world study provides insights into treatment patterns, outcomes, and the risk of ILD. 👉 doi.org/10.1016/j.esmoop.2025.105511
-
Sherene Loi, MD
@LoiSher
#bcsm 💊💉we really need more efficacious drugs!
OncoAlert
@OncoAlert
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial
idp.springer.com/transit?redirect_uri=https%3A%2F%2Flink.…
The NAME trial, a randomized phase II study, compared metronomic (daily low-dose) oral Vinorelbine with conventional scheduling (days 1 and 8 every three weeks) in 163 patients with metastatic #breastcancer . Conducted across Denmark 🇩🇰 between 2017 and 2022, the trial found no significant differences in efficacy or safety between the two approaches. Median progression-free survival was 3.9 months in the standard arm versus 2.3 months in the metronomic arm, and overall survival was 16.6 vs. 15.1 months, respectively. Both regimens were well tolerated, leading to the conclusion that metronomic Vinorelbine offers no clinical advantage over the conventional schedule.
Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets
#oncoalertaf
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua -
Sherene Loi, MD reposted
Yüksel Ürün
@DrYukselUrun
(Breast) Cancer care shouldn’t be a luxury.
We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many.
Innovation must reach every patient, everywhere!
@Nature @curijoey @LoiSher @myESMO @ASCO @BreastCancerNow @tmprowell @uicc -
Sherene Loi, MD
@LoiSher
🏃♀️🏋️🏋️♂️🎾👟Further evidence on the benefit of physical activity #exercise #strength training for chronic medical conditions from a RCT
rdcu.be/evps3
@NatureMedicine -
Sherene Loi, MD reposted
Kazuki Nozawa, MD
@kazuki_nozawa
JCOG1017 trial found that primary tumor resection (PTR) did not prolong overall survival in de novo Stage IV breast cancer. However, it improved local control and might benefit subsets like premenopausal patients or those with single-organ metastasis. @JGbreast @TADSHIEN
-
Sherene Loi, MD reposted
Shruti Patel, MD
@ShrutiPatelMD
“Who decides who decides?”
An editorial based on @rebeccampbell50 & @LauraBukavinaMD’s work in which we explore how altmetrics & digital clout are shaped by systemic bias.
Honored to cowrite this with @DrSGraff
🔗 ascopubs.org/doi/10.1200/OP-25-00283
#medtwitter #womeninmedicine -
Sherene Loi, MD
@LoiSher
😂🤩 @andy_murray
Tennis TV
@TennisTV
Andy Murray giving life advice to random fans is as good as you imagine it would be 🤣
Agony Andy at your service 🫡
#hsbcchampionships @andy_murrayThis media couldn't be displayed. See it on the original post. -
Sherene Loi, MD
@LoiSher
Given recent amazing results from Rand P3 study by Zheng et al, #asco25 on Chrono-IO (PD-1 before 3 pm vs after; HR 0.42), #circadian clocks are topical- but is it fit-patient bias? Broad aspirational review below from @NatureCancer @OncoAlert
⭐️also many new drugs have PK/PD longer than 24hrs...
www.nature.com/articles/s43018-025-00981-8 -
Sherene Loi, MD
@LoiSher
⭐️This study reinforces that treating upfront with the strongest targeted 🎯 combination will alter the natural history of disease & ⬆️ OS. We've seen it for #her2 Better pharmacology has & will improve tolerabilty, AE profile & 🔽discontinuations @NEJM #bcsm #breastcancer
NEJM
@NEJM
In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. Full INAVO120 trial results: www.nejm.org/doi/full/10.1056/NEJMoa2501796
#asco25 | @ASCO -
Sherene Loi, MD
@LoiSher
🚩Final results of IMpassion031👏neoadj Atezo in early #tnbc Final EFS HR~ Gepardouze. ctDNA neg by Signatera not sensitive enough to say patients are cured but small % who were pos did poorly. Hopefully next gen ctDNA assays will be better. #bcsm @NatureMedicine
-
Sherene Loi, MD reposted
Elvina Almuradova
@Dr_ElvinaA
Keynote by Sherene Loi at #esmobreast25
🔹 Pregnancy & breastfeeding may reprogram the breast immune environment, enhancing early cancer detection.
🔹 HR+ breast cancer may respond to immunotherapy if biologically selected (CheckMate 7FL).
@myESMO @OncoAlert @oncodaily -
Sherene Loi, MD
@LoiSher
informative censoring vs ITT analyses.-a problem for all studies of exercise in cancer patients I suspect
Timothée Olivier, MD
@Timothee_MD
-
Sherene Loi, MD reposted
John Mandrola, MD
@drjohnm
Good morning all. After yesterday's excitement about the CHALLENGE exercise trial, here is my critical appraisal on @Sensible__Med #asco25
-
Sherene Loi, MD
@LoiSher
👏👏amazing 40m med PFS with TDXD+P v 20m THP. If 2L TDXD (DB03) is 28m PFS v 6m TDM1, does the maths favour 1L THP➡️2L TDXD? +add Palbo? Esp as 1L TDXD may make 2L TDM1 less effective (down reg HER2). Potentially 1L DB09 may ⬆️ CNS control. Def need OS - are some patients cured by 1L DB09?#asco25
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
Impressive 40.7 months mPFS with TDXd and pertuzumab! This may represents a new SOC as 1st line therapy for patients with HER2 positive MBC @stolaney1 @AstraZeneca @DaiichiSankyoUS @OncoAlert
-
Sherene Loi, MD reposted
Matteo Lambertini, MD PhD
@matteolambe
Oral abstract session at #asco25 with 15-y follow-up data from @etop_ibcsg SOFT & TEXT trials…proper risk stratification is needed to optimize adjuvant endocrine therapy in premenopausal women with #breastcancer @OncoAlert
-
Sherene Loi, MD
@LoiSher
bravo #asco25 👏👏👏👏
NEJM
@NEJM
Presented at #asco25:
In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results: www.nejm.org/doi/full/10.1056/NEJMoa2415566
Editorial: Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option www.nejm.org/doi/full/10.1056/NEJMe2506475
@ASCO -
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Important to note that in the randomized trial showing equivalence of TCHP and THP that patients got 18 weeks of therapy with THP (not the more common 12 weeks) which might account for both higher pCR rates and lack of need for carboplatin.
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks.
@ASCO #asco25 @OncoAlert -
Sherene Loi, MD
@LoiSher
ASCENT-04- first randomized phase III study of ADC+ IO. #asco25. nice to see immune AEs so low in SG arm. 🤔Effect of targeted 🚩tumor death vs chemo non specific normal tissue tox?
Yakup Ergün
@dr_yakupergun
Two First-Line ADC Trials in mTNBC #asco25
-
Sherene Loi, MD
@LoiSher
Wow 🤩 hard to believe - recruitment > 15yrs, also 🤔does all that extra contact also affect other healthy behaviours? Is there a MET dose response effect? #asco25 even though I am a big 🏃🎾🚴fan - this is a complex area
Paolo Tarantino
@PTarantinoMD
The most impressive data of the day:
-
Sherene Loi, MD reposted
-
Sherene Loi, MD
@LoiSher
Here we need PFS2- changing to Cami vs an ineffective therapy for ESRmt is obvious- the qu is do the control arm do the worse/same if they change later #asco25
Paolo Tarantino
@PTarantinoMD
SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts on 1L treatment for a median of 6.9 mo longer. What it does not show (yet): that this strategy improves long term outcomes. @NEJM pub: www.nejm.org/doi/full/10.1056/NEJMoa2502929
-
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts on 1L treatment for a median of 6.9 mo longer. What it does not show (yet): that this strategy improves long term outcomes. @NEJM pub: www.nejm.org/doi/full/10.1056/NEJMoa2502929
-
Sherene Loi, MD reposted
Sally Church
@MaverickNY
10 key lessons learned on breast cancer and immunotherapy from @LoiSher's excellent keynote at #esmobreast25
biotechstrategyblog.com/2025/05/10-lessons-learned-from-d… -
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
Time to cast tour vote for the @myESMO elections.
Happy to support @LizzySmyth1 as director of education!
And for the Nomination Committee, full support to @LoiSher, @hoperugo, Pasi Jänne & Nicoletta Colombo
Vote here: www.esmo.org/about-esmo/how-we-work/esmo-elections
Lizzy Smyth
@LizzySmyth1
📢It's #esmo election time!
I am delighted to be nominated for ESMO Director of Education 😊
ALL the nominees are fantastic representing the global @myESMO community 🌍
🙏for all the good wishes
Rules this year for social media so that's it from me!
Now please vote 🗳️ -
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
#esmomembers vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee
📽️ Watch the ESMO President’s message
🔗 Vote now: www.esmo.org/about-esmo/how-we-work/esmo-elections
@FAndreMD -
Sherene Loi, MD
@LoiSher
Thank you 🙏 for listening @MaverickNY
Sally Church
@MaverickNY
10 key lessons learned on breast cancer and immunotherapy from @LoiSher's excellent keynote at #esmobreast25
biotechstrategyblog.com/2025/05/10-lessons-learned-from-d… -
Sherene Loi, MD reposted
Abi Siva MD
@AbiSivaMD
Hypothesis generating findings from the DIAMOND study presented by @LoiSher at#ESMOBreast25.
?is there role for IO in Her2+ mBCA? -
Sherene Loi, MD reposted
Elvina Almuradova
@Dr_ElvinaA
Relapse risk persists even after pathological complete response (pCR) in TNBC.
Low baseline TILs <30% + nodal involvement = worse 5-year DRFS (82.6%) & OS (84.3%)
Compared to TILs ≥30% & node-negative: DRFS 97.8%, OS 99.1%
#esmobreast25 #breastcancer #oncology @myESMO @Larvol -
Sherene Loi, MD
@LoiSher
🎈news day for #her2 pos #breastcancer. Will look fwd to seeing the HR and comparable toxicity profiles www.astrazeneca.com/media-centre/press-releases/2025/enhe…
-
Sherene Loi, MD reposted
The ASCO Post
@ASCOPost
Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer?
A phase II study led by @LoiSher explores this critical question.
Read more: ascopost.com/news/march-2025/triple-negative-breast-cance…
#triplenegativebreastcancer #immunotherapy -
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
What duration of immunotherapy is enough for treating TNBC?
@LoiSher reviews the data and provides her opinions.
Important to remember that IO duration matters for irAEs rate (sometimes permanent), whereas its impact on therapy efficacy is not always clear.
#sgbcc2025 -
Sherene Loi, MD
@LoiSher
Amazing consensus panel - world class MDM for #breastcancer decision making, lots of great discussion #sgbcc2025 @SG_BCC fanatstic panel chairing by @DrHBurstein @curijoey @MichaelGnant
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
That’s a wrap, @SG_BCC
Thanks for having me #sgbcc2025 — see you for #sgbcc2027 -
Sherene Loi, MD
@LoiSher
super fun to do the Poster session wtih the awardees #sgbcc2025 👏👏👏👏 congratulations for some great research!
SGBCC
@SG_BCC
Poster Awards 🏆
Yesterday, the 7 best abstracts of #sgbcc2025 were recognized and today the awardees were able to present their work during dedicated oral presentations at the e-poster terminals. Congratulations!
#breastcancerresearch #fromresearchtopractice #posterawards -
Sherene Loi, MD reposted
SGBCC
@SG_BCC
Thank you for being part of our panel!
-
Sherene Loi, MD reposted
Matteo Lambertini, MD PhD
@matteolambe
How lucky I am to be at the #sgbcc2025 expert consensus panel next to @LoiSher and @lab_kok 🤩
@SG_BCC @OncoAlert @MichaelGnant @curijoey @DrHBurstein @UniGenova @SanMartino_Ge -
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #sgbcc2025
-
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
Nick Turner reviews liquid biopsy technologies for eBC. Important to carefully select the assay (avoid genotyping assays or CTCs), utilize highly sensitive assays and realize the challenges with each technology. #sgbcc2025
-
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #sgbcc2025
-
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
Finally 😅
Missed the opening session, but excited to hear @LoiSher & company discuss the utility of liquid biopsy in Early Breast Cancer. #sgbcc2025 -
Sherene Loi, MD reposted
Breast Cancer Trials
@BCTrialsANZ
The first publication of the Neo-N trial has been published in The Lancet Oncology.
Congratulations to Professor @LoiSher, who led the study, all participating institutions and our trial participants.
Find out more: authors.elsevier.com/c/1kiL65EIIgPf2N -
Sherene Loi, MD reposted
Kazuki Nozawa, MD
@kazuki_nozawa
Very thoughtful #neon trial published by @LoiSher
Despite the high pCR rate, the window-of-opportunity randomized clinical trial did not show that lead-in nivolumab before chemotherapy was associated with pCR. Further data are warranted. @TheLancetOncol www.sciencedirect.com/science/article/abs/pii/S1470204524… -
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
📢 Announcing 7 new #cancergrandchallenges 📢
We're thrilled to announce 7 new challenges, now open for Expressions of Interest from global, interdisciplinary teams. Awards of up to £20m ($25m) are available.
Discover the new challenges: www.cancergrandchallenges.org/new-challenges -
Sherene Loi, MD
@LoiSher
🎈 pleased to share our latest on HER2–Low, HR–Pos Early #breastcancer From the BIG 1-98 & SOFT Clinical Trials | @JCOPO_ASCO #bcsm @OncoAlert
ascopubs.org/doi/10.1200/PO-24-00599 -
Sherene Loi, MD
@LoiSher
CM7FL- excited to share our results & biomarker insights from the trial now published @NatureMedicine
rdcu.be/d8ejp
#breastcancer #immunotherapy @OncoAlert
Sherene Loi, MD
@LoiSher
Our findings revealed that addition of the Nivo led to a significant improvement in PCR
Post not available here, view on X
Sherene Loi, MD
@LoiSher
PDL1 positive tumors also had higher PCR from Nivo. These two biomarkers were not 100% concordant showing that both can have value in identifying responding patients.
Sherene Loi, MD
@LoiSher
Finally, these findings along with KN756 will change the way we think about HR positive #breastcancer & T cell immune surveillance in BC
Sherene Loi, MD
@LoiSher
A huge thank you to all the trial teams globally, patients & the families, BMS, and my fellow steering committee members
-
Sherene Loi, MD
@LoiSher
A new subset of HR+ #breastcancer with #til present can respond to #nivolumab & chemo
➡️ rdcu.be/d65wu
@PeterMacCC @OncoAlert #bcsm
Peter Mac Cancer Centre
@PeterMacCC
A Peter Mac international clinical trial led by @LoiSher has shown adding #immunotherapy drug nivolumab + chemo before surgery can dramatically improve #breastcancer cure rates.
On the front page of today's @theheraldsun or more here: www.petermac.org/about-us/news-and-events/news/details/ne… -
Sherene Loi, MD
@LoiSher
👏👏👏congrats @IlanaSchlam
Ilana Schlam
@IlanaSchlam
Hot off the press “Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges”
@SandraSwainMD @LoiSher and Roberto Salgado @DFCI_BreastOnc
www.sciencedirect.com/science/article/pii/S205970292401891X -
Sherene Loi, MD
@LoiSher
Looking fwd to the joint annual meeting of 🇯🇵 #jcog #kbcs 🇰🇷#tibcs 🇹🇼 and @BCTrialsANZ 🇦🇺 in #nagoya #breastcancer trials
-
Sherene Loi, MD
@LoiSher
Hanging out in #nagoya #japan talking #immunotherapy in #breastcancer @hiromiwasan
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
We are incredibly proud to announce that five Peter Mac researchers have been named in @Clarivate's top 1% most cited researchers worldwide for 2024.
Read more: www.petermac.org/about-us/news-and-events/news/details/pe… -
Sherene Loi, MD reposted
Science Magazine
@ScienceMagazine
Scientists have identified how the redox sensor #keap1 promotes antiviral T cell activation and stem-like T cell responses during chronic viral infections in mice.
Read more in @SciImmunology: scim.ag/3ZhenU8 -
Sherene Loi, MD
@LoiSher
#tils @TILsWorkGroup
10 yrs! 👏👏
OncoAlert
@OncoAlert
The #oncoalerttoptweet Day TWO #sabcs24
Post by @OncoAlert 🚨Faculty @TanjaSpanic 🇸🇮
10 years later: TILs and lessons learned by Roberto Salgado. My personal take off: there are always more TILs than PDL1 😎
@lab_kok
@matteolambe 🇮🇹
@ErikaHamilton9 🇺🇸
@hoperugo 🇺🇸
@JaniceTNBCmets 🇺🇸
@DrSGraff 🇺🇸
@maryam_lustberg 🇺🇸
@double_whammied 🇺🇸
@Prof_Nadia_H 🇩🇪
@JavierCortesMD 🇪🇸
@raalbany 🇺🇸
@itsnot_pink 🇺🇸
@ElisaAgostinett 🇧🇪
@coffeemommy 🇺🇸
@christeeny513 🇺🇸
@MammaMiaMagazin 🇩🇪
@Icro_Meattini 🇮🇹
@itrisabel 🇪🇸
@E_de_Azambuja 🇧🇪
@aftimosp 🇧🇪
@TanjaSpanic 🇸🇮
@stolaney1 🇺🇸
@curijoey 🇮🇹
@kevinpunie 🇧🇪
@to_be_elizabeth 🇮🇹
@Lucarecco 🇮🇹
@FernandoOnco 🇧🇷
@stage4kelly 🇺🇸
@acampsmalea 🇫🇷
@jamecancerdoc 🇺🇸
@LoiSher 🇦🇺 -
Sherene Loi, MD reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Roberto Salgado, Justin Balko, and Priyanka Sharma (who joined virtually) explored "The Winding Road of Immune Biomarkers in Early Breast Cancer" in a State of the Art Session moderated by Sherene Loi.
#sabcs24 @BalkoLab @psharmalab @LoiSher -
Sherene Loi, MD reposted
OncoDaily
@oncodaily
Long-Term affects of Adjuvant Breast Cancer Treatment on Lymphocyte Counts - @LoiSher
oncodaily.com/blog/sherene-loi-176710
#cancer #oncodaily #oncology #radiotherapy #meded #medx #mednews #medicine -
Sherene Loi, MD
@LoiSher
🚩 Sharing our latest article: Here we show that dose dense AC-T, radiotherapy & age affects long-term lymphocyte counts post adjuvant #breastcancer treatment ?implications for IO therapy
www.nature.com/articles/s41523-024-00698-4
👏 @J_DixonDouglas @GustaveRoussy @PeterMacRes @BCRFcure -
Sherene Loi, MD
@LoiSher
congrats @StoverLab fantastic collboration with all involved- lets do it again soon #til @TILsWorkGroup -- cure #metastaticbreastcancer faster #bcsm
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
New📰| Association between #tumorinfiltratinglymphocytes and survival in patients with #metastaticbreastcancer receiving first-line chemotherapy: Analysis of CALGB 40502 from the @StoverLab @elmayermd @AnnPartridgeMD @LoiSher et al.
🔓Read it here:
pubmed.ncbi.nlm.nih.gov/39169033/ #tils -
Sherene Loi, MD reposted
Sherene Loi, MD
@LoiSher
join us at @PeterMacCC #melbourne, #australia for the 2nd annual #breastcancer #medicaloncology #education day Friday Oct 11th onsite or virtual. hope to see you all theere!
-
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
A beautifully crafted review “Towards targeting the breast cancer immune microenvironment” in @NatureRevCancer by @LoiSher et al not only closes a gap in our up to date understanding of immune microenvironment, but is graphically 🔝
Bravo. Required read.
www.nature.com/articles/s41568-024-00714-6 -
Sherene Loi, MD
@LoiSher
join us at @PeterMacCC #melbourne, #australia for the 2nd annual #breastcancer #medicaloncology #education day Friday Oct 11th onsite or virtual. hope to see you all theere!
-
Sherene Loi, MD
@LoiSher
Vale Shannon Doherty
#cure #metastatic #breastcancer
Libby Emmons
@libbyemmons
BREAKING: Shannen Doherty dies at 53 from breast cancer
thepostmillennial.com/breaking-shannen-doherty-dies-at-53… -
Sherene Loi, MD
@LoiSher
Our latest review is out now on targeting #breastcancer #immunity #tme #trm #cancerresearch many thanks to @NatureRevCancer
@PeterMacCC @PeterMacRes @TILsWorkGroup
Nature Reviews Cancer
@NatureRevCancer
Towards targeting the breast cancer immune microenvironment idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
-
Sherene Loi, MD reposted
Elisabetta Bonzano MD, PhD
@to_be_elizabeth
📌 Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Great talk by @LoiSher @OncoAlert #asco24 #breastcancer
✔️the largest study
➡️8% positive for ctDNA at baseline
➡️ ctDNA detection was highly prognostic of worse outcomes, particularly for patients who were persistently positive -
Sherene Loi, MD reposted
Sara Tolaney
@stolaney1
DESTINY Breast07: TDXd or TDXd +P in 1L MBC
~60% de novo
Of recurrent pts, ~50-60% H, 10-15% prior P
median f/u ~24-25 mo
TDXd, n75, ORR 76%
TDXd + P, n=50, ORR 84%
PFS at 12 mo: 89% TDXd +P , 80% TDXd
9-14% ILD, no g5 ILD events
@FAndreMD #asco24 @OncoAlert -
Sherene Loi, MD reposted
Sara Tolaney
@stolaney1
Data from ISPY2.2 demonstrated 32% of pts were able to skip chemo and go to surgery after 4 cycles of Dato-DXd, but did not meet the threshold to graduate
@jane_meisel #asco24 @OncoAlert #bcsm -
Sherene Loi, MD reposted
Nancy Lin, MD
@nlinmd
TBCRC 049: Tucatinib, trastuzumab, capecitabine for HER2+ LMD
-The first prospective LMD trial to show all of the following:
-therapeutic drug levels in CSF
-intracranial response
-improvement in symptoms and QoL
-extended OS compared to historical controls -
Sherene Loi, MD reposted
Deniz Can Guven
@DenizCanGuven1
Want to know more about the ADCs in lung and
and breast cancers 🤓🤓
A great review by the giants of the field to start 💯💯
☑️Summary of the available data
☑️A roadmap for further studies 💉💉
☑️Emphasizing the need for collaborations and biomarker-driven approaches 🔎🔎
#oncoalert #oncoalertaf
@peters_solange @LoiSher @FAndreMD @APassaroMD @elisabettasabet @CharlesSwanton
@EnriquetaFelip @MP_3855 @etop_ibcsg @Exon20Group @EGFRResisters @jillfeldman4 @OncoAlert @myESMO @Annals_Oncology @Erman_Akkus @ErulEnes @tkoraysahin @pulmonary_news @raffcolo
www.annalsofoncology.org/article/S0923-7534(24)00108-X/fu… -
Sherene Loi, MD
@LoiSher
➡️➡️🎈Looking for breast cancer (and other) research fellows in 2025 - see below - pls apply! #clinicaltrials #doctorsintraining
Linda Mileshkin
@LindaMileshkin
We are currently advertising for multiple medical oncology fellow positions for those interested to work with our team @PeterMacCC in 2025. Applications close Friday 3rd May! careers.petermac.org/search/?createNewAlert=false&q=&opti…
-
Sherene Loi, MD reposted
Paolo Tarantino
@PTarantinoMD
#tils: not only prognostic in TNBC. In a biomarker analysis of TRAIN2, among 389 patients with stage II-III HER2+ BC receiving neoadjuvant chemo + dual HER2 blockade, 13% had high TILs (≥60%) and experienced a 3-year iDFS of 100% (vs 92% if TILs <60%). www.nature.com/articles/s41523-024-00636-4
-
Sherene Loi, MD reposted
OncoAlert
@OncoAlert
Out on @JAMA_current 🚨
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
In patients with early-stage Triple Negative #breastcancer who did not undergo adjuvant or neoadjuvant chemotherapy🧪
➡️breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival.
✅These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage #tnbc.
Link:
jamanetwork.com/journals/jama/article-abstract/2816923
@rleonferre Roberto Salgado @LoiSher @curijoey @CarmenCriscit @vcockenpot @matteolambe
@ShuYazaki @vitti10 @AVincentSalomon
@FAndreMD @lab_kok @mpgoetz @StefanMichiels
#oncoalertaf
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth -
Sherene Loi, MD reposted
Prof Paul Beavis
@paulbeavis4
Excited to finally see this work come out online @NaturePortfolio. In this work we identify FOXO1 overexpression as a strategy to improve CAR T cell persistence and metabolic function using CAR T derived from mice, healthy donors and cancer patients.
www.nature.com/articles/s41586-024-07242-1 -
Sherene Loi, MD
@LoiSher
see out latest review article #tils #immunotherapy #breastcancer
"The Anti-Cancer Immune Response in Breast Cancer: Current and Emerging Biomarkers and Treatments"
free link for 40days
authors.elsevier.com/a/1ioXj8Z12yXiZ3 -
Sherene Loi, MD
@LoiSher
👏👏latest from @TILsWorkGroup #breastcancer #tils
Matteo Lambertini, MD PhD
@matteolambe
Out in @JAMA_current huge academic effort to clarify role of #tils tumor-infiltrating lymphocytes to avoid #chemotherapy in some patients with triple-negative #breastcancer: honored & grateful to have @UniGenova @SanMartino_Ge part of it!
@OncoAlert #bcsm
jamanetwork.com/journals/jama/fullarticle/2816923 -
Sherene Loi, MD
@LoiSher
See data from NeoPact and NeoN data
Chris Shepherd
@ChrisJ_Shepherd
So the big question in my head is....for pts treated with immunotherapy + CTx in the neoadjuvant setting or metastatic...how does pCR/EFS or ORR/PFS/OS correlate with TIL? Does CPS correlate with TIL?
-
Sherene Loi, MD reposted
Dr Sarah Sammons
@drsarahsam
Very interesting and useful! Will be cited for years to come. Helpful in de-escalation.
1) we should study chemo elimination in small high TIL tumors (underway)
2) for T1c tumors could help decide neo v adjuvant and which regimen
Roberto Leon-Ferre
@rleonferre
For stage I TNBC & TILs ≥50%, the 5y OS was 95% (without any chemo!). Contrast that with stage I TNBC & TILs <30%, where 5y OS was 82%. TILs were assoc w/ better survival and recurrence rates independently of other prognostic factors (age, T size, N status, grade) @OncoAlert
-
Sherene Loi, MD
@LoiSher
Congrats to @ChristineDesme2 @GeukensTatjana highlighting efforts of CASCADE @PeterMacCC @pssavas @PeterMacRes
Christine Desmedt
@ChristineDesme2
Research on metastatic cancer is limited by access to metastatic samples. We shed light on how rapid autopsy programs are organised & on their challenges & opportunities to enhance research. Team work🤝, patients & their families are central🙏. @OncoAlert
pathsocjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/… -
Sherene Loi, MD
@LoiSher
Out in Cell - Complexities of cancer research- massive effort thanks to @CRUKresearch authors.elsevier.com/c/1iqgjL7PXqPxO
@PeterMacCC @PeterMacRes @CellCellPress
Matt Kaiser
@marvel_matt
📣NEW PAPER ALERT!📣
We need to embrace cancer’s complexity!
New perspectives article today in @CellCellPress – technology is allowing us to truly see cancer’s interplay with all the body’s physiological systems
👉 authors.elsevier.com/c/1iqgjL7PXqPxO -
Sherene Loi, MD
@LoiSher
Thank you to all the patients @BCTrialsANZ @etop_ibcsg @PeterMacCC #bcsm
Let’s optimize use of chemo and IO for #tnbc
The ASCO Post
@ASCOPost
Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel ascopost.com/videos/2023-sabcs/sherene-loi-on-triple-nega… #bcsm #breastcancer #tnbc #sabcs23 @SABCSSanAntonio @LoiSher @PeterMacCC
-
Sherene Loi, MD
@LoiSher
#precisiononcology #breastcancer #pik3ca 👏👏 for targeted therapy- 1L triple therapy seems likely. #sabcs23
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
The cohort in INAVO120 was quite endocrine resistant. But PFS of 15m for triplet would be longer than 1st line F + palbo (7m) followed by F + capi (7.3m) even w/o the more limited PFS with F + capi in CDK46i-treated cohort (5.5M). If true would suggest triplet should be standard.
-
Sherene Loi, MD reposted
FabriceAndre
@FAndreMD
Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy @GustaveRoussy 1/2 www.thelancet.com/journals/lancet/article/PIIS0140-6736(2…
-
Sherene Loi, MD reposted
-
Sherene Loi, MD
@LoiSher
Excellent presentation 👏👏👏by @NickZdenkowski LBA3-03
#sabcs23
Breast Cancer Trials
@BCTrialsANZ
The primary results of Neo-N were announced at @SABCSSanAntonio @LoiSher.
Results have shown that over half of the breast cancer patients involved in the study had no evidence of cancer in the breast and lymph nodes at surgery following treatment.
www.breastcancertrials.org.au/media-releases/neo-n-clinic… -
Sherene Loi, MD
@LoiSher
😂 Gen X selfies
We missed you @FAndreMD @SABCSSanAntonio #sabcs23
FabriceAndre
@FAndreMD
QI=500 for @CharlesSwanton @DrChoueiri @LoiSher united… and they end up with the below selfie to say hello 👍. This is called collective intelligence. I miss you my friends of #sabcs2023 , see you next year !
-
Sherene Loi, MD reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Should we be treating ER positive breast cancer with immunotherapy?
Dr. Virginia Kaklamani, #sabcs23 co-director, explores this question with Dr. Sherene Loi in this episode of SABCS Snippets. Watch now:
@VKaklamani @LoiSher @AACR @UTHealthSAMDA youtu.be/H9vjg7hhyyI -
Sherene Loi, MD
@LoiSher
👏👏Great results for patients- nil further RT needed - interesting adverse signal for #tnbc maybe important to not kill lymphocytes which are very radiation sensitive in an immunogenic -#breastcancer type? 🤔
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
In patients who present with biopsy-proven axillary node involvement (cN+) and convert their axillary nodes to ypNo after NAC, CWI+RNI after mastectomy, or WBI+RNI after lumpectomy, did not improve the 5-year IBCRFI, LRRFI, DRFI, DFS, or OS
#sabcs23 @OncoAlert -
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
Published synchronously with #sabcs23 @reshmajagsi Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA ascopubs.org/doi/10.1200/JCO.23.02270 @JCO_ASCO @SABCSSanAntonio @OncoAlert
-
Sherene Loi, MD reposted
ETOP IBCSG Partners Foundation
@etop_ibcsg
Patients with HR-positive BC can use fertility preservation and assisted reproductive technologies to conceive without an increased short-term risk of recurrence.
Results of the IBCSG 48-14/BIG 8-13 POSITIVE trial presented today at #sabcs2023 -
Sherene Loi, MD
@LoiSher
The complexity of #tnbc genomes- fantastic data by #breastcancer @CharlesSwanton @FAndreMD @SABCSSanAntonio #sabcs23
-
Sherene Loi, MD
@LoiSher
🙏 important for these HR+ patients who historically have a poor prognosis #bcsm @OncoAlert
Dr Sarah Sammons
@drsarahsam
PDL-1 status further delineates which HR+ patients may benefit from neoadjuvant immunotherapy.
Amazing work @LoiSher and @bmsnews. -
Sherene Loi, MD
@LoiSher
Important information on use of #immunotherapy in patients with early stage #triplenegative #breastcancer #bcsm @OncoAlert
-
Sherene Loi, MD
@LoiSher
Would be interesting to see breakdown by BC subtype
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Kristen Brantley PhD presents the development of an absolute risk prediction model for premenopausal #breastcancer in an international consortium. #sabcs23 #danafarbersabcs23
-
Sherene Loi, MD reposted
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
High selected patients wit ER+ PR+ HER2 neg, node negative and RS score <= 18 may omit #radiotherapy. Longer Follow up is required #sabcs23 @OncoAlert
-
Sherene Loi, MD reposted
-
Sherene Loi, MD reposted
Mothaffar Rimawi
@mfrimawi
Excited to be moderating this educational session today about HER2+ breast cancer with wonderful speakers Dr Ron Bose, Dr Sherene Loi @LoiSher Dr Sarah Sammons @drsarahsam and advocate Terlissa Sheppard. Please join us #sabcs23
-
Sherene Loi, MD
@LoiSher
👋➡️➡️1pm TODAY Wed 6th Dec #bcsm #immunotherapy purpose, resistance and toxicity #breastcancer and other cancer types
JOIN me @DrChoueiri @kevlitchfield 👏👏👏at 1pm Stars at Night Ballroom 1 @SABCSSanAntonio #sabcs23 -
Sherene Loi, MD reposted
Kevin Punie
@kevinpunie
#sabcs23
#impassion030
Adding #atezolizumab to adjuvant chemotherapy does not improve EFS in stage 2/3 #tnbc @MIgnatiadis
@OncoAlert @SABCSSanAntonio @EORTC_BCG -
Sherene Loi, MD reposted
Kevin Punie
@kevinpunie
#sabcs23
@LoiSher presents the first biomarker results from the #checkmate7fl in general session 1️⃣
🔹nivo benefit was highest in patients with higher CPS score, sTILs >=5% and lower ER/PR expression
🔹increased pCR was observed in any sTILs
@Oncoalert @SABCSSanAntonio #bcsm -
Sherene Loi, MD reposted
Kevin Punie
@kevinpunie
So exciting to see these important data out @NEJM
Take a close 👀 at the HR scale in the forest plot 🤩Quite different scale then we are used to see. Grateful to the pts and our team @UZLeuven
Hoping for a swift @EMA_News review+approval !
@OncoAlert #bcsm #trodelvy #ascent 🚀
Paolo Tarantino
@PTarantinoMD
The #ascent trial of Sacituzumab Govitecan in pretreated mTNBC is finally published on @NEJM
❗️Impressive achievement - with the anti-Trop2 ADC doubling OS vs chemo in this relevant unmet need (12.1 vs 6.7 months, HR 0.48)
Congrats to all the authors!
www.nejm.org/doi/full/10.1056/NEJMoa2028485?query=feature… -
Sherene Loi, MD reposted
Mridula George
@MridulaGeorgeMD
KN756 - higher pCR rate with
📌⬆️ PDL1 expression
📌 node positive
📌 ⬇️ ER expression @OncoAlert
EFS data immature. #sabcs23
With MonarchE and NATALEE data, how does ICI fit with CDK4/6i? -
Sherene Loi, MD reposted
VIRGINIA KAKLAMANI
@VKaklamani
Dr Laura Huppert discussing IO in early HR+. Biomarkers are key. Should not tolerate anymore trials without biomarker subsets. Cannot assume all cancers are the same. Our treatments are toxic. We need to select tumors better. #sabcs23 @LoiSher @SABCSSanAntonio @AACR
-
Sherene Loi, MD
@LoiSher
Full of Optimism for #precisiononcology & finding that 🪡needle in the haystack #sabcs23 @VivekSubbiah
-
Sherene Loi, MD
@LoiSher
Looking fwd to @shomgoel talk at #sabcs23
Shom Goel
@shomgoel
Happy to share our new study describing the effects of CDK2 inhibition in solid cancers. It has been a fun and stimulating collaboration with @incyclixbio and fantastic to work with INX-315, their selective and potent CDK2 inhibitor.
doi.org/10.1158/2159-8290.CD-23-0954… -
Sherene Loi, MD
@LoiSher
😀😀 good news for #bcsm patients with PIK3CA mutations! a targeted therapy that works well (⬆️ PFS & OS) and tolerable! #sabcs23 @OncoAlert
Hope Rugo
@hoperugo
Hot off the presses. Inavo/palbo/fulv beats palbo/fulv for PFS as 1st line Rx for HR+ MBC! Safety noted 2b good. Where will this fit in with capi and alpelisib? Roche announces pos Ph III results for inavolisib combo in HR+, HER2- MBC with a PIK3CA mut. www.roche.com/media/releases/med-cor-2023-12-05
-
Sherene Loi, MD
@LoiSher
➡️👋Looking fwd to the science, practice changing new data & to catching up with #bcsm #sabcs23 @OncoAlert @PeterMacCC
AACR
@AACR
Immunotherapy: Purpose, Resistance, and Toxicity—
Toni K. Choueiri, Valentina Hoyos Velez, Sherene Loi, and Kevin Litchfield will address this topic in a State-of-the-Art session at #sabcs23. Learn more:
sabcs.org/Preliminary-Program-2023?sf183356219=1
@DrChoueiri @tinahoyosv @LoiSher @kevlitchfield -
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
The 'Breaking Science in Breast Cancer Video Series' now available on OncologyPRO. Leading experts reporting on the most important study results in #breastcancer at #esmo23. 👉 oncologypro.esmo.org/meeting-resources/esmo-congress/esmo…
@hoperugo @JavierCortesMD @kevinpunie @aftimosp @LoiSher #bcsm -
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
.@Clarivate has recognised 6 researchers from @PeterMacCC as Highly Cited Researchers. Of the world's researchers @paulbeavis4 @JohnstoneRicky @LoiSher @bensolomon1, John Seymour & Phil Darcy at in the top percent 1% #highlycited2023
Read more: www.petermac.org/about-us/news-and-events/events/details/… -
Sherene Loi, MD
@LoiSher
Thank you @TheMarkFdn
We look fwd to working with you! #bcsm @PeterMacCC @PeterMacRes
The Mark Foundation for Cancer Research
@TheMarkFdn
Congrats @TheMarkFdn ASPIRE awardees Charles Swanton, MD, PhD, The Francis Crick Institute and Sherene Loi, MD, PhD, University of Melbourne @CharlesSwanton @thecrick @LoiSher @UniMelb
-
Sherene Loi, MD
@LoiSher
Last call for registrations! Less than 20 spots on site left!!
Sherene Loi, MD
@LoiSher
🚩🚩 SAVE THE DATE Fri Nov 24th🚩🚩Peter Mac Breast Cancer Med Onc Updates: REGISTER TODAY (on site/virtual) 12:30pmAEST
👉www.eventbrite.com/e/peter-mac-breast-cancer-medical-onco…
Chaired by me with super panel of local speakers @SarahJ_Dawson @shomgoel @drkellyphillips @CuiWanda @pssavas @PeterMacCC #bcsm -
Sherene Loi, MD reposted
OncoAlert
@OncoAlert
The #oncoalerttoptweet Day1⃣ of #esmo23
@OncoAlert #breastcancer Faculty @hoperugo 🇺🇸
@LoiSher 🇦🇺presents checkmate 7FL. 500 pts with high risk ES HR+ BC with T/AC +/- nivolumab.
✅PCR dramatically increased in all and much more in PDL1+. Most grade 3⃣and N+. Very complementary to KN756🔑
Best,
@weoncologists
Hope Rugo
@hoperugo
#esmo23 @LoiSher presents checkmate 7FL. 500 pts with high risk ES HR+ BC with T/AC +/- nivolumab. PCR dramatically increased in all and much more in PDL1+. Most grade 3 and N+. Very complementary to KN756 and wow!!@OncoAlert
-
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
#esmo23 S. Hurvitz presents a pooled analysis of DB1,2,3 TDXd efficacy in HER2+ MBC with brain Mets. Remarkable data, suggesting an imp potential role in prevention in add to the impact on those with BMs. @OncoAlert
-
Sherene Loi, MD reposted
Toni Choueiri, MD
@DrChoueiri
Thought-provoking talk from @DouglasHanahan on the hallmarks of cancer in 2023 at #esmo23
@myESMO @OncoAlert @OncLive -
Sherene Loi, MD reposted
Oncology Brothers
@OncBrothers
Day 1 #esmo23 Highlights #communityoncology
NSCLS
1. #cm816 @DrMarkAwad
2. #kn671 @DoctorJSpicer
3. #attlas
Breast Ca
4. #monarche #bcsm
5. #kn756/#cm7fl @LoiSher
6. #kn522 TNBC @JavierCortesMD
#lcsm #onctwitter @myESMO #onced @OncoAlert @DrSGraff @g_mountzios
1/7 -
Sherene Loi, MD reposted
Matteo Lambertini, MD PhD
@matteolambe
Great presentation by super @LoiSher from @PeterMacCC at #esmo23 of #checkmate7fl trial showing increased pCR rate with the addition of #nivolumab to neoadjuvant #chemotherapy in patients with high-risk hormone receptor-positive HER2-negative #breastcancer
@myESMO @OncoAlert -
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
#esmo23 @LoiSher presents checkmate 7FL. 500 pts with high risk ES HR+ BC with T/AC +/- nivolumab. PCR dramatically increased in all and much more in PDL1+. Most grade 3 and N+. Very complementary to KN756 and wow!!@OncoAlert
-
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
#checkmate7fl high-risk, ER+ early stage breast cancer—addition of NIVO to NACT increased in pCR of 10.5% (24.5% in arm A vs 13.8% in arm B)
Greatest benefit in PDL1+ #esmo23 @LoiSher @OncoAlert -
Sherene Loi, MD reposted
Toni Choueiri, MD
@DrChoueiri
Superstar 🇦🇺 pride Pr. @LoiSher here with excellent outcomes optimizing pCR in early-stage breast cancer ! @PeterMacCC @myESMO #esmo23 @OncoAlert
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
#checkmate7fl high-risk, ER+ early stage breast cancer—addition of NIVO to NACT increased in pCR of 10.5% (24.5% in arm A vs 13.8% in arm B)
Greatest benefit in PDL1+ #esmo23 @LoiSher @OncoAlert -
Sherene Loi, MD
@LoiSher
➡️⛳️ #esmo2023
2pm CET join me for the exciting #breastcancer #bcsm session:
Checkmate7FL:
Randomized P3 trial of #nivolumab (NIVO) with neoadjuvant chemo + adjuvant ET in patients with high-risk, ER+ HER2− primary BC. @OncoAlert @myESMO -
Sherene Loi, MD
@LoiSher
#sabcs23 ⬇️⬇️ look fwd to catching up with everyone #bcsm @OncoAlert
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Immunotherapy: Purpose, Resistance, and Toxicity—
Toni K. Choueiri, Valentina Hoyos Velez, Sherene Loi, and Kevin Litchfield will address this topic in a State-of-the-Art session at #sabcs23. Learn more:
sabcs.org/Preliminary-Program-2023?sf179936591=1
@DrChoueiri @tinahoyosv @LoiSher @kevlitchfield -
Sherene Loi, MD
@LoiSher
Exciting news for high grade early HR+ #breastcancer : we know these women are younger, have ⬆️ TIL (immune enriched) yet do worse, & higher PCR. Hopefully see 7FL data @SABCSSanAntonio in Dec @bmsnews
Rebecca Shatsky, MD
@Dr_RShatsky
Big news for high rosk hormone positive breast cancer! Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer - merck.com www.merck.com/news/merck-announces-phase-3-keynote-756-tr…
-
Sherene Loi, MD
@LoiSher
🎊Congratulations 🎉🎊🎈 to the team @GustaveRoussy
Fantastic work on response & resistance to Tdxd 👏👏👏 #bcsm @OncoAlert
FabriceAndre
@FAndreMD
DAISY trial (TDXD) @NatureMedicine :
29% OR in pts Her2=0 but only 4 months PFS
Her2=0: pts w ultralow ERBB2 by RT-PCR present ORs
No uptake of TDXD by tumor in Her2=0 vs uptake in Her2+
No quantitative change of immune cells drg TDXD
Uptake of TDXD in 4/6 samples at resistance -
Sherene Loi, MD
@LoiSher
🚩🚩 SAVE THE DATE Fri Nov 24th🚩🚩Peter Mac Breast Cancer Med Onc Updates: REGISTER TODAY (on site/virtual) 12:30pmAEST
👉www.eventbrite.com/e/peter-mac-breast-cancer-medical-onco…
Chaired by me with super panel of local speakers @SarahJ_Dawson @shomgoel @drkellyphillips @CuiWanda @pssavas @PeterMacCC #bcsm -
Sherene Loi, MD
@LoiSher
Bidding farewell & good luck 🍀 to @GeukensTatjana going back to @Onco_KULeuven who are v. lucky to have her! thanks for lending her to us #loilab @ChristineDesme2 @PeterMacRes #bcsm
-
Sherene Loi, MD reposted
Mackay Lab
@LMackayLab
Exciting news from our lab! 🧵👇 Our latest study on tissue T cell heterogeneity, led by @maxevrard is now published in @ImmunityCP @TheDohertyInst authors.elsevier.com/c/1hL2j3qNrUu3i1
-
Sherene Loi, MD
@LoiSher
⬇️important information from a landmark @etop_ibcsg study for young women with #breastcancer @PeterMacCC @JCO_ASCO @PeterMacRes #bcsm @OncoAlert
Journal of Clinical Oncology
@JCO_ASCO
📽️ Watch a video abstract at #jco!
@etop_ibcsg, @BIGagainstBC, @BCTrialsANZ, @merregan, Dr. Prudence Francis, et al. have written an important article on adjuvant endocrine therapy in premenopausal #breastcancer #bcsm 👉 ascopubs.org/doi/full/10.1200/JCO.22.01065 -
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
With Expressions of Interest closing this week, hear from Mutographs and PRECISION team leads about forming a #cancergrandchallenges team.
More from @wesseling64 (@NKI_nl, @LUMC_Leiden) and Professor Sir Mike Stratton (@sangerinstitute) 🔽 @cr_uk
news.cancerresearchuk.org/2023/06/16/pearls-of-grand-chal… -
Sherene Loi, MD
@LoiSher
🚩🎌🚩 new from #loilab @ranli01
1/3 Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2+ #breastcancer #bcsm @oncoalert #her2 @PeterMacCC @SeagenGlobal
academic.oup.com/jnci/article-abstract/doi/10.1093/jnci/d…
Sherene Loi, MD
@LoiSher
2/3 here we show that tucatinib, a HER2 kinase inhibitor, can promote immune activation and synergises with PD-1 targeted therapies in HER2 BC models resistant to trastuzumab, resulting in better and longer responses to therapy
Sherene Loi, MD
@LoiSher
3/3 this data forms the preclinical rationale for a #clinicaltrial currently recruiting in Australia "TUGETHER" (NCT04789096) by @BCTrialsANZ thanks to @SeagenGlobal & congrats to @ranli01
DM me for the PDF 🙏 -
Sherene Loi, MD reposted
Susan G. Komen®
@SusanGKomen
Join us for Breast Cancer Breakthroughs on June 29! We’ll highlight the latest breast cancer research that was recently presented at #asco23! Experts @LoiSher & @ErikaHamilton9 will explain how patients with #breastcancer will be impacted. More info here: www.komen.org/about-komen/our-impact/breast-cancer/breast…
-
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
1 week to go 📅
We're almost there! The deadline to submit your Expression of Interest to take on one of our #cancergrandchallenges is 22 June. Remember also to submit your eligibility forms by today.
Apply: www.cancergrandchallenges.org/applications -
Sherene Loi, MD
@LoiSher
Congratulations 🎉🍾 Julia! @GustaveRoussy are lucky to have her! @FAndreMD
Breast Cancer Trials
@BCTrialsANZ
Dr. Julia Dixon-Douglas has been awarded support in the first year of the International Fellowship program and is heading to France. The aim of her research project is to investigate the impact of novel breast cancer treatments. www.breastcancertrials.org.au/the-impact-of-novel-therapies/
-
Sherene Loi, MD reposted
ETOP IBCSG Partners Foundation
@etop_ibcsg
Thoughtful article about our POSITIVE trial and what's next on the BIG RESEARCH IN FOCUS by @BIGagainstBC: bigagainstbreastcancer.org/wp-content/uploads/2023/05/big…
-
Sherene Loi, MD
@LoiSher
🚩🚩🏁calling ALL scientists, post docs, HMO, medical registrars, trainees in Victoria, Australia @PeterMacRes @PeterMacCC @PMpostdocs @WEHI_research @TheDohertyInst @MCRI_for_kids @TheFlorey @thewomens to sign up to this prospective survey of career choices. DM me for more info
A/Prof Laura Forrest PhD
@LEForrest
Workplace Experiences Longitudinal Survey (WELS) of clinicians & medical researchers working in Parkville
@PeterMacCC @TheRMH @thewomens @RCHMelbourne @MCRI_for_kids @WEHI_research @TheFlorey @TheDohertyInst
exetercles.eu.qualtrics.com/jfe/form/SV_b2u4rxZvZGtWou2
Collab: @PeterMacCC @UniofExeter @ANUmedia -
Sherene Loi, MD
@LoiSher
➡️Attention #lcsm @OncoAlert let’s talk about the amazing developments in #lungcancer research 👏👏👏🫁
-
Sherene Loi, MD reposted
Peter Mac Research
@PeterMacRes
Congratulations to Dr Lauren Brown from @LoiSher lab on a great presentation and an ASCO award for her oral in the early breast cancer session. Dr Brown is a #fellow and #phd student @PeterMacCC and definitely one to watch. #asco23 #breastcancer #research #cancer
-
Sherene Loi, MD
@LoiSher
Fantastic discussion of amazing plenary data @asco23 by fabulous @bensolomon1 #egfrmutant #nsclc @PeterMacCC @PeterMacRes
Christian Rolfo
@ChristianRolfo
Congrats @bensolomon1 for the great discussion of the unprecedented OS data of ADAURA. Important to guarantee access to medication for our patients around the world and TESTING! Great slide by @jillfeldman4 on toxicity considerations. #asco23 @EGFRResisters @asco @isliquidbiopsy
-
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Over the decades, we have consistently underestimated the importance of endocrine therapy in premenopausal women with ER+ breast cancer; first tamoxifen, and then, OFS. OFS yields 11% OS benefit at 20 years (some studies omitted tam). 5% DFS benefit on top of tamoxifen.
-
Sherene Loi, MD
@LoiSher
Congratulations to my PhD student Lauren Brown for a great presentation today @PeterMacRes @NBCFAus @asco23 #bcsm #young #breastcancer @etop_ibcsg
Matteo Lambertini, MD PhD
@matteolambe
Presented at #asco23 very important data from the #soft trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #breastcancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all!
@OncoAlert -
Sherene Loi, MD
@LoiSher
Hey 👋 #bcsm #asco2023 #asco23 Upcoming oral early #breastcancer session by #loilab @etop_ibcsg 2.45pm hall D1 ➡️ is PAM50 ROR prognostic In premenopausal HR+ BC❓
-
Sherene Loi, MD
@LoiSher
See you all soon for a very exciting session #asco23 #bcsm
Daniel Stover, MD, FASCO
@StoverLab
Excited for a great #breastcancer Clinical Science Symposium on immune biomarkers
➡️Sat, June 3 1:15PM in S406.
Looking fwd to hearing AURORA data, sharing our @ALLIANCE_org #mbc sTILs data, & context from Dr. Blenman @YaleCancer
@hoperugo @LoiSher @TILsWorkGroup -
Sherene Loi, MD reposted
Matteo Lambertini, MD PhD
@matteolambe
Finally out the #asco23 Educational Book with our contribution on managing menopausal symptoms, #fertility preservation & bone health in #breastcancer patients receiving #endocrinetherapy
Link for free download:
ascopubs.org/doi/10.1200/EDBK_390442
@ASCO @kristinrojasmd @Lucarecco @OncoAlert -
Sherene Loi, MD
@LoiSher
🎈ADCs: Just fancier & (more effective) chemotherapy? 🤔
Paolo Tarantino
@PTarantinoMD
Is targeted delivery necessary for ADCs to be active?
Likely not.
Binding Exatecan to a non-targeted peptide led to meaningful response rates in patients with breast and ovarian cancer.
Hypothesized MoA: slow/prolonged payload release -
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
On Monday, we're holding a pre-application webinar for our 9 new challenges ⤵️
Learn about our application process with an opportunity for Q&A. The webinar will be recorded.
Zoom details:
- 22 May, 4-5pm BST/ 11am-12pm ET
- nih.zoomgov.com/j/1616166539
- Meeting ID: 161 616 6539 -
Sherene Loi, MD
@LoiSher
Thank you @MonashBDI #csti2023 it was a a great meeting!
Lan K. Nguyen
@LanKhuyenNguyen
Congratulations to Prof. Sherene Loi @LoiSher on being awarded the Martin Lackmann Award for Translational Research in 2023! Your pioneering work in bringing cutting-edge cancer treatments to patients is an inspiration to us all #csti2023 @MonashBDI @PeterMacRes
-
Sherene Loi, MD reposted
Antonella Papa, PhD
@AntonellaPapa4
Congratulations to Sherene @LoiSher on receiving the Martin Lackmann Award for Translational Research at #csti2023 @MonashBDI @BioCurate @PeterMacCC
Lan K. Nguyen
@LanKhuyenNguyen
Congratulations to Prof. Sherene Loi @LoiSher on being awarded the Martin Lackmann Award for Translational Research in 2023! Your pioneering work in bringing cutting-edge cancer treatments to patients is an inspiration to us all #csti2023 @MonashBDI @PeterMacRes
-
Sherene Loi, MD reposted
Tatiana Prowell, MD
@tmprowell
In case you missed it: Women are less likely to be credited for their scientific contributions than men. It’s true across multiple fields & at all stages, with important repercussions for career progress. #womeninstem #womeninmedicine #medtwitter
www.nature.com/articles/s41586-022-04966-w.pdf -
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
New challenge: T-cell receptors
Hear from Professor René Bernards, member of our Scientific Committee, about one of our new #cancergrandchallenges, which seeks to decipher the T-cell receptor cancer-recognition code ⬇️ vimeo.com/819449853?ref=tw-share -
Sherene Loi, MD reposted
Charlotte Helena Rivas, M.S.
@CharlottesNiche
Excited to share our most recent publication from the Zhang Lab!
-
Sherene Loi, MD reposted
Matteo Lambertini, MD PhD
@matteolambe
Finally out in @NEJM results from #positive trial showing that temporary interruption of #endocrinetherapy to attempt #pregnancy is safe in #breastcancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm
www.nejm.org/doi/full/10.1056/NEJMoa2212856 -
Sherene Loi, MD
@LoiSher
Great session today on #cancer & potential of #mrna thanks also to @Vic_LeadSci @VCCCAlliance @ProfSharonLewin @moderna_tx @LMackayLab
Doherty Institute
@TheDohertyInst
…targeting T cells with #mrna and how differently they work to fight against cancer cells, opportunities available in VIC being largest biomedical precinct in Aus with expertise across research, industry and translated to public health. @Vic_LeadSci @LoiSher @LMackayLab
-
Sherene Loi, MD
@LoiSher
🚩🏁🚩 hi everyone, latest from the #loilab- happy weekend! @OncoAlert #bcsm @TILsWorkGroup @PeterMacRes @PeterMacCC
Shout out to @KarantzaValia & our longstanding TIL biomarker colloboration with @Merck -more to come hopefully 🙏
ascopubs.org/doi/10.1200/PO.22.00317
Sherene Loi, MD
@LoiSher
we show that PDL1 CPS, CD8 IHC, TILs, TMB, T cell activated GEP are sig. assoc. with ⏫outcomes with pembro monotherapy: pre-existing immunity is 🔥essential for response in met TNBC. Addition of chemo improves duration of PFS/OS/higher ORR but does not change the responding popn
-
Sherene Loi, MD reposted
Peter Mac Postdoc Society (PMPS)
@PMPostdocs
Abstract submission deadline EXTENDED: now 27th April ⏰⏳
vcccalliance.org.au/events/6th-vccc-alliance-postdoctoral…
Not in Melbourne - not a problem!! This is a hybrid event with the chance to present and attend online for interstate postdocs. Register now 🧑💻👩💻 -
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
It was great to have Dr Monica Bertagnolli @NCIDirector (@theNCI) join us at our stand (707) yesterday.
#cancergrandchallenges is a global funding initiative founded by @CR_UK and @theNCI.
If you’re at #aacr23, drop by to learn more and explore our interactive map ⬇️ -
Sherene Loi, MD reposted
Toni Choueiri, MD
@DrChoueiri
JUST IN at the right time during @AACR “The next big questions in cancer research” in @CellCellPress
From @LoiSher @PeterMacCC
I spot @CardioOncology and Bill Sellers @DanaFarber too
A must read ! www.sciencedirect.com/science/article/abs/pii/S0092867423… -
Sherene Loi, MD reposted
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM
@agingdoc1
The next big questions in cancer research
Leading researchers asked to comment: what questions are important to address in the coming years?
@LoiSher, @Johanna_A_Joyce, @cspramesh, @BernardsLabora1, @CardioOncology, @TheSellersLab
www.sciencedirect.com/science/authShare/S009286742300096X… @CellCellPress -
Sherene Loi, MD reposted
Cancer Discovery
@CD_AACR
In Focus—
Harnessing the Power of Discovery— a piece on the new @CancerGrand challenges, written by David Scott and Dinah Singer.
aacrjournals.org/cancerdiscovery/article/13/4/819/725024/… -
Sherene Loi, MD reposted
Australian Academy of Health and Medical Sciences
@AAHMS_health
"We have made enormous progress in breast cancer immunotherapy over the last decade..."Given the innovative immune-based agents already under development, the future of breast cancer immunotherapy is bright." Read more in this new article from #aahmsfellow @LoiSher.
Sherene Loi, MD
@LoiSher
🚩➡️Pleased to share our latest review on #breastcancer & #immunotherapy with #leishaemens
Free thanks to Cold Spring Harb Press 👏👏 @CSHLPress
#bcsm @OncoAlert @PeterMacCC @PeterMacRes @etop_ibcsg #loilab
perspectivesinmedicine.cshlp.org/cgi/content/long/13/4/a0…
💉🩺 -
Sherene Loi, MD
@LoiSher
🚩➡️Pleased to share our latest review on #breastcancer & #immunotherapy with #leishaemens
Free thanks to Cold Spring Harb Press 👏👏 @CSHLPress
#bcsm @OncoAlert @PeterMacCC @PeterMacRes @etop_ibcsg #loilab
perspectivesinmedicine.cshlp.org/cgi/content/long/13/4/a0…
💉🩺 -
Sherene Loi, MD
@LoiSher
Happy Easter fun 🐣 from 🇦🇺 #kidshavingfun
-
Sherene Loi, MD
@LoiSher
My clinical research fellows for the last 7 yrs - all super talented- thank you and farewell to Julia who’s off to ✈️ 🇫🇷 @GustaveRoussy @FAndreMD @StefanMichiels
-
Sherene Loi, MD reposted
Cancer Grand Challenges
@CancerGrand
1/2 For three decades, there has been a gradual rise in the number of people under 50 being diagnosed with cancer – and we don’t entirely know why.
More in @newscientist (£/$) with CGC Scientific Committee member, Sherene Loi @LoiSher and @TOptimisticc ⏬
www.newscientist.com/article/2366565-cancer-mystery-as-ca… -
Sherene Loi, MD reposted
Tanja Spanic
@TanjaSpanic
@SG_BCC consensus panel- world’s biggest breast cancer tumor board 💞@MichaelGnant @curijoey @Icro_Meattini @lab_kok @DrHBurstein @mjcard1964 @AnnPartridgeMD @hoperugo @LoiSher
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
Hot off the press this week, Peter Mac is front page of @Cancer_Cell, with work our biomedical animator @maja_divjak created to illustrate the work led by Dr Balaji Virassamy and @LoiSher in the March 13 edition. www.petermac.org/news/peter-mac-researchers-uncover-how-p…
-
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
A pragmatic approach to assessing adaptive immunity using % TILs on light microscopy🔬, an approach which is FDA approved ✅, would be available to LMIC 🌍, and which 55K users have trained online💻. @LoiSher #sgbcc2023
-
Sherene Loi, MD reposted
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
“pCR is an immune phenomenon in my opinion” —@LoiSher, discussing the profound response to treatment among tumors expressing high TILS which should be reported and used to better stratify treatment & trial design. #sgbcc2023
-
Sherene Loi, MD reposted
Richard Simcock
@BreastDocUK
TILs in #breastcancer
A clear summary of their importance and the work needed from @LoiSher
Carsten Denkert reassures that TIL evaluation is "very straightforward" - responding to it maybe less so!
An excellent website - bookmark it
www.tilsinbreastcancer.org
#sgbcc2023 -
Sherene Loi, MD
@LoiSher
Super excited to be part of this amazing issue & on the cover! Thanks @Montse_Rojo_PhD @Cancer_Cell Art by @maja_divjak @PeterMacCC #loilab @PeterMacRes #bcsm thanks again to our collaborators @LMackayLab @GBG_Forschung @CharlesSwanton &funders @nhmrc @NBCFAus
Cancer Cell
@Cancer_Cell
We are very proud to present our 2023 Special Issue dedicate to a holistic view of cancer! With 10 Reviews, a Perspective, and our Editorial, we lay out what we see as the future for impactful cancer research. You can read it now: www.cell.com/cancer-cell/issue?pii=S1535-6108(22)X0006-8
-
Sherene Loi, MD
@LoiSher
Thank you @NatureCancer for supporting our work #loilab @amy_winship @HuttLab #iwd2023 #womeninscience #womeninstem @PeterMacRes
Nature Cancer
@NatureCancer
Happy International Women's Day #iwd2023 !
@NatureCancer supports #womeninscience - please join us to celebrate some of the wonderful female scientists & clinicians who recently published their work with us – we hope you are inspired by them! 👩🔬 -
Sherene Loi, MD
@LoiSher
hi everyone, for those who have been asking for the PDF, the article is free online here for 50days #bcsm #breastcancer #tils #tcells #immunotherapy
authors.elsevier.com/a/1geQ35TA51dZ-f -
Sherene Loi, MD
@LoiSher
👉➡️ excited for our latest from the #loilab #til #bcsm @OncoAlert @PeterMacRes @PeterMacCC @UniMelb
1. Here we are investigating #breastcancer #tcell subsets. We have previously identified a T cell resident memory phenotype (TRM) in human #tnbc which stay in the local TME
Cancer Cell
@Cancer_Cell
Online Now: Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer www.cell.com/cancer-cell/fulltext/S1535-6108(23)00004-1?r…
Post not available here, view on X
Sherene Loi, MD
@LoiSher
5. We also have a great image by the brillant artist @maja_divjak
Sherene Loi, MD
@LoiSher
6. Many+++ thanks
@Cancer_Cell and to all involved
@pssavas @sneha_sant @LMackayLab @GBG_Forschung @WEHI_research @CharlesSwanton
@TheDohertyInst @PeterMacRes & our funders @nhmrc @NBCFAus
Our latest article is free online for 50 days - YAY!
authors.elsevier.com/a/1geQ35TA51dZ-f -
Sherene Loi, MD
@LoiSher
Quantity of immune infiltration on H&E slides: the advantage of a pragmatic method that can be applied globally #til #breastcancer #bcsm @OncoAlert
TILs Working Group
@TILsWorkGroup
We've reached 55,000 users from 164 countries in www.tilsinbreastcancer.org 🥳 only a few more countries left, help us complete the world map!
-
Sherene Loi, MD
@LoiSher
🚩🚩🚩🚩💡👉hi #bcsm our paper is now online and free for 80days. Why is prognosis for very #youngwomen with #breastcancer worse: it is enriched with aggressive genomic features. Targeted strategies needed @OncoAlert @myESMO
thanks @Annals_Oncology authors.elsevier.com/a/1geEy3I2OQerEV -
Sherene Loi, MD
@LoiSher
Thank you @DrSGraff . Look fwd to seeing you in #vienna #sgbcc2023. Any aspects you & other #bcsm would like me to focus on, specifically that would help in Mx of early #breastcancer #tnbc
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
One of the sessions that looks really great at #sgbcc2023 is this exploration of immunology in early breast cancer with @LoiSher @SG_BCC! (Vienna or Virtual—🇦🇹💻—
Who’s joining me?) -
Sherene Loi, MD
@LoiSher
🙌🎈👏👏Shout out to all those hard working, talented, inspiring women scientists for today’s International Day of Women & Girls in #science.
#womeninscience #womeninstem #genderequity #idwgis
#youcantbewhoyoucantsee
@PeterMacCC @OncoAlert @PeterMacRes
Australia's Chief Scientist
@ScienceChiefAu
Tomorrow is the International Day of Women and Girls in #science, a chance to reflect on the steps we still need to take to achieve #genderequity in science fields.
Here’s my message for #february11: youtu.be/fPE06mCC6FY
#womeninscience
#girlsinscience #idwgs -
Sherene Loi, MD
@LoiSher
🚩Very young women do poorly from #breastcancer 🤔. Here we characterise oncogenic drivers from >1200 patients BC samplesin the #soft trial to try to understand why. 1) women Dx <40yrs have sig. more HRD, CN amplification, TP53 mt and genomic instability
Annals of Oncology
@Annals_Oncology
In Annals of Oncology, genomic characterization 🧬of HR+ breast cancer in very young women enrolled in SOFT shed light on unfavourable prognostic features potentially informing future therapeutic strategies
www.annalsofoncology.org/article/S0923-7534(23)00047-9/fu…
@LoiSher @etop_ibcsg #bcsmPost not available here, view on X
Sherene Loi, MD
@LoiSher
4) We also thank 👏👏🙏 @SusanGKomen @NBCFAus @BCRFcure @nhmrc @etop_ibcsg & funders of the #soft study #loilab @PeterMacRes @PeterMacCC
Sherene Loi, MD
@LoiSher
5) RNA, TIL/immune/TME analysis coming very soon @TILsWorkGroup @OncoAlert
-
Sherene Loi, MD
@LoiSher
Worth a read - incredible effort 440 human #lungcancer #til 😳congrats to the authors @OncoAlert
Charlie Rudin
@charlesrudin
Out today — great work defining the role of CD39+ CD8 T cells in anti-cancer immunity led by @AndrewChowMDPhD with key support from @merghout, Jedd Wolchok, and many others. authors.elsevier.com/a/1gJgV3qNrUqGOf
-
Sherene Loi, MD
@LoiSher
#loilab Christmas party- thanks to a great team for a great year… lots more exciting things to come for #breastcancer research next year 🙏 to all our funders @NBCFAus @BCRFcure @nhmrc @PeterMacRes @PeterMacCC @UniMelb #bcsm
-
Sherene Loi, MD
@LoiSher
-
Sherene Loi, MD
@LoiSher
🎈Such an important study for #breastcancer patients #bcsm @sabcs22 @OncoAlert @etop_ibcsg
Ann Partridge MD, MPH
@AnnPartridgeMD
The POSITIVE trial initial results: no increased risk from temporary interruption of endocrine therapy for pregnancy at 3 years. Long-term followup is critical. Thank you @SABCSSanAntonio for highlighting and @etop_ibcsg @ALLIANCE_org @theNCI and so many others for supporting!
-
Sherene Loi, MD
@LoiSher
Check my PhD student’ poster P5-02-16 on SPEN mutations as a biomarker of CDK4i resistance- as well as a scholar in training award! 👏👏👏#bcsm @OncoAlert @PeterMacRes #sabcs22 #loilab
-
Sherene Loi, MD
@LoiSher
👏👏👏👏 how exciting @DanaFarber @DFCI_BreastOnc
Laurie Glimcher MD
@LGlimcherMD
We are proud to join with @PeterMacCC to form a new collaborative partnership that will help accelerate research into innovative new cancer therapies that can help patients around the world. www.dana-farber.org/newsroom/news-releases/2022/new-inter…
-
Sherene Loi, MD
@LoiSher
Hanging out with my lab #loilab @ResAustralia award night- 👏👏👏👏congrats to all the winners #resausawards thanks to @NBCFAus @PeterMacRes @PeterMacCC for the nomination!
-
Sherene Loi, MD
@LoiSher
👏👏👏👏Congrats @HollyTovey #sabcs22 #bcsm #oncoalert
Maggie Cheang
@MaggieCheang
Super proud of @HollyTovey and congrats again for scholar in training award @SABCSSanAntonio; and robust discussions among presenters and discussants; special thanks @LoiSher Chuck Perou, @ninnerl1306 Andrew Tutt @kahoadley and colleagues @ICR_London @unc_cn #womenincancer
-
Sherene Loi, MD
@LoiSher
#bcsm #sabcs22 is pregnancy safe post #breastcancer? An amazing -#clinicaltrial by #ibcsg and Alliance 👏👏👏congrats all
ETOP IBCSG Partners Foundation
@etop_ibcsg
The long-awaited initial results of the IBCSG 48-14/BIG 8-13 POSITIVE Trial will be presented at SABCS 2022 this Friday, Dec 9. Join online or in Hall 3 at 11:00am CT.
@BIGagainstBC, @ALLIANCE_org, @_SOLTI, @GEICAM, @SAKK_ch, @cancertrials_ie, @ABCSGVienna -
Sherene Loi, MD
@LoiSher
#esmoasia22 #esmoyoc super to meet younger trainees
Matteo Lambertini, MD PhD
@matteolambe
Super #esmoyoc #mentorship session led by @TeresaSAmaral & @DrLizConnolly at #esmoasia22: what a terrific faculty with @curijoey @HaanenJohn @LoiSher & #lisalicitra
#esmoyocrocks @myESMO @OncoAlert @VanBran44 @KFumasoli @franclongo -
Sherene Loi, MD
@LoiSher
Congrats too to all my fellow 2021 #pmprizes awardees- Profs @edwardcholmes Anthony Weiss, @BowenLabTweets, Keith Bannister @pleasefftme, Mr Scott Graham, @Mrs_Hayes2019 @ScienceGovAu 👏👏
-
Sherene Loi, MD
@LoiSher
More photos of superstar @MAF_Dawson 2020 winner of the Frank Fenner Life Scientist prize, us with Marilyn Fenner, daughter of the late Frank Fenner #pmprizes @ScienceGovAu @PeterMacCC @PeterMacCC
-
Sherene Loi, MD
@LoiSher
Super excited with @MAF_Dawson to receive our #pmprizes 2020 &2021 @ScienceGovAu with honorable @AlboMP @DrCathyFoley #edhusic @PeterMacRes @PeterMacCC
-
Sherene Loi, MD
@LoiSher
Super cool to hang with the band @mayhemtomi
for @PeterMacCC fundraiser despite the torrential rain
@TommyJohn00 (won't be giving up my day job anytime soon though😊)
#albumlaunch open.spotify.com/album/3bOwcIITZTBjWw4Cw0uPwZ
#theartofflyingwhilefalling
Linda Mileshkin
@LindaMileshkin
Not content with just being a wonderful clinician, teacher, researcher and leader @LoiSher was also up on the stage last night as back-up singer for the wonderful @mayhemtomi @TommyJohn00 last night at the launch of his album. It was a wonderful gig!
-
Sherene Loi, MD
@LoiSher
Congratulations 🍾🎉 to all especially @pssavas brilliant post doc in my lab 🤔 need to think about how we encourage more #clinicianscientist @nhmrc
Peter Mac Research
@PeterMacRes
Huge congratulations to our six very deserving recipients of #nhmrc grants. @AzadOncology @JohnstoneRicky @parkerlabPMCC @MilesPrince4, Dr Peter Savas, & Dr Najoua Lalaoui
www.petermac.org/news/nhmrc-grants-awarded-six-peter-mac-… -
Sherene Loi, MD
@LoiSher
Fantastic to meet @NatHutchins and many+++ 👏👏🍾🥂 amazing women at #honorher #vicforwomen @WomenVictoria many thanks to @PeterMacCC @PeterMacRes @maxVmor @ShelleyDolan2 @McArthurGrant #loilab @NBCFAus
Associate Professor Samantha Loi, MD, PhD
@Doctor_Samba
So proud!! #vicforwomen #honourher @LoiSher Inducted to the Vic Honour Roll for Women 2022. Congratulations on your achievements 👏 🥂
-
Sherene Loi, MD
@LoiSher
For those in #melbourne this Thursday 13th @TheToffInTown join the fundraiser for @PeterMacCC & great music @mayhemtomi new album on @SpotifyAU
Prof Tom John
@TommyJohn00
Sat down with @BeatMagazine to discuss the debut #album and the upcoming launch @TheToffInTown beat.com.au/380257-2/ This article gives you some insights into where it came from and the album is a little dark and emotive. You can link to it here:
mayhemtom.fanlink.to/Album -
Sherene Loi, MD
@LoiSher
Hanging out in #sydney at the #atrbcs discussing cool data thanks to @dralexswarbrick #elgenelim #chuckperou @GarvanInstitute #bcsm
-
Sherene Loi, MD
@LoiSher
#esmo22 #paris fantastic to see after all these years …@TILsWorkGroup my cochair Roberto Salgado & my previous mentor the amazing Martine Piccart #bcsm
-
Sherene Loi, MD
@LoiSher
Brava! 👏👏A great option for #mbc patients #breastcancer as oral tablets with no alopecia @myESMO #esmo22 @etop_ibcsg #bcsm
Elisabetta Munzone
@elisabettasabet
Proud to share the results of the METEORA-II trial. Metronomic oral VEX vs paclitaxel significantly improved TTF (HR 0.61), and mPFS (11.1 vs 6.9 mo HR0.67) in pts with ER+/HER2- metastatic #breastcancer.
#esmo22 @myESMO @etop_ibcsg @IEOufficiale -
Sherene Loi, MD
@LoiSher
👀 check it out @CD_AACR
Cancer Discovery
@CD_AACR
Read this week's CD #researchwatch: Immune Checkpoint Inhibitors Induce Apoptosis in Ovarian Follicles, a summary of the paper by Amy Winship, @Lauren_Alesi, @sneha_sant, @LoiSher, @HuttKarla, @HuttLab et al
aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
@MonashUni @MonashBDI @PeterMacCC @WEHI_research -
Sherene Loi, MD
@LoiSher
➡️today @NatureCancer
1. we show in a preclinical model how checkpoint inhibitors can cause ovarian inflammation potentially affecting #fertility #bcsm @OncoAlert Gr8 work w @Huttlab 🙏 @sneha_sant @Lauren_Alesi @amy_winship @PeterMacRes @MonashBDI
👉rdcu.be/cUlAA
Sherene Loi, MD
@LoiSher
2. This data should provide impetus for sex-specific and reproductive effects of #immunotherapy to be monitored/researched in patients in the future aas well as insights into non-cancer causes of #infertility
Sherene Loi, MD
@LoiSher
👉➡️special shout out to @drkellyphillips @CuiWanda for their efforts in this area @ASCO @myESMO @EMA_News for advancing this #cancerresearch for #breastcancersurvivor
-
Sherene Loi, MD
@LoiSher
Looking forward to your stay @Nchic5 @PeterMacCC @PeterMacRes
Nchic
@Nchic5
A bittersweet moment as I leave @hospitalclinic to start my fellowship at @PeterMacCC.
@hospitalclinic offered me so much-from befriending amazing people to developing my skills as an #oncolgist. So many thanks 🙏🏻 to all my colleagues for your support! @MuozMateu @prat_aleix -
Sherene Loi, MD
@LoiSher
very timely! thanks @hoperugo
Hope Rugo
@hoperugo
Now on line right after the historic FDA approval of T-DXd for HER2low MBC: Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer - ScienceDirect www.sciencedirect.com/science/article/pii/S2059702922001818 @OncoAlert
-
Sherene Loi, MD
@LoiSher
Help Move Medical Conferences Out of US States Without Full Access to Reproductive Care - Sign the Petition! www.change.org/p/move-medical-conferences-out-of-states-w… via @ChangeAUS
Especially relating to #breastcancer #bcsm where #youngwomen are sometimes diagnosed during #pregnancy -
Sherene Loi, MD
@LoiSher
Vale #olivianewtonjohn Thank you for your contribution to #breastcancer #cancerresearch #bcsm ‘a million lights are dancing & there you are a shooting star,
an everlasting world & you’re here with us eternally’ @ONJCRI -
Sherene Loi, MD
@LoiSher
Please join us LIVE to celebrate the very talented @TommyJohn00 on Oct 13 @TheToffInTown in #melbourne new album launch @PeterMacCC new single out Aug 8th @PeterMacRes #lcsm #bcsm @musicfeeds @mayhemtomi 👏👏
Music Feeds
@musicfeeds
Mayhemtom is the musical moniker of Tom John, who spends his day as the Deputy Director at the Peter MacCallum Cancer Centre in Melbourne.
musicfeeds.com.au/features/premiere-mayhemtom-combines-lo… -
Sherene Loi, MD
@LoiSher
#bct2022 @BCTrialsANZ annual (finally non virtual) meeting! Great to catch up & learn lots from @hoperugo @AnnPartridgeMD @shomgoel
-
Sherene Loi, MD
@LoiSher
Anti-tumor #immunity is very important for outcomes for patients with #tnbc, likely also #her2positive, most treatments including individualisation of #immunotherapy & #chemotherapy @TILsWorkGroup #bcsm
MarleenKokLab
@lab_kok
And validation in international pooled analysis following soon as well as trial with TIL as entry criteria! Stay tuned!
-
Sherene Loi, MD
@LoiSher
Nice to see for untreated advanced #tnbc addition of pembro improves #os in PDL1 positive pts 👉need pre-existing immunity, >=6moDFI, any chemo backbone
🤔Key Qus: how to improve OS, can we make PDL1 neg to pos with more potent anti-tumor drugs & can we use #til to refine #bcsm
Gil Morgan, MD
@weoncologists
Just Out at @NEJM by our @OncoAlert 🚨colleagues @JavierCortesMD @hoperugo @LoiSher & team
KEYNOTE355 🔑
See in patients w/adv triple-negative #breastcancer w PD-L1 expression
✅ addition of pembro to chemo resulted in longer OS 🆚 Chemo Alone
www.nejm.org/doi/full/10.1056/NEJMoa2202809 -
Sherene Loi, MD
@LoiSher
thanks @ElizSMcKenna! Here we show that single agent #alpelisib has activity in late line #pi3k-altered HR+ #breastcancer (ORR 30%, CBR 36%). #ctdna falls & #esr1 mutations could predict benefit, whilst FDG-PET did not. @OncoAlert @PeterMacCC @PeterMacRes #bcsm @CD_AACR
Elizabeth McKenna
@ElizSMcKenna
Now online in @CD_AACR: Alpelisib Monotherapy for #pi3k-altered, Pre-treated Advanced #breastcancer: a Phase 2 Study by @pssavas, Louisa Lo, @SarahJ_Dawson @LoiSher and colleagues @PeterMacCC @UniMelb @UMCCR #ctdna aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
-
Sherene Loi, MD
@LoiSher
#asco22 open access educational read #bcsm ‘Integrating Immunotherapy Into the Treatment Landscape for Patients With #tnbc Triple-Negative Breast Cancer’ ascopubs.org/doi/full/10.1200/EDBK_351186 with @LoiblSibylle @melindatelli @OncoAlert
-
Sherene Loi, MD
@LoiSher
#asco22 educational session on #immunotherapy in #tnbc #breastcancer thank you @LoiblSibylle @melindatelli
-
Sherene Loi, MD
@LoiSher
#asco22 it seems like it's out for precision medicine for #metastatic #breastcancer patients (do we really need to do ER and HER2 IHC anymore? 🤔) and #tdxd for everyone with advanced disease.
@OncoAlert
#bcsm
NEJM
@NEJM
DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #asco22 www.nejm.org/doi/full/10.1056/NEJMoa2203690
-
Sherene Loi, MD
@LoiSher
👏👏Looking fwd to Chicago & #asco22 @asco #bcsm @OncoAlert after 3 years! Hoping for an easy transit @flyLAXairport
-
Sherene Loi, MD
@LoiSher
Hanging out today at @GIWLANU #genderequality
-
Sherene Loi, MD
@LoiSher
Start of the new era of #adcs for #tnbc @NBCFAus @PeterMacCC on the @theprojecttv
Peter Mac Cancer Centre
@PeterMacCC
Peter Mac’s Professor Sherene Loi @LoiSher on tonight’s @theprojecttv to talk about the drug Trodelvy, which is used to treat women with unresectable locally advanced or metastatic triple-negative #breastcancer.
-
Sherene Loi, MD
@LoiSher
☝️The question is not if #serds are superior to fulvestrant in all comers but at least the same (who wants an injection in their bum monthly? 😱) better in ESR1 mt, & better side effect profile c/w AI #asktherightquestion #bcsm endpts.com/breaking-roche-hit-with-another-key-rd-setback…
-
Sherene Loi, MD
@LoiSher
great article by @shellkryan congratulations! #genderequity @Nature @Smith_Lorey @LEForrest
Prof Michelle Ryan
@shellkryan
I wrote a thing for @Nature outlining 3 common workplace gender equality mistakes:
1 Focusing on quantity rather than the quality of women’s experiences
2 Initiatives that try to fix women rather than change systems
3 An overestimation of progress www.nature.com/articles/d41586-022-01045-y -
Sherene Loi, MD
@LoiSher
In this @JCO_ASCO special article we (@paulbeavis4) discuss Challenges of Creating New #til for Combating #breastcancer in a trial using #adoptivecelltherapy by Rosenberg et al. @TILsWorkGroup #bcsm @OncoAlert @PeterMacRes @PeterMacCC
ascopubs.org/doi/full/10.1200/JCO.22.00284 -
Sherene Loi, MD
@LoiSher
Fantastic #wiss22 conference today. #breakthebias @PeterMacCC congrats 🎉 @JunyunLai @michyong2 many thanks to @shellkryan @ShelleyDolan2 @maxVmor @Smith_Lorey @LEForrest @JaalaPulford @UniMelb @GIWLANU
-
Sherene Loi, MD
@LoiSher
#australians living with #cancer during #covid #loneliness #isolation on the cancer journey #cancerresearch @GuardianAus @callapilla @PeterMacCC www.theguardian.com/australia-news/2022/feb/14/delayed-di…
-
Sherene Loi, MD
@LoiSher
Integrating biomarkers into the TNM staging is important in the 8th Ed of the American Joint Committee on Cancer (AJCC) Staging. Here #tils can strongly up or downstage eTNBC. #openaccess #tnbc #breastcancer @BCRFcure @NBCFAus @OncoAlert @TILsWorkGroup
www.nature.com/articles/s41523-021-00362-1
Sherene Loi, MD
@LoiSher
What could this mean for incorporation of PD-L1/PD-1 inhibition into NAC for eTNBC? It suggests higher pCR rates in higher TIL patients will likely be achieved with less chemo + IO, with probably better quality pCR (i.e. cured) 👉 individualized & shorter NAC IO/chemo 😊 #bcsm
-
Sherene Loi, MD
@LoiSher
#closethecaregap #worldcancerday And the need for more investment in #cancerresearch as everyday for me is a cancerday!🙏 @oncoalert @NBCFAus @PeterMacCC @BCTrialsANZ #breastcancer
ScienceGovAu
@ScienceGovAu
Today is #worldcancerday. Learn more about #pmprizes recipient, Professor Sherene Loi's (@LoiSher) who is leading research into breast cancer immunology that can improve the survival of #breastcancer patients in Australia and around the world: www.industry.gov.au/data-and-publications/prime-ministers…
-
Sherene Loi, MD
@LoiSher
Hopefully see you all in #berlin @myESMO #bcsm
G Curigliano MD PhD
@curijoey
Submit your abstract! If you are a breast cancer doctor, this is your meeting @myESMO @prat_aleix @PTarantinoMD @OncoAlert @NicoleKuderer @ErikaHamilton9 @stolaney1
-
Sherene Loi, MD
@LoiSher
Congrats @BCTrialsANZ this #clinicaltrial is for early stage #tnbc in #italy #bcsm #breastcancer
Breast Cancer Trials
@BCTrialsANZ
Our first international site for Neo-N has opened at the Instituto Europeo di Oncologia in Italy! Neo-N is investigating whether an immunotherapy drug can help the body's own immune system to fight cancer cells, in people with early-stage triple-negative breast cancer.
-
Sherene Loi, MD
@LoiSher
New from #loilab
Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update @oncoalert #bcsm #immunotherapy #breastcancer
www.thebreastonline.com/article/S0960-9776(21)01025-0/ful… -
Sherene Loi, MD
@LoiSher
#hny everyone near & far. Hoping I see everyone safe & sound in #2022newyear @OncoAlert
-
Sherene Loi, MD
@LoiSher
🍾🥂😀Thank you all for this great honour! Especially Roberto Salgado @TILsWorkGroup @NBCFAus @PeterMacCC @PeterMacRes #loilab @StefanMichiels @sneha_sant @annbyrne27 @BCRFcure
ScienceGovAu
@ScienceGovAu
Congratulations to Professor Sherene Loi @LoiSher from the Peter MacCallum Cancer Centre @PeterMacCC, recipient of the 2021 Frank Fenner Prize for #lifescientist of the Year. Fantastic! More at www.industry.gov.au/pmprizes #pmprizes
-
Sherene Loi, MD
@LoiSher
Review on the last 5years and #tils research @TILsWorkGroup #bcsm #breastcancer
-
Sherene Loi, MD
@LoiSher
Congrats @dradityabardia Amazing 🤩 year for new therapies in #breastcancer and in #breastcancerawareness month #bcsm @OncoAlert
Aditya Bardia, MD
@dradityabardia
Released today: Positive results with elacestrant, the first oral SERD with topline results in a pivotal phase 3 trial (EMERALD), vs standard endocrine therapy, for ER+ MBC. Full data at @SABCSSanAntonio @OncoAlert #bcsm ir.radiuspharm.com/news-releases/news-release-details/men…
-
Sherene Loi, MD
@LoiSher
check ➡️ the video of the project of my very clever graduate student @rashindrie on #artificiallintelligence #digitalpathology #til &postdoc @pssavas Artificial Intelligence (AI) and Lymphocytes #bcsm let me know what you think youtu.be/ijrIDch882M @TILsWorkGroup
-
Sherene Loi, MD
@LoiSher
#abemaciclib approved for early -stage high risk Ki67 high HR+ #breastcancer #pathology pathologists are going to LOVE (not) this CdX (will they need to buy a whole new platform?) @myESMO virtual plenary for updated DFS today #monarche
Erika Hamilton, MD, FASCO
@ErikaHamilton9
This is super helpful, many (including me) have been confused.
Approval based on specific ki-67 endpoint....aka subset of whole trial population....for now.
#abemaciclib #monarche -
Sherene Loi, MD
@LoiSher
ok #bcsm, getting ready to run everyday for the next 10days. @PeterMacCC @PeterMacRes #loilab If anyone is feeling generous #loilab #runner my.unitetofightcancer.org.au/sherene-loi
Sherene Loi, MD
@LoiSher
Thanks @maverybrown! will shout you beer or several next time I'm in Boston 🍾
-
Sherene Loi, MD
@LoiSher
Congrats @parkerlabPMCC awesome and novel work #bcsm #cancerresearch #artificialintelligence #digitalpathology @TILsWorkGroup
nature
@Nature
The results of a study in Nature support the hypothesis that histoplasmonics can be used as a novel alternative or adjunct to general staining. The paper also highlights opportunities for improvements to digital pathology that have yet to be explored. go.nature.com/3mDDuNY
-
Sherene Loi, MD
@LoiSher
Thank you @NBCFAus for your vision #breastcancerawareness #breastcancer
NBCF Australia
@NBCFAus
Congratulations to NBCF-funded researcher and Endowed Chair Prof @LoiSher, who has been awarded the prestigious Australian Academy of Health and Medical Sciences’ Jian Zhou medal for 2021 for her outstanding achievements in breast cancer research. #zeroby2030
-
Sherene Loi, MD
@LoiSher
#tils on the cover of this month's @Annals_Oncology 😊
sciencedirect.com/journal/annals-of-oncology/vol/32/issue/10
@TILsWorkGroup -
Sherene Loi, MD
@LoiSher
Of course it’s a meritocracy. #needherscience #womeninstem
Prof Nisreen Alwan 🌻
@Dr2NisreenAlwan
How sad is this graph?
-
Sherene Loi, MD
@LoiSher
can I ask how people are managing T-DXd CINV? I am finding this to be delayed nausea, mainly D8-12, & not pleasant for many patients #bcsm #breastcancer
Paolo Tarantino
@PTarantinoMD
Small, but significative case series on CINV with T-DXd, suggesting that management as high (rather than moderate) emetic risk may improve tolerance
Appropriate management of T-DXd toxicities will be 🔑 for a safe expansion across oncological indications
pubmed.ncbi.nlm.nih.gov/34602948/ -
Sherene Loi, MD
@LoiSher
October is #breastcancerawarenessmonth. Thank you @BCRFcure for all you do for #breastcancerresearch @PeterMacCC @PeterMacRes
The Breast Cancer Research Foundation
@BCRFcure
"It's a privilege to see how the work we do in the lab is used to design clinical trials that benefit patients."
We're excited to turn our Instagram over to one of BCRF's international researchers, @LoiSher, this #breastcancerawarenessmonth. Follow along: www.instagram.com/bcrfcure/ -
Sherene Loi, MD
@LoiSher
Languishing in times of #covid19 (ie watching #netflix rather than writing papers). Thanks @AdamMGrant Anyone for MarioKart Cancer Docs? @OncoAlert
www.ted.com/talks/adam_grant_how_to_stop_languishing_and_… via @TEDTalks -
Sherene Loi, MD
@LoiSher
Hi #bcsm if you or a friend have met #her2 #breastcancer in Australia, please consider my #clinicaltrial of dual #immunotherapy & #trastuzumab. We know that #immunotherapy can make a big difference to living longer & this trial will help us learn more @BCTrialsANZ @BCNAPinkLady
Breast Cancer Trials
@BCTrialsANZ
The DIAmOND clinical trial is aiming to improve outcomes for patients with metastatic breast cancer, by testing the effectiveness, safety and side effects of a new drug combination. Learn more: www.breastcancertrials.org.au/current-clinical-trials/dia…
-
Sherene Loi, MD
@LoiSher
Now this is a pretty cool idea from @BCTrialsANZ. Cooking lesson (whilst in lockdown boredom #groundhogday) and then party on with your friends at home (post lockdown!). Please have a look! #partytime #athome #masterchef Raise money for #breastcancer reaseach #bcsm and invite me!
Breast Cancer Trials
@BCTrialsANZ
Join the 3 Course Challenge and raise funds for research by challenging yourself to cook a 3 course meal for friends and family. Top chef Sarah Todd will teach you her menu via a livestreamed cooking class. Help save lives, one tasty course at a time! www.3coursechallenge.com.au
-
Sherene Loi, MD
@LoiSher
🍾😊 v. happy to see this ➡️sig.⬅️ improved OS for met #tnbc #immunotherapy congrats to all investigators #keynote355 @hoperugo @JavierCortesMD @Merck thank you to the patients and families! #esmo21 @myesmo @OncoAlert @TILsWorkGroup
Matteo Lambertini, MD PhD
@matteolambe
Oral abstract session on advanced #breastcancer at #esmo21: presented by @hoperugo updated results from #keynote355 trial showing significant #os benefit with addition of #pembrolizumab to #chemotherapy in #tnbc patients with #pdl1 pos (CPS >=10) disease
@OncoAlert @myESMO #bcsm
Sherene Loi, MD
@LoiSher
Will highlight that CPS10 HR, median OS and absolute improval in OS is identical to IMpassion130 PDL1 pos 🤦🏻♀️
-
Sherene Loi, MD
@LoiSher
Join us now on channel 5 #esmo21 @myesmo with @ChristianRolfo
Christian Rolfo
@ChristianRolfo
We are now at the #liquidbiopsy session with @LoiSher. Very well explained presentation by Minetta Liu on WG methtylation for early detection @myESMO #esmo2021 @CharlesSwanton @OncoAlert
-
Sherene Loi, MD
@LoiSher
Fun educational #breastcancer symposium by @NovartisCancer with Drs Peter Fasching, Sandra Franco @MammaMiaMagazin on CDK4i & alpelisib @myESMO#ESMO21
-
Sherene Loi, MD
@LoiSher
Jawdropping waterfall plot, HR (!!) & PFS curves. The cure is here for Stage 4 #her2 #breastcancer! Reassuring safety #bcsm #esmo21 @myESMO 🍾Congrats @JavierCortesMD wish I was there to celebrate!
Matteo Lambertini, MD PhD
@matteolambe
So excited to see in person these data...no comments needed!!!!
#esmo21 #presidentialsession @myESMO @OncoAlert @JavierCortesMD #destinybreast03 -
Sherene Loi, MD
@LoiSher
‘Taliban rename women’s ministry as department ‘for promotion of virtue and prevention of vice’ | 😶 www.independent.co.uk/asia/south-asia/taliban-women-s-min…
-
Sherene Loi, MD
@LoiSher
food for thought: #geparneuvo Durva pCR patients had 100% DDFS; RD DDFS, iDFS was nearly identical to #kn522. note no Durva post op & no Carbo. Will be interesting if adjuvant #atezo and RD pembro trials have any efficacy (I bet no 🤔) #esmo2021 @myESMO @OncoAlert @GBG_Forschung
Erika Hamilton, MD, FASCO
@ErikaHamilton9
Prof. Schmid discusses #kn522
✅ distant events 7.5% different
🚫 diff in benefit from N+ or N- or by PDL1 status
🔆EFS better w/ pCR and pembro than pCR and no pembro
‼️absence of pCR may not rule out EFS benefit
#esmo21 @OncoAlert #bcsm -
Sherene Loi, MD
@LoiSher
Congrats @RebeccaDSing Well deserved & a good friend as well #esmo21 @myESMO
Stephanie Graff, MD, FACP, FASCO
@DrSGraff
So powerful to hear @RebeccaDSing story of how a career unfolds & mentorship against a backdrop of her experience with TNBC #bcsm #womeninmedicine #esmo21
-
Sherene Loi, MD
@LoiSher
Agree that there are other ‘bigger’ things to de-escalate, pity TIL was not done on all these studies too doi.org/10.1093/annonc/mdz007 And we now treat most HER2+ neoadjuvantly so unclear how we can extrapolate #esmo21 #bcsm
Erika Hamilton, MD, FASCO
@ErikaHamilton9
So how do we integrate this into practice @matteolambe? Clear that some can be shortened- lower risk, elderly, travel challenges.
But where do you draw the line? I wouldn't for all at this point. ❓ for all of us.
@curijoey @RebeccaDSing @LoiSher @stolaney1 @OncoAlert -
Sherene Loi, MD
@LoiSher
#esmo21 @myesmo not sure I understand differences with CALGB40603: #brightness differences in recurrences is loco-regional and not distant?
Paolo Tarantino
@PTarantinoMD
Highly anticipated long-term survival results from #brightness
👉the addition of neoadjuvant carboplatin to NACT for stage II-III #tnbc improved pCR & 4y EFS, with a trend in improved OS
❓Qx: is carbo benefit the same in the presence of pembro?
#kn522 #esmo21 #bcsm -
Sherene Loi, MD
@LoiSher
#esmo21 @myESMO well! I think the question about optimal duation of AI in most postmenopausal HR+ #breastcancer is answered! 7-8 years @OncoAlert #bcsm
Kevin Punie
@kevinpunie
#esmo21
😍Magnificent overview of extended adjuvant endocrine trelandmark trials in early #breastcancer
@myESMO #bcsm @OncoAlert
@delmastro_lucia -
Sherene Loi, MD
@LoiSher
#brightness trial post hoc analysis is different to CALGB40603 where 5yr EFS 70.9%, DRFI 76.3%, OS 76.9% not sig. for adding carbo @myESMO #esmo21
Paolo Tarantino
@PTarantinoMD
Wow - impressive EFS benefit of adding carboplatin to NACT for TNBC in #brightness trial!
👉4-year EFS was 79% with carbo vs 68% w/o (HR 0.57, p=0.02)
Just released by @myESMO Daily Reporter, these data will be presented by S.Loibl on 17 Sept @ #esmo21
dailyreporter.esmo.org/esmo-congress-2021/all-articles/br… -
Sherene Loi, MD
@LoiSher
Looking fwd to practise changing data #esmo21 @myESMO for #breastcancer #bcsm rise of #adc the beginning of the end of #chemotherapy 😊
Paolo Tarantino
@PTarantinoMD
With less than 10 days to the official kickoff of #esmo21, it is time for the usual #bcsm top10 & comments!
Incredibly relevant data to be presented during the Congress - expected to reshape the way we’ll treat breast cancer in future times -
Sherene Loi, MD
@LoiSher
Latest from the #loilab Thanks to @pssavas "Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers" pubmed.ncbi.nlm.nih.gov/34487294/ 🌴🎋🌳
-
Sherene Loi, MD
@LoiSher
🙏🙏🥂Thank you @AAHMS_health, @PeterMacRes @PeterMacCC @TILsWorkGroup Loi lab and many, many others along the way @NBCFAus @CancerVic @SusanGKomen @nhmrc @UniMelb @BCTrialsANZ @IBCSG @JulesBordet @myESMO @BIGagainstBC
www.petermac.org/news/professor-sherene-loi-awarded-jian-…
Australian Academy of Health and Medical Sciences
@AAHMS_health
NEWS: the 2021 Jian Zhou Medal winners are @PeterMacCC's @LoiSher, a medical oncologist, & @UQMedicine's @DrD_Immunology, an immunologist. Congratulations to these outstanding scientists! aahms.org/news/scientists-honoured-with-jian-zhou-medals/ (1/2)
-
Sherene Loi, MD
@LoiSher
Seriously #america 😳 dewormer (#ivermectine) as a treatment for #covid19??? #covidvaccine #bias - hear what you want to hear- see what you expect to see
-
Sherene Loi, MD
@LoiSher
Deriving #tcell phenotypes #til
stefan.schattgen
@sschattgen
After long last, I’m excited to introduce CoNGA, our new tool for identifying T cell phenotypic features associated with TCR sequence and specificity using mutliomics datasets.
-
Sherene Loi, MD
@LoiSher
➡️check this! the mental & physical effects of #isolation modelled using #flies 🪰 #lockdown #covid19vic #covid19 #covid19aus 🙏 the benefits of social interaction 🤼🧑🤝🧑 @Nature
www.nature.com/articles/d41586-021-02194-2 -
Sherene Loi, MD
@LoiSher
Peter Mac Virtual lab Tour for National Science Week fb.watch/7tlka1t9q7/ via @FacebookWatch
@PeterMacRes @PeterMacCC @VCCCAlliance #cancerresearch #scienceweek #phdposition @UniMelb featuring #loilab at the very end! 👏😀 -
Sherene Loi, MD
@LoiSher
#tragic OMG So sad #covid19 #covid19aus #covid19nsw look out
WesElyMD
@WesElyMD
1/🧵#covid19 is a disease of blood vessels that can affect your lungs, heart, brain, or any organ. Blood clotting sucks life from vital organs. This pt asked to have her story shared so that others may learn & seek #vaccination. COVID caused blockage of blood to her arms & legs.
-
Sherene Loi, MD
@LoiSher
👇⬇️⬇️👏good news for #bcsm #her2 #breastcancer 👏will be very interesting to see efficacy & #biomarker data as I have had many long term responders to T-DM1
Hope Rugo
@hoperugo
Exciting continued advances in rx of HER2+ disease! Enhertu significantly improved PFS in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer @oncoalert @UCSFCancer www.astrazeneca.com/media-centre/press-releases/2021/enhe…
-
Sherene Loi, MD
@LoiSher
important for #cancer patients in #melbourne #victoria #melbournelockdown
Cancer Council Victoria
@CancerVic
We want to ensure people with cancer know that priority COVID-19 vaccine appointments are available.
If you're unsure about how to make a priority appointment, go to www.cancervic.org.au/get-support/guides/cancer-and-covid/… or call our Cancer Information & Support Line on 13 11 20 (Mon-Fri 9am-5pm). @VicGovDH -
Sherene Loi, MD
@LoiSher
Hi #bcsm it’s apparently #mytwitteranniversary and I’m on 1999 followers.. can I get to 2000 today? 🙏 @OncoAlert #lifeinthetimesofcovid
-
Sherene Loi, MD
@LoiSher
And again! @OncoAlert Drinks on Merck this month!
Valia Karantza
@KarantzaValia
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment www.merck.com/news/fda-approves-keytruda-pembrolizumab-fo…
-
Sherene Loi, MD
@LoiSher
👏Pembro having a good month in #tnbc #bcsm @OncoAlert #keynote355 #immunotherapy
Javier Cortes MD PhD
@JavierCortesMD
Pembrolizumab improves OS in triple negative MBC. Terrific news for our patients today #breastcancer www.merck.com/news/merck-announces-phase-3-keynote-355-tr…
-
Sherene Loi, MD
@LoiSher
Agree! Every birthday is a blessing - an important lesson from #metbc patients
Julia Maués
@itsnot_pink
As someone doing all I can to stay alive, let me say this: getting old beats the alternative!
-
Sherene Loi, MD
@LoiSher
🙏👏Thanks @PTarantinoMD for the shout out!
@TILsWorkGroup #tils #bcsm #breastcancer
Paolo Tarantino
@PTarantinoMD
Don’t miss this Review by @LoiSher & colleagues - just published on @Annals_Oncology - recapitulating the epic journey of TILs in breast oncology
Link: www.annalsofoncology.org/article/S0923-7534(21)02185-2/fu… -
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
Now available to watch on OncologyPRO 👇 #esmovirtualplenary - KEYNOTE-522: addition of pembrolizumab to neoadjuvant #chemotherapy in early #tnbc
Access the recording w/ your free ESMO account: oncologypro.esmo.org/meeting-resources/esmo-virtual-plena…
@FAndreMD @curijoey @LoiSher @DrLisaCarey #breastcancer #bcsm -
Sherene Loi, MD
@LoiSher
Live now #keynote522 #bcsm live question & answer after - submit your questions! #tnbc @myESMO
Paolo Tarantino
@PTarantinoMD
🚨 Don’t miss 2nd day of #esmovirtualplenary, starting in few minutes!
An outstanding panel of experts will discuss the practice-changing data of KEYNOTE-522, navigating the evidence to guide the optimal implementation of pembrolizumab in eTNBC
Link: www.esmo.org/meetings/keynote-522-phase-iii-study-of-neoa… -
Sherene Loi, MD
@LoiSher
#bcsm Join us again later for live discussion of this important study #tnbc with yours truly😊➡️ Friday 16th 9pm AEST, 13h CEST 12noon BST, 7am EDT @OncoAlert 👏
ESMO - Eur. Oncology
@myESMO
July #esmovirtualplenary starting soon 🤩 Join top #oncology experts in this live presentation of the latest data in #breastcancer. Connect with us at 19:30 CEST (13:30 EDT)
👉 www.esmo.org/meetings/keynote-522-phase-iii-study-of-neoa…
@FAndreMD @curijoey @LoiSher @DrLisaCarey #bcsm -
Sherene Loi, MD
@LoiSher
anyone need something to do Friday?
#bcsm #immunotherapy @oncoalert
ESMO - Eur. Oncology
@myESMO
One day to go 🔔 #esmovirtualplenary: Don’t miss this opportunity to discover the latest data in #tnbc and submit your questions to top experts in #oncology 👉 www.esmo.org/meetings/keynote-522-phase-iii-study-of-neoa…
@FAndreMD @curijoey @LoiSher @DrLisaCarey #breastcancer #bcsm -
Sherene Loi, MD
@LoiSher
Congrats all @TILsWorkGroup #tils
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
Understanding the role of #tils in non-invasive #breastcancer patients @ElisaAgostinett @LoiSher @AliceFranzoi @PenaultLlorca @mybsmo @OncoAlert
www.sciencedirect.com/science/article/pii/S096097762100415X -
Sherene Loi, MD
@LoiSher
👀👀 FINALLY EFS #results of #keynote522 a must for #bcsm #breastcancer #immunotherapy - will PD-1 therapy become a std of care???
ESMO - Eur. Oncology
@myESMO
Does the addition of #pembrolizumab to neoadjuvant #chemotherapy improve event-free survival in women with early #tnbc? Join us on 15 & 16 July to discover the latest data in TNBC
👉 More details: www.esmo.org/meetings/keynote-522-phase-iii-study-of-neoa… #bcsm @FAndreMD @curijoey @LoiSher @DrLisaCarey #bcsm -
Sherene Loi, MD
@LoiSher
no, we haven't seen any MSI-H. Responders are immune enriched..
-
Sherene Loi, MD reposted
TILs Working Group
@TILsWorkGroup
Catching up on the latest paper on digital #tils and #tnbc published in @CCR_AACR - #ml #biomarkers eur01.safelinks.protection.outlook.com?url=https%3A%2F%2F…
-
Sherene Loi, MD
@LoiSher
#congratulations Dr Mileshkin- 🥂 to one of our own- @PeterMacCC @PeterMacRes #gyncsm #asco21 #needherscience #plenary 👏👏👏
The ASCO Post
@ASCOPost
Linda R. Mileshkin, MBBS, MD, on Cervical Cancer: Adjuvant Chemotherapy After Chemoradiation ascopost.com/videos/2021-asco-annual-meeting/linda-milesh… #asco21 #gyncsm #oncology #cancer @PeterMacCC
-
Sherene Loi, MD
@LoiSher
30,000 users!! 😊😊
TILs Working Group
@TILsWorkGroup
3⃣0⃣,0⃣0⃣0⃣ users have visited www.tilsinbreastcancer.org!! If you're not one of them, check out our latest initiatives and collaborations (including AI and ML), stay up to date with resources available for pathologists, patients and researches and get in touch! #tils #tilsincancer
-
Sherene Loi, MD
@LoiSher
Hey #bcsm #breastcancer doctors
Quick #poll: at first glance how do you find this image on a website from an international organization dedicated to #breastcancer research? feel free to comment
@OncoAlert
thanks!
Sherene Loi, MD
@LoiSher
poll here
-
Sherene Loi, MD
@LoiSher
Congrats to my #sister researching #dementia #needherscience @TheRMH
Associate Professor Samantha Loi, MD, PhD
@Doctor_Samba
A blood test to potentially diagnose dementia earlier #yod Refer to our @themindstudy for details www.abc.net.au/news/2021-05-25/dementia-diagnosis-with-si…
-
Sherene Loi, MD
@LoiSher
I’d like to say this is not a surprise but good to see it finally confirmed (by press release)🤔 #bcsm @OncoAlert #tnbc #immunotherapy www.merck.com/news/merck-announces-phase-3-keynote-522-tr…
-
Sherene Loi, MD
@LoiSher
Hi everyone involved in #breastcancer care #bcsm can you please complete our survey so we can work out how best to use #tils for patients esp reducing unnecessary treatment #chemo @OncoAlert thank you 🙏
TILs Working Group
@TILsWorkGroup
We've recently launched a global survey on the potential use of #tils for future trial designs and use in daily practice. We would love to hear what you have to say 👇fd7.formdesk.com/BQA/TILs_TNBC_GRAND_FINAL
-
Sherene Loi, MD
@LoiSher
#esmobreast21 education session in #immunotherapy in #tnbc thanks to @lab_kok @curijoey @myESMO hopefully see everyone in Berlin in 2022
-
Sherene Loi, MD
@LoiSher
See you all later! @OncoAlert #bcsm @PeterMacRes @PeterMacCC 🥂🍾
ESMO - Eur. Oncology
@myESMO
#esmobreast21: Join us tomorrow for the ESMO Breast Cancer Award 2020 Keynote lecture by @LoiSher: 'Stories in #breastcancer #immunology and #genomics'.
8 May at 12:00 CEST
👉cattendee.abstractsonline.com/meeting/10470?hit=some
#bcsm -
Sherene Loi, MD
@LoiSher
Don’t see the logic of this argument #bcsm
Sara Tolaney
@stolaney1
could early breast cancer studies serve as confirmatory studies for IMP130? #bcsm
-
Sherene Loi, MD
@LoiSher
Patient selection bias, underpowered, PDL1 assay issues... I’d like to see results by other immune markers as we know they influence survival esp OS in met #tnbc #bcsm #tils
Sara Tolaney
@stolaney1
ODAC discussion: Differences in outcomes between IMP130 vs IMP131. OS in IMP131 in PDL1+ control arm (28 mo) seems quite unexpected based on what we know, and makes one wonder if this is chance. #bcsm
-
Sherene Loi, MD
@LoiSher
Next move for #atezo in met #tnbc #immunotherapy
-
Sherene Loi, MD
@LoiSher
Hi #bcsm @OncoAlert breast cancer doctors pls take 10 min to compete out #tils survey fd7.formdesk.com/BQA/TILs_TNBC_GRAND_FINAL thank you 🙏
-
Sherene Loi, MD
@LoiSher
Very nice explanation @peripatetical of benefit vs risk; the crux of modern medicine & treatment decision making...
Why we decided to put the Pfizer vaccine ahead of AstraZeneca for under-50s www.smh.com.au/national/why-we-decided-to-put-the-pfizer-… -
Sherene Loi, MD reposted
VJ Oncology
@VJOncology
🎧 Check out our latest podcast evaluating the role of predictive & prognostic biomarkers in #breastcancer
Featuring Judy Garber (@DanaFarber), Martine Piccart (@ULBruxelles) and @LoiSher (@PeterMacCC)
Listen here 👉 www.vjoncology.com/podcast/predictive-and-prognostic-biom…
@VJOncology #bcsm #tailorx #mindact -
Sherene Loi, MD
@LoiSher
Congrats to all @TILsWorkGroup #bcsm @prat_aleix @Nchic5
-
Sherene Loi, MD
@LoiSher
Thanks everyone for a great panel discussion #sgbcc21 check my companions #bostonterrier
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Another incredible session at St Gallen breast cancer meeting, this time in TNBC. @curijoey @LoiSher
-
Sherene Loi, MD
@LoiSher
🤔😳
#march4justicemelbourne #marchforjustice #enoughisenougth😡 #scottydoesnothing -
Sherene Loi, MD
@LoiSher
Pls join us online #bcsm #sgbcc21
Always amazing talks and consensus panel
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
The biennial St Gallen Breast Cancer Consensus Conference is in 2 weeks. Join us for the Panel discussions, the most exciting two days in breast oncology, as the world's top experts debate standards of care.
@curijoey @DrEricWiner @LoiSher @breastDoktor
mailchi.mp/919b3772137e/sg-bcc-2021-we-have-some-exciting… -
Sherene Loi, MD
@LoiSher
Check it out #bcsm #tils #breastcancer #immunology #immunotherapy #machinelearning
TILs Working Group
@TILsWorkGroup
🧐Checkout our latest publication, NuCLS, describing the crowdsourcing and public release of 200,000 annotations of breast cancer nuclei including TILs. 👇 www.tilsinbreastcancer.org/tils-machine-learning-projects/
-
Sherene Loi, MD
@LoiSher
👏👏👏great news for all #brca germline carriers - adjuvant #olaparib trial positive for primary endpoint in early #breastcancer www.astrazeneca.com/media-centre/press-releases/2021/olym… Congrats @BIGagainstBC @OncoAlert
-
Sherene Loi, MD
@LoiSher
#tils Scoring youtu.be/qkrXf50fBqE via @YouTube learn how to score TILs yourself @TILsWorkGroup in #breastcancer #bcsm
-
Sherene Loi, MD
@LoiSher
#lockdown2021 reading #immunology #immunotherapy @PeterMacRes @OncoAlert
Nature Medicine
@NatureMedicine
🌟 New Review Article out now from Ilio Vitale, @deadoc80 and colleagues, discussing the sources and impact of intratumoral heterogeneity in #cancer progression and treatment. @ShemaEfrat @LoiSher. #epigenetics #intratumoralheterogeneity @WCM_MeyerCancer
www.nature.com/articles/s41591-021-01233-9 -
Sherene Loi, MD
@LoiSher
FDA summary of ##neoadjuvant pembro for unselected early #tnbc
www.fda.gov/media/145654/download
1. pCR-clinically relevance of 7.5%⬆️unknown
2.effect on EFS too early
3. pembro can be assoc. with life-long severe immune side-effects, hence benefit:risk ratio unclear @OncoAlert -
Sherene Loi, MD
@LoiSher
👀👀 friends of #tils #bcsm @OncoAlert #breastcancer
The Breast Cancer Research Foundation
@BCRFcure
Learn more about tumor infiltrating lymphocytes (TILS)—what they are and how they apply to breast cancer—in this informative video from the BCRF-supported International TILS Working Group. @LoiSher
www.youtube.com/watch?v=aPa-pXIBBlU -
Sherene Loi, MD
@LoiSher
Congrats for this important study for #breastcancer @OncoAlert #palbociclib
Erica Mayer
@elmayermd
So grateful to our global team as well as the many patients participating in PALLAS. Now in press!
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study www.thelancet.com/journals/lanonc/article/PIIS1470-2045(2… -
Sherene Loi, MD
@LoiSher
#cancer research perspectives from around the #world hopefully moving past #covid in 2021 @PeterMacRes @PeterMacCC
Cancer Cell
@Cancer_Cell
Happy New Year! We want to share our hopes and optimism for 2021, as well as the great cancer research that is in the pages of our January 2021 issue. Read it now: www.cell.com/cancer-cell/issue?pii=S1535-6108(20)X0002-X
-
Sherene Loi, MD reposted
Allen Cheng
@peripatetical
Why would we use a vaccine that mightn't prevent transmission? Should we use one particular vaccine, or roll out the vaccines we have as broadly and quickly as possible?
-
Sherene Loi, MD
@LoiSher
Hi everyone! Check our 👀#tils Education video: What They Are and What They Do youtu.be/aPa-pXIBBlU via @YouTube also www.tilsinbreastcancer.org #bcsm #immunotherapy #tnbc #breastcancer
Sherene Loi, MD
@LoiSher
@OncoAlert thanks to @BCRFcure
-
Sherene Loi, MD
@LoiSher
🍸
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Make sure to watch @AACR Outstanding Investigator Award Recipient @LoiSher discuss using genomics to better understand the breast cancer microenvironment. #sabcs20 #bcsm @MedMtgNews
www.sabcsmeetingnews.org/aacr-outstanding-investigator-aw… -
Sherene Loi, MD
@LoiSher
Congrats @KalinskyKevin I think ovarian suppression is only part the story & there is a different biology of young #breastcancer Stay tuned for data from our analysis of the SOFT Study #sabcs20 🔬
Hope Rugo
@hoperugo
Remarkable results from RxPonder from Kevin Kalinsky. Is this at least in part ovarian suppression? Impact of post chemo hormone rx? More data to follow. Some need more and some need less. Now how to improve outcome with ET? @sabcs2020 @OncoAlert
-
Sherene Loi, MD
@LoiSher
Congrats @prat_aleix➡️ is PAM50 basal-like "ER-low" (<10%)? & importantly what is "HER2-enriched" made of, if not HER2+. Maybe should be named "Luminal-H" . Copy Number unstable? CCND1 amp? ER poor <50%: more analysis needed pls 👏
Debora Fumagalli
@DebFumagalli
👏 Congratulations @prat_aleix for the great and insightful presentation!💥Impressive benefit observed in patients with HER2E breast cancers treated with ribociclib and ET across the #monaleesa trials. #sabcs2020
-
Sherene Loi, MD
@LoiSher
#penelope-B- negative for IDFS; ➡️ why ?underpowered (n=1100); only 1 yr (curves do separate early on) ~25% highKI67 (central path), 50% N2-3 some differences c/w #monarch-E (apart from palbo/abema) @OncoAlert
Erika Hamilton, MD, FASCO
@ErikaHamilton9
#penelope-B presented by Dr. Loibl does not show a difference 🚫 in disease free survival at almost 4 year f/u, HR0.93, p=0.5 when patients with HR+ disease w/ non-pCR to neoadjuvant therapy were given palbociclib x 1yr.
#bcsm @OncoAlert #sabcs20 -
Sherene Loi, MD
@LoiSher
The Breast Cancer Research Foundation
@BCRFcure
Meet BCRF investigator @LoiSher (and her pup Basil!) in this @SABCSSanAntonio quick interview.
-
Sherene Loi, MD
@LoiSher
Thank you @myESMO @PeterMacRes @PeterMacCC And thank you to all my many collaborators @TILsWorkGroup & my lab! 🍸
Peter Mac Research
@PeterMacRes
Peter Mac's @LoiSher has received the ESMO Breast Cancer Award. She and fellow awardees praised for their "will to improve cancer patients’ lives ... a worthwhile reminder that progress is possible through adversity". More: perspectives.esmo.org/news/keeping-progress-in-oncology-o…
-
Sherene Loi, MD
@LoiSher
Out today KEYNOTE355 m#TNBC #bcsm #immunooncology @oncoalert 1. Pembro sig. improves PFS in PDL1 high mTNBC added to chemo 2. Effect ⬆️with higher PDL1 levels 3. No OS data yet www.sciencedirect.com/science/article/pii/S0140673620325319
-
Sherene Loi, MD
@LoiSher
Congrats to my graduate student Dr Ran Li surgeon #sabcs20 Don’t miss his poster #tucatinib @SeagenGlobal #bcsm #immunooncology @PeterMacCC @PeterMacRes
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Meet Ran Li of @peterrmacc, #sabcs20 Basic Science Scholar for: Tucatinib favorably modulates the immune microenvironment and synergizes with anti-PD1 therapy in a trastuzumab resistant HER2+ murine model, PS10-04 Wednesday, Dec. 9
-
Sherene Loi, MD
@LoiSher
👀➡️hi #bcsm friends of #tils - check out our #breastcancer movie preview and pls leave comments on what can be improved for #cancer patients understanding #til thank you
www.tilsinbreastcancer.org/tils-movie/ -
Sherene Loi, MD
@LoiSher
#sabcs20 #bcsm eagerly awaiting new data in #lockdown. PenelopeB, KN355, RxPONDER; de-escalation RT in #dcis, meditation & mindfulness for #young #breastcancer #survivors; IPAT130 @OncoAlert
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
What @AACR said.
-
Sherene Loi, MD
@LoiSher
#tnbc #bcsm #immunotherapy #tils
Hope Rugo
@hoperugo
Great news for patients with mTNBC. More options are good!! FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer | FDA www.fda.gov/drugs/drug-approvals-and-databases/fda-grants…
-
Sherene Loi, MD reposted
-
Sherene Loi, MD
@LoiSher
Congratulations @JoeBiden @KamalaHarris #usaelection2020 #usavotes #election2020 well done #usa finally! This selfie when @joebiden opened @PeterMacCC was worthwhile! #bcsm
-
Sherene Loi, MD
@LoiSher
#dancing for #democracy 😍
-
Sherene Loi, MD
@LoiSher
huge shout out to @annbyrne27 for leading this amazing effort. #whatastar @PeterMacCC #unitetofightcancer
Ann Byrne
@annbyrne27
Extremely proud of Team Loi Lab for raising over $8900 for the #unitetofightcancer 2020 Event! Such a fantastic effort from the lab, together we covered over 1220kms in 10 days to raise funds for #cancerresearch 🏃♀️🚴♂️Huge Congratulations!! 🎉@PeterMacCC @PeterMacRes @LoiSher
-
Sherene Loi, MD
@LoiSher
lovely data 👏. also need to understand interaction of recurrent co-mutations, combinations to stop pathway convergence mutations as well as tumor microenvironment #personalised #cancer #therapy
FabriceAndre
@FAndreMD
Precisio Medicine (PM) v1 has reached its plateau with around 20 genomic alterations validated (no more). we must move PM to next level: integrate X dimensions of biology, ex vivo modelling, mutational process, subclones, PK, MoA of ADC/BiSpe Ab ascopubs.org/doi/full/10.1200/JCO.19.03010
-
Sherene Loi, MD
@LoiSher
Hey @ESSOnews what’s with your #manels? @ManelWatchUS @OncoAlert #breastcancerawarenessmonth
European Society of Surgical Oncology (ESSO)
@ESSOnews
NEXT WEEK🗓️16 Oct 2020 ⏰12:30 CEST
🗣️Moderated by @tiborkovacsdr, panelists: Christian Jackisch, Michael Knauer & Fabien Reyal ⤵️
www.staging.medscape.org/sites/townhall/public/her2-pos-e…
#her2positive #breastcancer #earlybreastcancer #breastcancerawarenessmonth #neoadjuvant #some4surgeryery Medscape Education
Sherene Loi, MD
@LoiSher
@peters_solange @FAndreMD no female breast surgeons in Europe?
-
Sherene Loi, MD reposted
FabriceAndre
@FAndreMD
Shocking news this sunday. The risk now is that negationists will deny the overall impact of palbociclib. Nice quote by C Boschoff: "We are proud of the transformative impact palbociclib has had on the treatment of HR+, HER2- metastatic breast cancer" www.pfizer.com/news/press-release/press-release-detail/pe…
-
Sherene Loi, MD
@LoiSher
Second negative study in early- stage disease for #palbociclib: the plot deepens for differences between it & #abema 🤔Rate of discontinuations? www.businesswire.com/news/home/20201009005066/en/PENELOPE…
-
Sherene Loi, MD
@LoiSher
#map2020 >250 viewers currently online, great talks on #biomarkers in #immunotherapy in #cancer. Join the live Q&A discussion shortly @myESMO
-
Sherene Loi, MD
@LoiSher
#map2020 #metastatic #cancer patients with #covid19 had higher rates of progression, longer viral carriage and poorer response to ant-cancer treatment
-
Sherene Loi, MD
@LoiSher
Going live shortly @myESMO #map2020
Paolo Tarantino
@PTarantinoMD
Stellar lineup for the upcoming @myESMO #map20 session on immunotherapy biomarkers
👉IO can be transformative for some pts, but no activity in seen in many others.
Biomarkers are 🔑 to discern these populations, and adapt strategies to the expected outcome
@LoiSher @OncoAlert -
Sherene Loi, MD
@LoiSher
#bcsm #breastcancerawarenessmonth #breastcancerawareness #breastcancer
Breast Cancer Trials
@BCTrialsANZ
Our online live Q&A is tomorrow! Have you registered?
Join us and four of Australia's leading breast cancer experts tomorrow night at 6pm AEDT to have your breast cancer questions answered. Register here: www.eventbrite.com.au/e/breast-cancer-2020-the-medicine-t… -
Sherene Loi, MD
@LoiSher
Results of KATE2: phase 2 of TDM-1+atezo/placebo
What did we learn? 1) met #her2+ & #immunotherapy needs #til #pdl1 enrichment 2) TDM-1 cannot change PDL1 - to + 3) Atezo HR stronger for OS in PDL1+
www.sciencedirect.com/science/article/pii/S1470204520304654 #oncoalert #bcsm P3 KATE3 to start! -
Sherene Loi, MD
@LoiSher
#covid19vic #melbournelockdown #covid_19 From blurry vision to heart arrhythmia, the Covid survivors www.bloomberg.com/graphics/2020-opinion-covid-long-hauler… via @bopinion
-
Sherene Loi, MD
@LoiSher
#map2020 @myESMO should be fun
ESMO - Eur. Oncology
@myESMO
#map2020: Register today, free of charge, for MAP 2020 Virtual. Learn more about: Molecular Targeting, Clonal Evolution, Epigenetics, Mechanisms of IO Toxicity, Biomarkers for Immunotherapeutics and new Technologies for Therapeutic Targeting www.esmo.org/meetings/map-virtual-2020/registration?hit=some
-
Sherene Loi, MD
@LoiSher
great editorial by @awolff @ASCO_pubs #esmo20 of #monarche data #bcsm
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)
@awolff
Here are the #monarche data presented by Stephen Johnston, beautifully discussed by @GeorgeSledge51, and simultaneously published in #jco @ASCO_pubs. Congratulations to all and a deep appreciation to study participants. A lot still to learn. #esmo20
-
Sherene Loi, MD
@LoiSher
No doubt #stil should be routine #breastcancer pathology reporting. Use as stratification, prognostication, future #immunotherapy treatment allocation & de-escalation studies. @TILsWorkGroup
FabriceAndre
@FAndreMD
Very consistent data ! the hypothesis is now robust enough to allow starting prospective trials on the topic
-
Sherene Loi, MD
@LoiSher
Summary of MONARCH-E presentation #esmo20
OncoAlert
@OncoAlert
Friends at #esmo20
An Honor to present our @OncoAlert 🚨Colleague @ErikaHamilton9 👩⚕️🇺🇸
Discussing:
#monarche presented at ESMO presidential by Dr.Johnston
✅adding #abemaciclib to adjuvant #et improves the outcomes of #hr+/#her2- high risk #breastcancer
@weoncologistsThis media couldn't be displayed. See it on the original post. -
Sherene Loi, MD
@LoiSher
Interesting 🧐 that pCR rates look similar across 031 & KN522 studies with Atezo/pembro despite carbo & difference in %PDL1 pos by assay. @OncoAlert #esmo20 #bcsm
Sara Tolaney
@stolaney1
Impressive pCR benefit seen in IMP031 regardless of PD-L1 status with the addition to atezo to anthracycline + taxane chemotherapy (no platinum in backbone); study won't be powered adequately for EFS, and still waiting on KN522 final EFS data @EMittendorfMD @OncoAlert #esmo20
-
Sherene Loi, MD
@LoiSher
Unfortunately high rate of #palbo discontinuations (>40%) most likely influenced results of #pallas and will make #translational research difficult to interpret @OncoAlert #esmo20 ☹️
Kevin Punie
@kevinpunie
#esmo20
#pallas efficacy
#palbociclib added to adjuvant endocrine therapy in early HR+/HER2- #breast cancer does not improve iDFS and DRFS
@OncoAlert @myESMO #bcsm -
Sherene Loi, MD
@LoiSher
TIL reading training free for everyone on our website below @OncoAlert #esmo20
-
Sherene Loi, MD
@LoiSher
ready for another late night watching virtual #esmo20 in #melbournelockdown2020 looking fwd to data in early-stage #breastcancer #bcsm adjuvant CDK4i and #immunotherapy
-
Sherene Loi, MD
@LoiSher
AMAZING data @bensolomon1 👏pharmacology matters! #esmo20 @OncoAlert
Manuel Dómine, MD, PhD
@ManuelDomine
CROWN Ph III Trial: Lorlatinib vs crizotinib as 1St line treatment in ALK + advanced NSCLC. Excellent results showing an significant improvement in PFS (NE vs 9.3; HR 0.28). Proud to participate in this trial.
@Hospital_FJD @OncoAlert @gecp_org @myESMO -
Sherene Loi, MD reposted
Erika Hamilton, MD, FASCO
@ErikaHamilton9
#nextmonarch OS at #esmo20:
Remember all pts had at least 2 chemo & HR+ MBC
🌟 abema 150 BID + tam ⬆️ OS to 24.2 mo compared to 17.0 mo w/ abema 200 BID monotherapy
💫 PFS & ORR not statistically different
✨ abema alone arms still gave PFS >7 mo
@OncoAlert @SarahCannonDocs -
Sherene Loi, MD
@LoiSher
Impressive OS #ascent #tnbc @ImmunomedicsInc #bcsm #esmo20 @OncoAlert 👀look out for many more #adcs in the future
-
Sherene Loi, MD
@LoiSher
Congrats @bensolomon1 #lcsm @OncoAlert @PeterMacCC #esmo20
Ben Solomon
@bensolomon1
Looking forward to presenting the results of the CROWN phase 3 study at the #esmo2020 Presidential Symposium & sharing the virtual podium with the brilliant @christine_lovly and @peters_solange #lcsm @myESMO
-
Sherene Loi, MD
@LoiSher
Similar to KEYNOTE119 data but there #tmb was independent of PDL1 #esmo2020 show #breastcancer has low #tmb but still important in immune responses
Kevin Punie
@kevinpunie
#esmo20 👇#tmb and outcomes in 1⃣line M+ #tnbc < #impassion130
🔹median TMB 4,39 mut/Mb
🔹no correlation between TMB and PD-L1 SP142 nor #stils
🔹trend between ↗️TMB and ↗️clinical benefit of #atezolizumab in PD-L1+ but not in PD-L1-
#oncoalert #bcsm @hoperugo @LoiSher -
Sherene Loi, MD reposted
Kevin Punie
@kevinpunie
🚨Less then 🔟days before the start of virtual #esmo20 and 2⃣weeks before the start of the science weekend, besides looking forward to our #youngoncologistcommittee track, i'm eagerly awaiting so many new exciting data in #breastcancer
My top 10 selection🤗 👇@OncoAlert @myESMO -
Sherene Loi, MD
@LoiSher
Good #lockdownmelbourne reading #covid19aus #commonsense well done @P_Charles_ID_Dr @theage
-
Sherene Loi, MD
@LoiSher
latest from the Loi Lab: genomic sequencing is important for met BC patients #mbc @mbcalliance #bcsm #breastcancer #genomics #precisionmedicine
@BioMedCentral congrats @pssavas
funded by @PeterMacRes @PeterMacCC @BCTrialsANZ
breast-cancer-research.biomedcentral.com/articles/10.1186… -
Sherene Loi, MD
@LoiSher
#covidvic19 #melbournelockdown #winter #daiquiri #midweekmotivation
-
Sherene Loi, MD
@LoiSher
#agta2020 #genomics and #cancer
Australasian Genomic Technologies Association AGTA
@agtaGenomics
We have secured speakers for #agtalive #agta2020: @SerenaNikZainal, @thedawsonlab, @apfelnz, @ElinSGrayPhD, @dralexswarbrick, @LoiSher and many more. Special thanks to Cris Print, @markjcowley, Nic Waddell, @TamsinRobb, @VikkiMareeMarsh @helenspeirs1 @MarcelDinger, Ruby Lin & LOC
-
Sherene Loi, MD
@LoiSher
Elimination of #covid19vic in NZ. Published @NEJM
Norman Swan
@normanswan
Successful Elimination of Covid-19 Transmission in New Zealand | NEJM www.nejm.org/doi/full/10.1056/NEJMc2025203?query=featured…
-
Sherene Loi, MD
@LoiSher
Very timely @MaverickNY - @RimmPathology always has good points to make on #tmb #pdl1 #macrophages
Sally Church
@MaverickNY
Quick update on the ongoing story for atezolizumab in TNBC for BSB subs:
pxlme.me/bCQ56MkE -
Sherene Loi, MD
@LoiSher
IMpassion131 primary endpoint (PFS) NEGATIVE for 1L PD-L1 pos met TNBC. Disappointing.
Is the paclitaxel (chemo backbone), steroid premed, or Atezo (vs pembro)? #bcsm #immunotherapy #tnbc what about #til and #tmb?www.businesswire.com/news/home/20200806005915/en/Genentec… -
Sherene Loi, MD
@LoiSher
As if #lebanon #beirut needed this ☹️ #beirutblast
sina
@sinabooeshaghi
Using dimensional analysis I estimate that the energy contained in the awful #beirut explosion was approximately 12 Terajoules = 3 kilotons of TNT. For reference the "Little Boy" dropped on #hiroshima was ~13-18 kilotons of TNT. #orderofmagnitudephysics
-
Sherene Loi, MD
@LoiSher
1918 Flu, Masks and Lessons for #covid19vic #covid19 #maskupmelbourne #lockdownmelbourne #historyrepeats thanks @nytimes @DrHBurstein www.nytimes.com/2020/08/03/us/mask-protests-1918.html
-
Sherene Loi, MD
@LoiSher
the potential of #immunotherapy in #her2 #malebreastcancer #bcsm #clinicaltrials @BCTrialsANZ The DIAmOND Clinical Trial - Richard - Trial Participant youtu.be/D87ZK6I-k_c via @YouTube
-
Sherene Loi, MD
@LoiSher
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
We can't wait to see you in December! So check your internet connections because #sabcs20 is going VIRTUAL. Same amazing content and collaboration. Serious social distancing. Stay tuned for more details.
-
Sherene Loi, MD
@LoiSher
This is my 12yr son #homeschooling #lockdownmelbourne #covidー19 #covid19vic #bostonterrier
-
Sherene Loi, MD
@LoiSher
That’s awesome 👏 #antiaging #happymonday #exercise
Science Magazine
@ScienceMagazine
New research demonstrates that the beneficial effects of exercise in mitigating brain aging can be conveyed from exercising mice to sedentary mice through plasma transfer. Learn more in this #scimagperspective: ($) science.sciencemag.org/content/369/6500/144
-
Sherene Loi, MD reposted
-
Sherene Loi, MD reposted
Global Immunotalks
@globalimmuno
We are looking forward to the next #globalimmuno talk this Wednesday 7/22 at 9am PST noon EST 4pm GMT by Dr. Alexander Rudensky
Title: "Regulatory T cells"
LINK: ucsd.zoom.us/j/91053505061
Meanwhile catch up with the terrific previous talks at: youtube.com/channel/UCXn0y -
Sherene Loi, MD
@LoiSher
I reckon 80% mask 😷compliance at local @woolworths which is great news 👏#maskupmelbourne a #smallstep by #everyone can make a difference #covidvic
-
Sherene Loi, MD
@LoiSher
Good pic @DrJaneMunro #maskupmelbourne #covid19vic
Prof Jane Munro
@DrJaneMunro
It’s simple #maskupmelbourne
-
Sherene Loi, MD
@LoiSher
Congrats @WheatleyAtotheK @unimelb @TheDohertyInst #melbournelockdown important article on #covid19 #covid19aus
Nature Medicine
@NatureMedicine
In recovered #covid19 patients, virus spike-specific #antibodies were consistently elicited, but neutralizing activity was variable and inversely correlated with the proportion of CCR6+CXCR3- spike-specific circulating T follicular helper cells. @unimelb go.nature.com/2ATrwf4
-
Sherene Loi, MD
@LoiSher
Thanks for the shout out!@Annals_Oncology @PeterMacRes @unimelb #bcsm
Annals of Oncology
@Annals_Oncology
In press in Annals of Oncology: association of late recurrence with genomic alterations 🧬 identified in primary tumors of ER+/HER2- #breastcancer from the BIG 1-98 study www.annalsofoncology.org/article/S0923-7534(20)39934-8/fu… @LoiSher @RositaKammler @pssavas @Merregan #bcsm
-
Sherene Loi, MD
@LoiSher
Tragic is the toll of #breastcancer #research #theanswer vale
The New York Times
@nytimes
Kelly Preston, an actress known for her role in the 1996 film “Jerry Maguire,” died Sunday at 57. The cause was breast cancer, her husband, the actor John Travolta, said in an Instagram post. www.nytimes.com/2020/07/13/movies/kelly-preston-dead.html…
-
Sherene Loi, MD
@LoiSher
Day 2 #lockdownmelbourne #sunset tonight
-
Sherene Loi, MD reposted
SBS News
@SBSNews
See how Victoria's spike compares to other second waves around the world. www.sbs.com.au/news/article/coronavirus-resurgence-in-gra…
-
Sherene Loi, MD
@LoiSher
our latest article: Identifying oncogenic drivers associated with late distant recurrence in post-menopausal, HR+ BC #bcsm @Annals_Oncology with @pssavas @Merregan
www.annalsofoncology.org/article/S0923-7534(20)39934-8/pdf -
Sherene Loi, MD
@LoiSher
#covidvic #covid19vic #lockdown starts again in #melbournelockdown #sigh 🤔back to #zoom drinks and catchups
Pat Hudson Cartoons
@phudsonink
-
Sherene Loi, MD
@LoiSher
congrats to @BCTrialsANZ @PeterMacCC Neo-N first patient enrolled today! #bcsm #tnbc #immunotherapy @bmsnews
Sherene Loi, MD
@LoiSher
Proud to announce “Neo-N” new #breastcancer #tnbc #clinicaltrial for #australianwomen with less #chemo and #nivolumab @bmsnews @BCTrialsANZ #bcsm www.breastcancertrials.org.au/current-clinical-trials/neon
-
Sherene Loi, MD
@LoiSher
Proud to announce “Neo-N” new #breastcancer #tnbc #clinicaltrial for #australianwomen with less #chemo and #nivolumab @bmsnews @BCTrialsANZ #bcsm www.breastcancertrials.org.au/current-clinical-trials/neon
-
Sherene Loi, MD reposted
Breast Cancer Trials
@BCTrialsANZ
CAPTURE is a new clinical trial from Breast Cancer Trials which hopes to improve outcomes for women and men with ER+, HER-2 negative metastatic breast cancer with the PIK3CA genetic mutation. Learn more about CAPTURE here: www.breastcancertrials.org.au/current-clinical-trials/cap…
This media couldn't be displayed. See it on the original post. -
Sherene Loi, MD
@LoiSher
Amen to that #2020worstyear
-
Sherene Loi, MD
@LoiSher
#covid19aus, some history on the common #cold #covid19
-
Sherene Loi, MD
@LoiSher
👍🏻🍾
The New York Times
@nytimes
Australia and New Zealand will serve as co-hosts for the 2023 Women’s World Cup, which will also be FIFA's first 32-team women’s championship www.nytimes.com/2020/06/25/sports/soccer/womens-world-cup…
-
Sherene Loi, MD
@LoiSher
See the beauty still left around us and be happy #whosaidthat #theworld #covid19
CNN
@CNN
Barcelona opera house reopens with performance to 2,292 plants edition.cnn.com/style/article/barcelona-opera-plants-scli…
-
Sherene Loi, MD
@LoiSher
Or (IMO) also reflects differences in the host between early stage and advanced disease. #bcsm #immunotherapy #tnbc when will we see the data @Roche @genentech
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
IMPASSION031 study from Roche shows atezo improves pCR in early stage TNBC, regardless of PDL1 status. Interesting that both neoadj trials (KEYNOTE 522, IMP031) show activity regardless of PDL1; not so in IMP130 or KN355 in metastatic TNBC.
www.globenewswire.com/news-release/2020/06/18/2049851/0/e… -
Sherene Loi, MD
@LoiSher
Let’s speculate why 😉 1. Need to target earlier recurrences 2. Rate of Palbo discontinuations early on? 3. Logic of such an early futililty analysis in Pallas? 4. ET alone does a great job curing stage 2 #bcsm #palbo #abemaciclib
-
Sherene Loi, MD reposted
Cancer Cell
@Cancer_Cell
Join us in congratulating our new Advisory Board Members and in thanking members who have continuously supported us throughout the years 👏👏
-
Sherene Loi, MD reposted
Peter Dubsky
@breastDoktor
Disappointing: Stop of active #pallas Tx phase due to likely futility www.businesswire.com/news/home/20200529005610/en/Pfizer-U…
But: 5796 pt remain in 10-year follow up, largest luminal BC (blood and FFPE-tissue) biomarker sample, ever.
@ABCSGVienna,@ALLIANCE_org,@BIGagainstBC, @elmayermd @MichaelGnant #bcsm -
Sherene Loi, MD
@LoiSher
Agree- I think just goes to show how well we are curing low risk patients with Stage II #breastcancer , and that Stage 4, even de novo, is a different biological entity.
FabriceAndre
@FAndreMD
PALLAS (adjuvant palbo): " unlikely to be + at the 2nd interim". when a drug w HR:0.5 in M+ is - in adj; there is an urgent need to use new mol methods for pt selection: ctDNA , path / AI. @archerdxinc @GuardantHealth @NateraOncology @OWKINscience www.businesswire.com/news/home/20200529005610/en/Pfizer-U…
-
Sherene Loi, MD
@LoiSher
congrats @breastDoktor #asco20
Peter Dubsky
@breastDoktor
My first virtual presentation: acc. to technician >2000 participants! Take away1: it’s lonely, take away2: Audio can be terrible.. misunderstood question , take away3: Twitter account goes crazy. Thank you all for comments and rt..but I still miss hugging people.@myESMO #bcsm
-
Sherene Loi, MD
@LoiSher
fantastic for breast cancer patients #bcsm #her2 #asco2020
Tatiana Prowell, MD
@tmprowell
#asco20 #bcsm:
HER2CLIMB RCT (trastuzumab/capecitbine + placebo/tucatinib)➡️FDA approval of tucatinib in 4/20 in HER2+ MBC
Expl analysis in pts w/ #brainmets (N=291), incl untreated & active BM:
👉OS HR 0.58 (0.4-0.85)
👉Med OS 18.1 v 12 mos
ascopubs.org/doi/figure/10.1200/JCO.20.00775
@nlinmd et al -
Sherene Loi, MD
@LoiSher
#esmobreast20 Presenting from #downunder #australia at 2am. Though if I was in Berlin I’d be very jet lagged too by this time @FAndreMD
-
Sherene Loi, MD
@LoiSher
Starts today #bcsm
#esmobreast20
ESMO - Eur. Oncology
@myESMO
⏰#esmobreast20: The countdown is on! Sibylle Loibl and @curijoey (Chairs) give their take on what to expect and what not to miss 😀youtu.be/rT807Whc0zk
-
Sherene Loi, MD
@LoiSher
Congrats @paulbeavis4 Et al @PeterMacCC @PeterMacRes #immunotherapy @NatImmunol
Junyun Lai
@JunyunLai
Our study is out in Nature Immunology today! URL: www.nature.com/articles/s41590-020-0676-7
Brief description of our study below (1/7): -
Sherene Loi, MD reposted
FabriceAndre
@FAndreMD
A selection of 10 papers related to breast cancer published in the last 12 months in @Annals_Oncology . thanks to the authors for trusting us to disseminate their research.
Annals of Oncology
@Annals_Oncology
With #esmobreast20 just around the corner, Annals of Oncology has prepared a collection of most read #breastcancer articles. Free access using this link: www.annalsofoncology.org/content/esmobreast2020 #bcsm @myESMO
-
Sherene Loi, MD
@LoiSher
Virtual #esmobreast20
@myESMO #breastcancer -
Sherene Loi, MD
@LoiSher
Comment on KEYNOTE522 #breastcancer # immunotherapy authors.elsevier.com/a/1b2W85TA51THJl
-
Sherene Loi, MD
@LoiSher
The new virtual world #esmo #breastcancer
-
Sherene Loi, MD
@LoiSher
Great explanation #covid2019au
Benjamin Alvarez
@BenjAlvarez1
This is how Angela Merkel explained the effect of a higher #covid19 infection rate on the country's health system.
This part of today's press conf was great, so I just added English subtitels for all non-German speakers. #flattenthecurve -
Sherene Loi, MD
@LoiSher
Loi Lab meeting in times of #covid19aus #breastcancer research #immunotherapy @PeterMacCC @PeterMacRes
-
Sherene Loi, MD
@LoiSher
I’m in and I’m sure the lab will come too @annbyrne27 @PSavas @sneha_sant
Maurizio Scaltriti
@ScaltritiLab
#cancer research scientific community, when #covid2019 emergency is over, I propose to have a retreat in my home town in #italy. I promise to have my mum to cook at least one meal everyday for the attendants. Who is in? @sloan_kettering #medtwitter #sciencetwitter
-
Sherene Loi, MD
@LoiSher
Everyone take note #covid19aus #coronavirusaustralia #coronavirus
FabriceAndre
@FAndreMD
seriously ? France had almost the same guidelines 11 days ago and is now in big trouble...
-
Sherene Loi, MD
@LoiSher
Time is now @PeterMacCC @VicCompCancerCr @PeterMacRes
Ben Ewen-Campen
@BenForWard3
“There are vanishingly few experiments that take precedence over life and death in our community.”
-
Sherene Loi, MD
@LoiSher
Forza 🇮🇹 Italia
G Curigliano MD PhD
@curijoey
The latest Italian #coronavirus confirmed numbers
-17550 positive
-1441 died
-8372 hospitalised with symptoms
-1518 in intensive care with ARDS
-7860 asymptomatic at home -
Sherene Loi, MD reposted
-
Sherene Loi, MD reposted
Research To Practice
@DrNeilLove
Unable to attend all 3 of our #cme events during SABCS? Don't worry, the video proceedings are available, beginning with our exploration of the evolving triple-negative #breastcancer landscape with Drs @ErikaHamilton9, @LoiSher, @MarkRobsonMD & @hoperugo:
www.researchtopractice.com/SanAntonioBC19/TNBC/Video -
Sherene Loi, MD
@LoiSher
Congrats to my graduate student @annbyrne27 and the Loi Lab for our latest review #immunotherapy #bcsm @TILsWorkGroup @NBCFAus
Ann Byrne
@annbyrne27
Delighted to have our review on Tissue Resident Memory T cells in Breast cancer published in @NatRevClinOncol 🎉A lot of teamwork went into putting this together! @PeterMacCC @PeterMacRes @unimelb #breastcancer #immunotherapy
www.nature.com/articles/s41571-020-0333-y -
Sherene Loi, MD
@LoiSher
Vale a godfather of breast cancer research.
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
It is a sad moment... the oncology community loses a pioneer: Prof Aron Goldhirsch who made several progress for breast cancer patients @BIGagainstBC @myESMO @OncoAlert
-
Sherene Loi, MD
@LoiSher
#bcsm #immunotherapy PD-1 inhibition changing the way we treat #tnbc @TILsWorkGroup
FabriceAndre
@FAndreMD
Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: 60% pathological complete response, high TILs and/or PDL1 = higher pCR. by P Schmid, @LoiSher and coll www.annalsofoncology.org/article/S0923-7534(20)36032-4/fu…
-
Sherene Loi, MD
@LoiSher
congratulations and great summary
@DSolit and @sloan_kettering,
David B. Solit, MD
@DSolit
The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff @sloan_kettering who have made this initiative possible. A few thoughts on what we have learned.
-
Sherene Loi, MD
@LoiSher
Metastatic Breast Cancer: TIL it is Too Late | Clinical Cancer Research #bcsm #immunotherapy clincancerres.aacrjournals.org/content/early/2020/01/03/1…
-
Sherene Loi, MD reposted
The Breast Cancer Research Foundation
@BCRFcure
ICYMI: Our Facebook Live interview with BCRF researcher Dr. Sherene Loi discussing research updates in immunotherapy. Tune in: www.facebook.com/TheBreastCancerResearchFoundation/videos…
-
Sherene Loi, MD
@LoiSher
Congratulations Geoff Lindemann and Jane Visvader #sabcs19 @SusanGKomen @PeterMacCC @WEHI_research for receiving the Brinker award for scientific distinction
-
Sherene Loi, MD
@LoiSher
NEJM
@NEJM
Trastuzumab deruxtecan produced responses in 60% of women with HER2+ breast cancer who had received a median of six prior types of therapy. The agent is associated with myelotoxicity and gastrointestinal toxicity. #sabcs19 www.nejm.org/doi/full/10.1056/NEJMoa1914510
-
Sherene Loi, MD
@LoiSher
Great data for #her2 #bcsm #breastcancer #sabcs19
NEJM
@NEJM
In heavily pretreated patients with HER2+ metastatic breast cancer, including those w/ brain metastases, adding tucatinib to trastuzumab and capecitabine results in better progression-free survival & overall survival outcomes than adding placebo. #sabcs19 www.nejm.org/doi/full/10.1056/NEJMoa1914609
-
Sherene Loi, MD reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
It's #onequestion time with Dr. Sherene Loi! Ask your #onequestion using the #onequestion hashtag and we will post her answer tomorrow afternoon. Learn more about @LoiSher here: www.petermac.org/users/prof-sherene-loi We will post Dr. Baru Arun's response this afternoon.
-
Sherene Loi, MD
@LoiSher
Hello #sabcs2019
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Time to meet the panel of experts who will answer your queries during the #onequestion campaign on Twitter. Visit the SABCS blog to learn who they are and get your #onequestion ready for #sabcs19. www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/182/Mee…
-
Sherene Loi, MD reposted
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
Atezolizumb + bevacizumab as first line improves the overall survival of patients with unresectable hepatocellular carcinoma #esmoasia19 @myESMO @OncoAlert
-
Sherene Loi, MD reposted
Nisha Brown
@DrNishaBrown
Baby Development workshop (learn the latest!) for families next Saturday Nov 30th - places still available 👣 - mailchi.mp/83b6cc6066a7/baby-development-workshop-next-sa…
-
Sherene Loi, MD
@LoiSher
Congratulations!
-
Sherene Loi, MD
@LoiSher
Fun today modelling designer “lab coats” with @chykak for #bcsm breast cancer research @BCTrialsANZ @PeterMacCC @VicCompCancerCr @vogueaustralia
See @BCTRIALSANZ for online auction details -
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer | Business Wire www.businesswire.com/news/home/20191021005169/en/Seattle-…
-
Sherene Loi, MD reposted
Nature Medicine
@NatureMedicine
A sardonic professor once told @LoiSher, “If you want a good next life, come back as a phase I or II trial as they are all positive.”
Read her heartfelt account of the moments that led her to research the #cancer #genome in #breastcancer: go.nature.com/33laDTg -
Sherene Loi, MD
@LoiSher
Incredible
-
Sherene Loi, MD
@LoiSher
Potential clinical utility for #til In #bcsm
TILs Working Group
@TILsWorkGroup
🚨#esmo2019 #bcsm
sTILs ≥ 30% in pStage I #tnbc
=> EXCELLENT prognostic subgroup (5Y OSR: 98%)
=> absolute survival benefits of adjuvant chemotherapy could be minimal, with regards to associated risks and co-morbidities
#tilsincancer #tils2deescalate -
Sherene Loi, MD reposted
Antonio Marra
@antoniomarraMD
Interesting work just presented at #esmo19 and simultaneously published in @Annals_Oncology
- sTILs can identify a subgroup of stage I #tnbc pts with excellent prognosis without adjuvant CT
@curijoey @FAndreMD @LoiSher @vitti10 @OncoAlert academic.oup.com/annonc/advance-article-abstract/doi/10.1… -
Sherene Loi, MD reposted
TILs Working Group
@TILsWorkGroup
Looking fwd to seeing you all at #esmo19 @ESMO
Follow us to know what’s hot what’s new about #tilsincancer #biomarkers #tils2deescalate
🚨YES 🚨
you saw this right TILs-to-De-Escalate
👇...more soon...👇
(psssst - this will be presentation 175O ✍️)
cslide.ctimeetingtech.com/esmo2019/attendee/confcal/show/… 👇 -
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Very interesting for 3 reasons:
1. No PDL1 selection
2. Good test case for FDA pCR endpt for accelerated approval as DFS in part of phase 3 study
3. Good for TNBC
Pembo in combo with TC/AC Met Primary Endpoint of pCR in Phase 3 KEYNOTE-522 Trial in TNBC shar.es/aXmTRm -
Sherene Loi, MD
@LoiSher
#abcnews #fakenewssportinglawyer all athletes (and coaches) know what goes into their bodies #coverup? #shaynajack
-
Sherene Loi, MD
@LoiSher
#tils hits #jeopardy in the US!
TILs Working Group
@TILsWorkGroup
🎯A question on #tils at @Jeopardy ? Isn’t that a sign that #tils are now part of genera public knowledge
➡️ wouldn’t it be time to consider it for clinical guidelines (oh that AND the HUGE body of clinical evidence/data 👉 resources on our website tilsincancer.org ) -
Sherene Loi, MD
@LoiSher
Hey everyone we are reaching nearly 10000 users! #bcsm #tils #immunotherapy
TILs Working Group
@TILsWorkGroup
Hey hey !
Our website is flirting with the 10000 users ! If you want to:
1) Stay on top of the game in the #tils field
2) Train yourself to score TILs
& more…
Register and regularly go check:
www.tilsinbreastcancer.org www.tilsincancer.org
#tilsincancer -
Sherene Loi, MD
@LoiSher
Thank you to all #aphinitytrial Patients @BIGagainstBC -this data will tell us which #her2 #bcsm patients need more
TILs Working Group
@TILsWorkGroup
More biomarker data from @ASCO 🤳 High TILs associated with good outcome in the APHINITY trial #asco19 👉 #tilsincancer #tilsmatter
-
Sherene Loi, MD
@LoiSher
Agree, always looking for good post-docs or potential students
Jonathan Kipnis 🟦
@jonykipnis
Advice for postdoc candidates: If there is a lab you really want to join, don’t wait for an advertised position. Reach out to PI, explain what excites you about the lab/research, explain briefly what you want to do and attach your CV. This applies to my lab too 😉
-
Sherene Loi, MD
@LoiSher
Congrats @FAndreMD @SamitHirawat finally a win for #pi3k #bcsm
FabriceAndre
@FAndreMD
Alpelisib/mBC:
short term: increase value / pt > better selection (Hb1c), early tt with anti-hist/metformin, definition of clonality for pik3ca mut.
lg term: mol mechanisms of resistance, new indications, positioning implication: implement DNA seq in mBC
www.nejm.org/doi/full/https://www.nejm.org/doi/full/10.10… -
Sherene Loi, MD
@LoiSher
ESMO Webinar Series | ESMO @curijoey @myESMO @TILsWorkGroup learn about #immunotherapy #bcsm in breast cancer www.esmo.org/Conferences/Webinar-Series
-
Sherene Loi, MD reposted
TILs Working Group
@TILsWorkGroup
🚨 Breakthrough in #tilsincancer
➡️ TILs reach consensus at #stgallen2019 in TNBC 🙌
➡️ 64% expert panel : "#tils should routinely be characterized & reported according to consensus criteria in TNBC" 💯
➡️ 1st step towards implementation of #tils in daily practice settings 💪 -
Sherene Loi, MD
@LoiSher
Disgrace #freenasrin
Amnesty International
@amnesty
Nasrin Sotoudeh is a national treasure in #iran. Why? Because she has bravely stood up for women’s rights. For children’s rights. For a safer, fairer Iran. Yet, for this, she is serving 38 years in prison & will be flogged 148 times.
#freenasrin now. -
Sherene Loi, MD
@LoiSher
Win for #tnbc #immunotherapy
-
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
FDA approval for @Roche atezolizumab in PDL1+ #tnbc.
Implications:
1. All TNBC cases need PDL1 testing though suspect that, as in NSCLC, the testing debate is just beginning.
2. Survival is new benchmark in first-line therapy; no more nihilism in TNBC.
3. win for nab-paclitaxel -
Sherene Loi, MD
@LoiSher
Trials now open around Australia- for early stage TNBC as well as metastatic HER2+ disease - please contact BCTrials below for the nearest site to you #bcsm #tnbc #immunotherapy #her2 @PeterMacCC @BCTrialsANZ
Breast Cancer Trials
@BCTrialsANZ
We are proud to announce the launch of two world-first clinical trials, that are looking at how immunotherapy can improve breast cancer treatments. Study Chair Professor Sherene Loi @LoiSher describes our new trials in this article from @theheraldsun www.heraldsun.com.au/news/victoria/worldfirst-doublecombo…
-
Sherene Loi, MD
@LoiSher
Nearly 8 years of work to get this paper: Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial www.thelancet.com/journals/lanonc/article/PIIS1470-2045(1…
There is a signal: what's next? #bcsm #her2bc #merck -
Sherene Loi, MD
@LoiSher
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers: ascopubs.org/doi/abs/10.1200/JCO.18.01010
TILs can help us estimate prognosis in early-stage TNBC. Next step- how to get more TILS! #bcsm #tnbc -
Sherene Loi, MD reposted
Tatiana Prowell, MD
@tmprowell
Dr. Sherene Loi @LoiSher & colleagues making progress on a more granular assessment of response to neoadjuvant therapy in #breastcancer. Important step in efforts to #optimizeearlybc. #bcsm
FabriceAndre
@FAndreMD
combining post-chemo TILs and RCB could predict relapse in patients with TNBC and residual disease post neoadj chemo. a very useful tool to stratify pts for trials. academic.oup.com/annonc/advance-article-abstract/doi/10.1…
-
Sherene Loi, MD reposted
David Gyorki
@davidgyorki
Congrats @simpak and team on a huge effort and important discovery.
Simone Park
@simpak
A great start to 2019: our paper on TRM cell control of #cancer is out today in @nature ! www.nature.com/articles/s41586-018-0812-9 Congratulations and thank you to everyone who helped make it happen 🎉👩🔬👨🔬 #melanoma #immunotherapy @TheDohertyInst @telethonkids @LMackayLab
-
Sherene Loi, MD reposted
Tatiana Prowell, MD
@tmprowell
Nice read from the always insightful @LoiSher. #bcsm
Gideon Blumenthal
@BlumenthalG
Fine-tuning chemotherapy in the era of dual HER2 targeting. www.thelancet.com/journals/lanonc/article/PIIS1470-2045(1…
-
Sherene Loi, MD reposted
FabriceAndre
@FAndreMD
pembrolizumab 1st line setting in PDL1+ mTNBC ; 21% objective response. looking forward the publication of TILs in this population @LoiSher 👀 academic.oup.com/annonc/advance-article-abstract/doi/10.1…
-
Sherene Loi, MD reposted
roweafr
@roweafr
lest we forget @FinancialReview #armisticeday100 #trump
-
Sherene Loi, MD reposted
CancerCouncilOz
@CancerCouncilOz
"I really like just living, because I really find it's just much more fun in life to go through it, just being happy." ❤️ Wise words from a spirited young man taken far too soon. Our deepest condolences to the Symons family.
🎥: @AustralianStory tonight 8pm on @ABCTV -
Sherene Loi, MD reposted
Hope Rugo
@hoperugo
Thanks to @BCRFcure and the incredible donors for your support!
The Breast Cancer Research Foundation
@BCRFcure
Our New York Symposium and Awards Luncheon raised $2.5M for breast cancer research! Over 200 of our investigators joined us at this special event today where we honored their groundbreaking work that is fueled by the tremendous support of our community. #researchisthereason
-
Sherene Loi, MD
@LoiSher
#esmo2018 #bcsm #tnbc #immunmotherapy
FabriceAndre
@FAndreMD
Comment on Impassion130 by @LoiSher , E Winer & M Kok in @Annals_Oncology ; what are the findings, implications, perspectives ?
1st paper of a new series where we ll publish comments from KOL few days after report of practice-chang trials fdslive.oup.com/www.oup.com/pdf/production_in_progress.pdf -
Sherene Loi, MD
@LoiSher
Passion for Immune checkpoint blockade in triple negative breast cancer? A commentary on the IMpassion130 study | @DrEricWiner @Annals_Oncology #esmo2018 #bcsm #tnbc academic.oup.com/annonc/advance-article-abstract/doi/10.1…
-
Sherene Loi, MD
@LoiSher
interesting take on the biggest OS survival seen for a subset of met TNBC patients ever...
-
Sherene Loi, MD
@LoiSher
the NYT reports on the IMpassion130 data- first read out in TNBC #bcsm #esmo2018 @TILsworkinggroup @PetermacCC www.nytimes.com/2018/10/20/health/breast-cancer-immunothe…
-
Sherene Loi, MD
@LoiSher
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer | NEJM www.nejm.org/doi/full/10.1056/NEJMoa1809615
-
Sherene Loi, MD reposted
-
Sherene Loi, MD
@LoiSher
Immun oncology biomarkers edited by @TILsWorkGroup #immunotherapy #cancerresearch www.sciencedirect.com/journal/seminars-in-cancer-biology/…
-
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Important phase 1 on PDL1 inhibitor in TNBC.
Subsets defined by PDL1 expression are interesting but company did not use the info in ITT phase III trial design, preferring post hoc analyses jamanetwork.com/journals/jamaoncology/fullarticle/2701722 -
Sherene Loi, MD
@LoiSher
Good news for PI3K inhibitors! Pharmacology matters #esmo18 @FAndreMD #breastcancer
Dr Sunil Verma
@cancermd
SOLAR-1 Trial (PI3-k Inh. Alpelisib in Metastatic Breast Cancer) met primary endpont of PFS. Key things to look when data is reported(likely #esmo18 ): 1. Toxicity profile 2. Magnitude of diff. in PFS 3. Efficacy in CDK4/6 tx patients 4. PI3k test profile www.novartis.com/news/media-releases/solar-1-trial-novart…
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
Thanks to @VicGovernor the Honourable Linda Dessau AC for visiting Peter Mac today - included meeting members of our youth advisory board, senior nurses and also talking immunotherapy with @LoiSher in her lab.
-
Sherene Loi, MD
@LoiSher
Farewell @LeeLinChinSBS on #sbsnews I'll miss you every weekend on @SBSNews #forever ! 😥 🍺🥂 www.sbs.com.au/news/article/lee-lin-chin-departs-sbs-afte…
-
Sherene Loi, MD
@LoiSher
Trying to teach our PM and @GregHuntMP about cancer #immunotherapy
Peter Mac Cancer Centre
@PeterMacCC
Delighted to host @TurnbullMalcolm and @GregHuntMP for the announcement of $5m additional funding for the Zero Childhood Cancer Program under the Australian Brain Cancer Mission. He stopped for a selfie with Prof @LoiSher in the lab (top) and our Chief Exec Dale Fisher.
-
Sherene Loi, MD
@LoiSher
More evidence supporting our hypothesis that TRM T cells are tumor specific T cells #breastcancer #immunotherapy www.nature.com/articles/s41467-018-05072-0
-
Sherene Loi, MD reposted
Dr Sunil Verma
@cancermd
Interesting article in @nature by @DrSidMukherjee and colleagues on interplay between diet and efficacy of targeted cancer drugs (PI3k- Inhibitors) Very important to assess in ongoing trials and in clinical practice www.nature.com/articles/s41586-018-0343-4
-
Sherene Loi, MD
@LoiSher
Good news for #tnbc #breastcancer first major read out for TNBC - Phase III IMpassion130 showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer www.roche.com/media/releases/med-cor-2018-07-02.htm
-
Sherene Loi, MD
@LoiSher
latest from my lab, comprehensive TIL profiling of breast cancers identifies a tumor-specific tissue resident T cell (#trm) @TILsWorkGroup @NatureMedicine @PeterMacCC #tnbc #breastcancer @BCRFcure www.nature.com/articles/s41591-018-0078-7
-
Sherene Loi, MD
@LoiSher
Just published! Somatic Driver Alterations in Hormone Receptor–Positive, HER2-Negative Breast Cancer jamanetwork.com/journals/jamaoncology/fullarticle/2684637 #breastcancer #endocrinetherapy
-
Sherene Loi, MD reposted
Daniel Stover, MD, FASCO
@StoverLab
Review out in BCRT w @melindatelli @LoiSher @DrEricWiner +more: "Homologous recombination deficiency & host anti-tumor immunity in triple-negative #breastcancer." @TNBCFoundation's Forum led to this review, helping advance how we tackle #tnbc.
link.springer.com/article/10.1007%2Fs10549-018-4807-x -
Sherene Loi, MD
@LoiSher
#atezolizumab #immunotherapy #mek failure in CRC
Genentech
@genentech
Today we shared Phase III study results in a specific type of heavily pre-treated advanced #colorectalcancer www.gene.com/media/press-releases/14717/2018-05-09/genent…
-
Sherene Loi, MD
@LoiSher
#courage- about time recognition for a great Australian athlete🇦🇺
roger casement
@rogersghost
Peter Norman saw the right side of history and had the courage to stand on it. A great Australian who towers down on small minded racists dressed in Australian Nationalism.
-
Sherene Loi, MD reposted
Chief Executive Officer VCCC Alliance
@Prof_G_McArthur
Professors Doherty, Loi & Hicks from #vccc partners present the biology and clinical translation of immunotherapies for cancer to the world nuclear medicine community #wfnmb2018
-
Sherene Loi, MD reposted
Science and Innovation at Cancer Research UK
@CRUKresearch
Calling those who are interested in the clinical interpretation of molecular tests! Abstract submission is now open for MAP 2018 with @myESMO. Deadline is 20 June Find out more: www.esmo.org/Conferences/MAP-2018-Molecular-Analysis-for-…
-
Sherene Loi, MD
@LoiSher
Heart attacks of the mega-fit: how safe is extreme sport? www.theage.com.au/sport/heart-attacks-of-the-mega-fit-how…? csp=bef6c028a08552214f24dffaf3979b65 via @theage
@ALaGerche #extremesport -
Sherene Loi, MD reposted
Evandro de Azambuja, MD, PhD
@E_de_Azambuja
Save the date for ESMO Breast cancer in 2019! Co-chairs @curijoey @Sibylle Loibl and @myESMO #breastcancer
www.esmo.org/Conferences/ESMO-Breast-Cancer-2019 -
Sherene Loi, MD
@LoiSher
nice job @FAndreMD
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Great story and editorial on TRK targeting @FAndreMD gives superb commentary
This post is unavailable. See it on X. -
Sherene Loi, MD
@LoiSher
Out today- Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data: Journal of Clinical Oncology: ascopubs.org/doi/full/10.1200/JCO.2017.74.8301
-
Sherene Loi, MD reposted
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Excellent @JCO_ASCO update on opportunities for targeting HEr2. First "new look" HER2 figure in years.
Journal of Clinical Oncology
@JCO_ASCO
Targeting HER2 by combination therapies ascopubs.org/doi/abs/10.1200/JCO.2017.77.1899
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
How #clinicaltrials can be used to test the importance of gene mutations. New research involving Peter Mac patients and Prof Sherene Loi @LoiSher published in @nature today reporting the impact of HER protein mutations on #cancer response to drug. More: www.petermac.org/news/trial-reveals-importance-her2-and-h…
-
Sherene Loi, MD
@LoiSher
-
Sherene Loi, MD reposted
TILs Working Group
@TILsWorkGroup
DYK that we have an education website where you can learn how to score TILs (and more)? @BCRFcure is talking about our initiative right here 👉 www.bcrf.org/international-team-announces-launch-tils-tra… 👉find us at tilsincancer.org or tilsinbreastcancer.org #tilsinbreastcancer #tilsincancer
-
Sherene Loi, MD reposted
Sally Church
@MaverickNY
Updated our interview with experts including @ericwiner and @LoiSher on APHINITY following FDA approval this week: icar.us/APHINITYfda
-
Sherene Loi, MD reposted
TILs Working Group
@TILsWorkGroup
Role for Immune Therapy in Advanced Breast Cancer cancerdiscovery.aacrjournals.org/content/early/2017/12/11… #tils #breastcancer @METUPorg @her2bc @big
-
Sherene Loi, MD
@LoiSher
thanks @cancermd #tils #breastcancer @TILsWorkGroup
Dr Sunil Verma
@cancermd
Great work by @LoiSher #sabcs17
This post is unavailable. See it on X. -
Sherene Loi, MD reposted
The Policy Shop
@The_PolicyShop
Nearly 50,000 people will die from cancer in Australia this year. Why despite the great strides in medical knowledge, does the world continue to struggle in finding a cure for cancer? pursuit.unimelb.edu.au/podcasts/why-can-t-we-cure-cancer @GlynDavisVC @LoiSher
-
Sherene Loi, MD reposted
Jennifer Wright
@JenAshleyWright
Hey women: retweet if you've ever been shown a penis you did not want or expect to see.
-
Sherene Loi, MD reposted
Eoin Hahessy
@hahessy
Just out - Why can’t we cure cancer? | Nobel Laureate Dr. Harold Varmus & @LoiSher discuss on @The_PolicyShop 🎧 pursuit.unimelb.edu.au/podcasts/why-can-t-we-cure-cancer
-
Sherene Loi, MD reposted
Sally Church
@MaverickNY
After 5 years and 2 clinical trials, Patient #1 stops cancer treatment of pembrolizumab - nice story!
www.philly.com/philly/health/after-5-years-and-2-clinical… -
Sherene Loi, MD reposted
Richard Simcock
@BreastDocUK
Now 3 x CDK4/6 showing similar activity. Like AIs 10 yrs ago. Don't split hairs over data, lowest price should win #bcsm #esmo17
ecancer
@ecancer
CDK4/6 abemaciclib as initial therapy improves PFS, ORR for HR+, HER2- #breastcancer patients #esmo17
-
Sherene Loi, MD reposted
-
Sherene Loi, MD reposted
NEJM
@NEJM
Original Article: Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer (PACIFIC) www.nejm.org/doi/full/10.1056/NEJMoa1709937 #esmo17
-
Sherene Loi, MD reposted
Andre La Gerche
@ALaGerche
www.goldcoastbulletin.com.au/lifestyle/why-did-fit-former…
Irresponsible and ill-informed. -
Sherene Loi, MD
@LoiSher
Clinical Validity & Utility of Tumor-Infiltrating Lymphocytes for Breast Cancer Patients. #breastcancer
journal.frontiersin.org/article/10.3389/fonc.2017.00156 -
Sherene Loi, MD
@LoiSher
all too often we are reminded of why we do what we do. #breastcancer
-
Sherene Loi, MD reposted
The New York Times
@nytimes
Opinion: "Liu Xiaobo died with dignity and honor, true to his principles. Everybody else, not so much." archive.nytimes.com/kristof.blogs.nytimes.com/2017/07/13/…
-
Sherene Loi, MD reposted
The Breast Cancer Research Foundation
@BCRFcure
BCRF-supported study shows combining 2 immunotherapy drugs could be effective in treating TNBC in women w/ BRCA1 www.eurekalert.org/pub_releases/2017-06/waeh-nth060517.ph…
-
Sherene Loi, MD
@LoiSher
Australian journalist's 'searing assessment' of Trump strikes a chord around the world in viral video www.theage.com.au/entertainment/tv-and-radio/australian-j… via @theage
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
See how @MaddiesVision supports research into bone marrow failure syndrome at Peter Mac. Thanks to @stkildafc, @Richmond_FC & footy fans.
St Kilda FC
@stkildafc
140 Aussies are diagnosed with Bone Marrow Failure Syndrome each year. Help @MaddiesVision find a cure. #highfiveformaddie
This media couldn't be displayed. See it on the original post. -
Sherene Loi, MD reposted
Nature Portfolio
@NaturePortfolio
A personalized RNA-based vaccine approach which targets neo-epitopes in 13 patients with melanoma is presented go.nature.com/2tRSajd
-
Sherene Loi, MD
@LoiSher
great podcast on novel targets in breast cancer from @TargetsPodcast @3NT
NovelTargets Podcast
@TargetsPodcast
Listen to what breast cancer experts such as @LoiSher thought about the OlympiAD data presented at #asco17 3nt.co/Ep18NT
-
Sherene Loi, MD reposted
Science Magazine
@ScienceMagazine
A new @ScienceTM study could pave the way to treatments for triple-negative breast cancers: scim.ag/2qY21yY
-
Sherene Loi, MD
@LoiSher
Today I am a cover girl! stm.sciencemag.org/content/9/393/eaal4922
#breastcancer @PeterMacCC @BCRFcure -
Sherene Loi, MD reposted
Science Translational Medicine
@ScienceTM
The new issue of Science Translational Medicine is out now! stm.sciencemag.org/content/9/393
-
Sherene Loi, MD reposted
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)
@awolff
A good list.
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
My most anticipated breast cancer abstracts for #asco17
-
Sherene Loi, MD reposted
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)
@awolff
It does .... As Pogo wisely said, "We have met the enemy and he is us."
-
Post not available here, view on XPost not available here, view on X
Sherene Loi, MD
@LoiSher
Perhaps discuss on 3AW Friday 7.45am?
@ringsau @TimLaneSport -
Sherene Loi, MD reposted
Tim Lane
@TimLaneSport
Yes, but it would be simpler. Substances beyond La Gerche's 'small list of commonly used drugs' would put athletes in breach. QED
-
Sherene Loi, MD reposted
Baker Institute
@BakerResearchAu
In @theage & @smh today A/Prof Andre La Gerche writes: Athletes are the victims in the push to use drugs in sport bakeridi.edu.au/news/in-the-media/stop-drugs-in-sport
-
Sherene Loi, MD
@LoiSher
#plosmedicine:Cancer Genomics: Large-Scale Projects Translate to Therapeutic Advances dx.doi.org/10.1371/journal.pmed.1002209
#bcsm #breastcancer #genomics -
Sherene Loi, MD
@LoiSher
Subclonal Architecture of Metastatic #breastcancer: Results from Prosp Rapid Autopsy program @PeterMacCC @BCRFcure journals.plos.org/plosmedicine/article?id=10.1371/journal…
-
Sherene Loi, MD reposted
FabriceAndre
@FAndreMD
whole exome seq 216 metastatic breast cancers thks @FondationARC @Institut_cancer @Inserm @BCRFcure @GroupeUNICANCER journals.plos.org/plosmedicine/article?id=10.1371/journal…
-
Sherene Loi, MD reposted
Clifford Hudis
@CliffordHudis
Congrats @DrEricWiner McGuire Awardee #sabcs16 - great state of #breastcancer & his life/career as an example! vimeo.com/195039402
-
Sherene Loi, MD reposted
Lurie Cancer Center
@LurieCancer
-
Sherene Loi, MD reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
Vogl #sabcs16
www.medscape.com/viewarticle/735352?src=soc_tw_share -
Sherene Loi, MD
@LoiSher
The genomic landscape of breast cancer and its interaction with host immunity #breastcancer www.sciencedirect.com/science/article/pii/S0960977616301242
-
Sherene Loi, MD
@LoiSher
Biden visits Melbourne to progress Cancer Research @CancerVCCC @PeterMacCC #breastcancer www.abc.net.au/news/2016-07-17/us-vice-president-joe-bide… via @ABCNews
-
Sherene Loi, MD reposted
Peter Mac Cancer Centre
@PeterMacCC
.@VP toured lab & talked cancer research with Peter Mac's Sherene Loi, Grant McArthur & Sarah-Jane Dawson. #vpinoz
-
Sherene Loi, MD reposted
Gabriel Siqueira
@gabrieldread
Well that escalated quickly x.com/H_L_Thompson/status/746304145515216897/photo/1
-
Sherene Loi, MD
@LoiSher
TNBC & low TILs: MEK it? #breastcancer #tnbc #triplenegativebreastcancer clincancerres.aacrjournals.org/cgi/content/long/1078-0432…
-
Sherene Loi, MD
@LoiSher
A moment that changed me – saying goodbye to my mother when I was 10 | Fay Schopen gu.com/p/49ydp/stw #breastcancer
-
Sherene Loi, MD
@LoiSher
now open PANACEA study clinicaltrials.gov no:NCT02129556 Keytruda & trastuzumab for HER2-positive met BC #breastcancer @PeterMac_News
-
Sherene Loi, MD
@LoiSher
Important advance for advanced ER+ BC #asco2015 #breastcancer www.nejm.org/doi/full/10.1056/NEJMoa1505270 … x.com/cancermd/status/605366839233757186 …
Dr Sunil Verma
@cancermd
Paloma-3 Significant improvement in PFS with the addition of Palbociclib to Fulvestrant #asco15 #breastcancer
-
Sherene Loi, MD reposted
Maria Popova
@themarginalian
Gail Lewis Phillips, who revolutionized breast cancer research by working on the HER2 gene for 30 years, is my hero explore.noodle.com/post/118720893103/the-remarkable-story…
-
Sherene Loi, MD
@LoiSher
TILs and Outcomes in primary HER2 Breast Cancer Treated With Lapatinib &Trastuzumab oncology.jamanetwork.com/article.aspx?articleid=2279849 #breastcancer
-
Sherene Loi, MD
@LoiSher
Good news for breast cancer patients: PALOMA-3 meets primary endpoint www.pfizer.com/news/press-release #breast #cancer #breastcancer
-
Sherene Loi, MD reposted
Jimmy B.
@marksy12
#coinforaustralia very happy to take our billion back from Indonesia, we won't charge interest. We can use it at home for Australia #bali9
-
Sherene Loi, MD
@LoiSher
#boycottbali for the #bali9. Barbaric @JulieBishopMP @tanya_plibersek
-
Sherene Loi, MD
@LoiSher
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer — NEJM www.nejm.org/doi/full/10.1056/NEJMoa1408440?query=TOC; @PeterMac_News #lungcancer
-
Sherene Loi, MD
@LoiSher
Host Antitumor Immunity Plays a Role in the Survival of #triplenegativebreastcancer #breastcancer jco.ascopubs.org/content/32/27/2935.long …
-
Sherene Loi, MD
@LoiSher
Consensus on how to evaluate timor infiltrating lymphocytes (TILs) in #breastcancer and why annonc.oxfordjournals.org/cgi/content/long/mdu450v1
-
Sherene Loi, MD
@LoiSher
Poor get poorer #threewordbudget
-
Sherene Loi, MD
@LoiSher
More on PIK3CA mutations- my favourite topic! jnci.oxfordjournals.org/cgi/content/long/105/13/960
-
Sherene Loi, MD
@LoiSher
Genome Sequencing Clears Up a Cancer Medical Mystery - ScienceNOW news.sciencemag.org/sciencenow/2012/08/genome-sequencing-…
-
Sherene Loi, MD
@LoiSher
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape go.nature.com/TTgpCG
-
Sherene Loi, MD
@LoiSher
Our latest article- will pharma please invest in immunotherapies in breast cancer? jco.ascopubs.org/cgi/content/long/JCO.2011.39.5624v1
-
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
Late registration for #impakt12 breast cancer conference has been extended to 02/04! Register and save www.esmo.org/events/breast-2012-impakt/registration.html
-
Sherene Loi, MD reposted
ESMO - Eur. Oncology
@myESMO
Genomic signatures in clinical practice - don't miss #impakt12! www.esmo.org/events/breast-2012-impakt/program.html
-
Sherene Loi, MD
@LoiSher
In cancer science, many "discoveries" don't hold up www.reuters.com/article/2012/03/28/us-science-cancer-idUS… via @reuters
-
Sherene Loi, MD
@LoiSher
early registrations IMPAKT closing next week AMAZING Program! @MaverickNY @teamoncology check it out! #myesmo discount for pathologists too
-
Sherene Loi, MD
@LoiSher
Today is World Cancer Day:Prevention, yet do no harm, early diagnosis for those that are curable, the right treatment for those who need it.
-
Sherene Loi, MD
@LoiSher
Subtyping of breast cancer needs only 3 genes- until the clinical & biological relevance of PAM50 (&others) are shown
www.ncbi.nlm.nih.gov/pubmed/22262870 -
Post not available here, view on X
Sherene Loi, MD
@LoiSher
exactly! @teamoncology I agree and unplanned subset analyses are often wrong... #sabcs
-
Sherene Loi, MD
@LoiSher
IMPAKT 2012 Training course for young researchers- interested Pi3K, new technologies and drug development? @my ESMO shar.es/o0zRj
-
Sherene Loi, MD
@LoiSher
IMPAKT 2012 program is out! breast cancer translational research, great speakers, abstracts due Jan 2012 @myESMO shar.es/o0zwx
-
Sherene Loi, MD
@LoiSher
pathologic complete response (pCR) in HER2+ BC assoc. with excellent 3yr DFS and OS- jco.ascopubs.org/cgi/content/long/29/25/3344
-
Sherene Loi, MD
@LoiSher
IMPAKT 2012 PrelimProgram now out- the breast cancer translational event in Europe- thanks to my cochair FAndre @myESMO shar.es/bf079
-
Sherene Loi, MD
@LoiSher
Epub Sept 13: Curr Opin Oncol. 2011
HER2-overexpressing breast cancer: time for the cure with less chemotherapy? journals.lww.com/co-oncology/toc/9000/00000 -
Sherene Loi, MD
@LoiSher
which women can we withhold adjuvant systemic therapy after surgery for breast cancer? jnci.oxfordjournals.org/cgi/content/long/djr331v1
-
Sherene Loi, MD reposted
BBC News (World)
@BBCWorld
Australia refugee deal 'illegal' www.bbc.co.uk/go/rss/int/news/-/news/world-asia-pacific-1…
-
Sherene Loi, MD
@LoiSher
Long side effects of Chemo highlights the need for better prognostic and predictive biomarkers annonc.oxfordjournals.org/cgi/content/long/22/9/1939
-
Sherene Loi, MD reposted
TIME
@TIME
We snuck into the Syrian city of Hama, where possibly hundreds of protesters were massacred. Here's what we found | ti.me/mSokV8
-
Sherene Loi, MD
@LoiSher
Feedback regulation: the bane of targeted therapies:Reciprocal feedback regulation of PI3K and AR signaling; www.ncbi.nlm.nih.gov/pubmed/21575859
-
Sherene Loi, MD
@LoiSher
How many gems of observation, data, thinking were lost by suppression, narrowness of thinking that is peer-review? ht.ly/5ZHEX
-
Sherene Loi, MD
@LoiSher
Shame Ms Gillard- for becoming like Howard. Gillard's iron fist on boats clings to office | The Australian www.theaustralian.com.au/national-affairs/commentary/gill…
-
Sherene Loi, MD
@LoiSher
Another gene predictor in ER+ BC...but at least they take on Ki67!
clincancerres.aacrjournals.org/cgi/content/long/1078-0432… -
Sherene Loi, MD
@LoiSher
Parenting Australian style- Show me the terrified parent and I shall show you some rules | The Australian www.theaustralian.com.au/news/opinion/show-me-the-terrifi…



















































































































































































































































































































































































































































































































































































